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Abstract
The spectrum of diseases caused by mitochondrial dysfunction is very broad and 
encompasses the archetypal mtDNA mutation diseases, mutations of nuclear 
genesencoding mitochondrial proteins (including those of the oxidative phosphorylation 
system), and a variety predominantly neurodegenerativediseases in which the primary 
cause of mitochondrial dysfunction remains undefined.
The last two decades have seen an explosion in our understanding of the archetypal
i
mitochondrial disorders. Attention has now focused on the nuclear encoded 
mitochondrial disorders. Furthermore, nuclear factors may be of significance in the 
pathogenesis of the archetypal disorders associated with mitochondrial DNA mutations. 
These conditions are typified by their clinical diversity and poor phenotype-genotype 
correlation. One of several potential explanations for this is that nuclear genes determine 
the fate of mtDNA mutations, or that secondary mtDNA mutations have a modulating 
effect upon the expression of the primary mutation.
In this thesis I have sought to address several aspects of the biochemical and clinical 
features of mitochondrial diseases. In chapter 3 cell cybrids have been used to study the 
role of the nuclear genome on the biochemical expression of mtDNA mutations in an 
attempt to understand potential influences on phenotypic expression. An extension of this 
was the use of xenomitochondrial cybrids to analyse nuclear-mitochondrial interactions 
and thre function of the respiratory chain. At the biochemical/clinical interface, skeletal 
muscle from patients with focal dystonia has been used as a model to investigate the role 
that mitochondrial dysfunction might play in this movement disorder. Finally, the clinical 
role of therapy for mitochondrial disorders has been investigated in the context of 
Friedreich’s ataxia (FRDA). Existing rating scales have been assessed and new ones 
developed to lay a firm foundation for evaluating disease-modifying therapies. These 
have been piloted in a long term intervention trial for FRDA.
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1 INTRODUCTION
Our understanding of the role of mitochondria in human disease has expanded 
exponentially in the last 25 years. Mitochondria were first described in 1856, however it 
was not until 1946 that Albert Lehninger, Eugene Kennedy and others identified 
mitochondria as the major site of energy metabolism within the cell. Mitochondrial DNA 
(mtDNA) was identified in 1963 and the human mtDNA sequence was published in 
19811. Subsequently the mtDNA sequence of many other species has been determined, 
revealing a high degree of conservation between mammals .
There is now good evidence that mitochondria are the ancestors of free living, oxygen
/
metabolising (i.e. aerobic) purple bacteria that were engulfed by ancestral eukaryotic 
anaerobic cells approximately 1.5 billion years ago. They typically measure 2 x 0.5 pm. 
As a consequence of their endocytic origins mitochondria are enclosed by both a 
relatively permeable outer membrane, and a relatively impermeable inner membrane. The 
outer membrane is permeable due to the abundant presence of porin, a transmembrane 
protein with a large pore. It is this inner membrane folded into numerous cristae that is 
the site of the mitochondrial respiratory chain. Like bacteria, mitochondria contain their 
own genome, ribosomes, and tRNAs. However, in order to function fully they rely upon a 
close symbiotic relationship between the nuclear and mitochondrial genome. The nuclear 
genome contributes the vast majority of mitochondrial proteins
Initially it was believed that disease caused by mitochondrial dysfunction would prove 
fatal in utero. However, a rapidly expanding number of diseases caused by mutations in 
mtDNA have been identified, and more recently diseases caused by mutations in nuclear 
genes have been found to have mitochondrial dysfunction at the centre of their 
pathogenesis. In a number of instances this is because the responsible mutation lies in a 
nuclear encoded mitochondrial protein.
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Over the last decade mitochondrial biology has expanded into the fields of ageing, 
oxidative stress, and programmed cell death. These organelles now occupy a cornerstone 
of human biology.
1.1 MITOCHONDRIAL FUNCTION -BIOCHEMISTRY
Mitochondria are the site of numerous metabolic pathways including the Kreb cycle, fatty 
acid p oxidation, and amino acid pathways. In fact all pathways of fuel oxidation except 
glycolysis are located within mitochondria. These organelles are also involved in the 
cellular homeostasis of calcium, the protection of the cell from damage caused by 
reactive oxygen species generated during oxidative phosphorylation, and necrosis and 
apoptosis. These multiple functions are intricately interconnected.
In aerobic organisms, all energy yielding metabolic pathways culminate in oxidative 
phosphorylation. Five discrete protein-lipid complexes, embedded in the mitochondrial 
inner membrane, orchestrate this final stage of cellular respiration to generate adenosine 
triphosphate (ATP) the universal currency of energy (Fig 1.1). The process of oxidative 
phosphorylation is encompassed by the chemiosmotic theory proposed in 19613. Reduced 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) 
formed during glycolyisis, fatty acid p oxidation, and the Kreb cycle are oxidised to 
NAD+ and FAD. NADH and FADH2 are energy rich molecules because each contains a 
pair of electrons that have a high transfer potential. The donated electrons are passed 
through a series of electron donors and electron acceptors that include quinoid structures 
(flavin mononucleotide, FAD, and ubiquinone (coenzyme Qio), and transition metal 
proteins (iron-sulphur clusters (Fe-S), hemes, and protein bound copper). Electrons are 
transferred to molecular oxygen via a chain of enzyme complexes in a series of 
oxidation/reduction reactions. These are driven by differences in the redox potential 
between the electron donor and acceptor. The free energy of these reactions is linked to 
the pumping of protons from the mitochondrial matrix, across the inner mitochondrial 
membrane, to the intermembrane space. A pH gradient and a transmembrane electrical 
potential is thus generated. The flow of these protons back to the matrix through complex
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V, the final complex of the mitochondrial respiratory chain, is linked to the 
phosphorylation of adenosine diphosphate (ADP) to ATP 4(Fig 1.2). The transmembrane 
electrical potential is also used to drive the electrophoretic importation of nuclear DNA 
encoded proteins across the mitochondrial membranes. The proton gradient also serves to 
drive the transport of ions across the inner mitochondrial membrane 5.
The ATP generated by this process is used to meet energy demands in the mitochondrial 
matrix, or is transported to the cytosol in exchange for ADP by the adenine nucleotide 
translocator (ANT) the most abundant protein of the inner membrane. If OXPHOS is 
impaired cells become reliant on glycolysis for their supply of ATP. In order to 
regenerate NAD from NADH, pyruvate is converted to lactate via lactate dehydrogenase;. 
Glycolysis is a far less efficient ATP synthesis pathway than OXPHOS. Catabolism of a 
single glucose molecule via the glycolytic pathway generates four ATP molecules, 
whereas catabolism via OXPHOS will generate twenty-six. ATP produced by fatty acid 
metabolism comes entirely from OXPHOS 6.
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Figure 1.1
The five complexes of the mitochondrial respiratory chain are located in the 
mitochondrial inner membrane, (coutesy of M Cooper)
The Mitochondrial Respiratory Chain
Succinate CoQ Ubiquinol
reductase cytochrome
reductase
Complex NADH CoQ 
reductase
Cytochrome c ATP synthase 
oxidase
H+H+ H+H+
Inner membrane
ETF
Matrix
NAD FADH, FAD FAD^  ^
NAD] TCA
Cycle
ADP + Pi i p  ATP 
H+B-Oxidation
Fatty acids
21
Figure 1.2
The five complexes of the mitochondrial respiratory chain are shown. Nuclear encoded 
(clear hexagons) and mitochondrial DNA encoded (coloured hexagons) combine to form 
these multimeric complexes. A proton gradient is generated and the flow of these protons 
back to the matrix through complex V, the final complex of the mitochondrial respiratory 
chain, is linked to the phosphorylation of adenosine diphosphate (ADP) to ATP. (CoQ = 
coenzyme Q; H* = protons; cyt c = cytochrome c; e" = electrons; roman numerals refer to 
the mitochondrial respiratory chain complexes) (from AHV Schapira with permission)
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1.2 THE BIOCHEMISTRY OF OXIDATIVE PHOSPHORYLATION
As described above electrons are transferred from NADH to O2 through the complexes of 
the mitochondrial respiratory chain. These are complex I (NADH-CoQ reductase), 
complex III (ubiquinone cytochrome c reductase), and complex IV (cytochrome oxidase). 
Electrons from FADH2 are transferred through complex II (succinate dehydrogenase 
ubiquinone oxidoreductase) to complex III.
1.2.1 Complex I: fNADH dehydrogenase ubiquinone oxidoreductase)
This enzyme has two major domains, a hydrophobic horizontal arm buried in the 
mitochondrial inner membrane, and a vertical arm containing the peripheral membrane 
proteins of the complex projecting into the matrix. The whole enzyme consists of 42 
subunits. Of these 7 are encoded by mtDNA all of which lie within the horizontal arm. 
This also contains a single 2Fe-2S cluster and mobile coenzyme Q 10. The vertical arm 
contains the site of NADH binding, FMN, and three 4Fe-4S clusters and tightly bound 
coenzyme Q 1 0 6.
NADH binds to complex I and transfers its two high potential electrons to the flavin 
mononucleotide (FMN) prosthetic group to generate a reduced form FMNH2 . Acceptance 
of one electron generates a semiquinone intermediate. Electrons are then transferred to a 
second type of prosthetic group within complex I (a series of Fe-S clusters ) before being 
shuttled to coenzyme Q 10.
1.2.2 Iron sulphur clusters
Iron sulphur clusters within iron-sulphur proteins (non heme iron proteins) are critical for 
a large number of reduction reactions in biological systems. They can exist as several 
varieties: 1) Fe-S: a single iron atom linked to the sulfhydryl group of four cysteine 
residues of a protein 2) 2Fe-2S: two iron atoms and two inorganic sulfides, in addition to 
four cysteine residues 3) 4Fe-4S: four iron atoms, four inorganic sulfides, and four
23
cysteine residues. The iron atoms in these clusters cycle between the reduced (Fe2+) and
oxidised (Fe3+) state. Complex I contains both 2Fe-2S and 4Fe-4S types of Fe-S clusters
6
1.2.3 Ubiquinone fCoenzvme O)
Coenzyme Q is found ubiquitously in biological systems. In the mitochondria respiratory 
chain it serves to carry electrons from complex I to III and II to III, and from the 
oxidation of fatty acids and branched chain amino acids via the flavin linked 
dehydrogenases. A long isoprenoid tail containing five carbon units makes this quinone
strongly hydrophobic so that it diffuses rapidly within the hydrocarbon core of the
)
mitochondrial inner membrane. The number of isoprene units varies between species, the 
most common form in mammals if 10 units (coenzyme Qio). Ubiquinone is reduced to a 
free radical semiquinone anion by the reduction of a single electron. This enzyme bound 
intermediate is reduced by the acceptance of a second electron to form ubiquinol (QH2).
24
Reduced Fe-SFMN
Oxidized Fe-S
NADH
NAD
Figure 1.3: Ubiquinone / Ubiquinol reactions.
The flow of two electrons from NADH to QH2 leads to four protons being pumped across 
the inner mitochondrial membrane. Coenzyme Q 10 may also plays a role as an antioxidant
7 8and membrane stabiliser ’ .
1.2.4 Complex II (succinate dehydrogenase ubiquinone oxidoreductase)
In the citric acid cycle succinate is oxidized to fumarate by succinate dehydrogenase with 
the reduction of FAD to FADH2 . This enzyme is part of complex II and, like the other 
OXPHOS enzymes, resides in the mitochondrial inner membrane. Following the 
oxidation of FADH2 electrons are transferred to the Fe-S clusters of complex II, and then 
via coenzyme Q to thecytochrome b of complex III. Complex II consists of four subunits 
all encoded by nuclear genes. The free energy change of the catalysed reaction is small 
and therefore this enzyme does not translocate protons.
1.2.5 Complex III (ubiquinone-cvtochrome c oxidoreductase)
Complex III is the second of the three proton pumps of the respiratory chain. It catalyses 
the transfer of electrons from QH2 to cytochrome c, a water-soluble protein loosely 
associated with the inner membrane. This is linked to the pumping of protons across the 
inner mitochondrial membrane. Due to its lower thermodynamic driving force the 
transfer of one electron pumps only two protons, making it half as effective as complex I. 
Complex III contains cytochromes b and cj, an iron sulphur protein, and 11 polypeptide 
subunits only one of which is encoded in mtDNA. The prosthetic group of all three of 
these cytochromes is iron-protoporphyrin IX (i.e. the same heme as found in myoglobin 
and haemaglobin). QH2 transfers one of its electrons to the Fe-S cluster of complex III. It 
then passes to cytochrome c\ and then cytochrome c. The second electron, now residing 
in a semiquinone (Q '), is transferred through the two heme groups of cytochrome b. Th^ 
different polypeptide microenvironments of each of these creates different electron 
affinities. The cytochrome b pathway enables the complex to efficiently funnel electrons 
from the two electron carrier QH2 to the one electron carrier cytochrome c 6.
1.2.6 Cytochromes
These are electron transferring proteins that contain a heme prosthetic group. Their iron 
atoms oscillate between the reduced ferrous (Fe2+) and oxidised ferric (Fe3+) state during 
electron transfer. Cytochrome c has been extremely well characterised since its high 
water solubility has made it easy to isolate. It consists of 104 amino acids and a 
covalently attached heme group. It is able to interact with both its oxidase and reductase 
through the strong electrostatic charges generated by its cluster of lysine side chains 
around the heme crevice on the face of the protein. Cytochrome c is present in all 
organisms that have mitochondrial respiratory chains. The cytochrome c of any species 
will interact with the cytochrome oxidase of any other species. Cytochrome c has 
remained highly conserved over the 1.5 billion years since the mitochondrial symbiotic 
relationship began, with 26 of the 104 residues remaining unchanged over this time.
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1.2.7 Complex IV (cytochrome c oxidase)
Complex IV consists of 13 polypeptide subunits, three encoded by mtDNA. It catalyses 
the transfer of four electrons from reduced ferrocytochrome c to molecular oxygen to 
form H2O. Complex IV consists of a protein backbone bound by two copper containing 
prosthetic groups, and two non-covalently attached heme A groups (a and a3).
Molecular oxygen is an ideal terminal acceptor of electrons, because its high affinity for 
electrons generates a large thermodynamic driving force for OXPHOS, and in contrast to 
other strong electron acceptors (e.g. F2) it reacts very slowly unless catalysed. However, 
partial reduction leads to the generation of superoxide anions. Complex IV reduces
2 1 j
molecular oxygen, via peroxy intermediates, between the Fe and Cu ions of its hemfe 
a3-Cue centre located in the mitochondrially encoded subunit I. This provides a strong 
reducing environment designed to prevent the release of partially reduced moieties. Four 
protons are translocated when a pair of electrons flows through the oxidase 9.
1.2.8 Complex V (ATP synthase)
Complex V phosphorylates ADP via a mechanism that differs from the synthesis of ATP 
during glycolysis. The latter occurs via high energy intermediates (e.g. 1,3-
biphosphoglycerate). Complex V consists of a 378 kDa FI unit of an o ^ y S s  subunit 
composition. This can act as an ATP synthase or an ATP hydrolase. It is attached to and 
transverses the inner membrane by a Fo stalk unit that acts as the proton channel. The role 
of the proton gradient is not to form ATP but to release it from the ATP synthase 10.
ATP and ADP do not cross the inner mitochondrial membrane freely, but rely upon a 
specific transport protein, adenine nucleotide translocator. The translocase is abundant 
accounting for 14% of inner mitochondrial membrane proteins.
The main factor regulating the rate of OXPHOS is the level of ADP. This regulation is 
called respiratory control. The level of ADP also affects the rate of the citric acid cycle.
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Therefore the system is designed so that electrons do not flow from fuel molecules to O2 
unless there is a requirement for ATP synthesis 6.
1.3 MITOCHONDRIAL DNA
The human nuclear genome of three billion base pairs contains within it only 
approximately 30,000 genes. The human mitochondrial genome is small by comparison, 
consisting of 16,569 base pairs arranged in a covalently closed, double stranded, circular 
molecule. Cells contain hundreds of mitochondria, and each of these mitochondria 
contains multiple copies of mtDNA located in the matrix n .
I
A diagram of the human mtDNA molecule is shown in figure 1.4. It encodes 13 
polypeptides, all of which are subunits of the MRC, 22 tRNAs, and 2 rRNAs 1>12’13. The 
two strands of the mtDNA duplex have different base compositions, and this allows the 
identification of a light (L) and a heavy (H) chain. The H strand contains most 
information, encoding 12 polypeptides, 2 rRNAs, and 14 tRNAs.
MtDNA has a number of features that distinguish it from nuclear DNA. Some genes 
overlap, and intergenic sequences are absent or limited to only a few base pairs. In this 
absence of introns, non-coding regions are limited primarily to the displacement or D- 
loop which plays a central role in the regulation of replication and transcription. In 
replicating cells this region contains a triple helix due to the binding of a short DNA 
strand to the L strand causing displacement of the H strand. Mitochondrial tRNA and 
rRNA genes are small, and termination codons of most protein genes are generated post 
transcriptionally 14.
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Figure 1.4
Map of the human mitochondrial genome, showing the 13 polypeptide-coding genes, and 
24 protein synthesis genes (12S and 16S ribosomal RNAs and 22 transfer RNAs (1-letter 
amino-acid code). OH = origin of replication of Heavy strand. Numbers refer to base 
pairs and those in bold print show common mutation sites, (from n )
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1.3.1 MtDNA replication
Mammalian mtDNA maintenance and propogation is wholly dependent upon nuclear 
encoded proteins, only a few of which have been identified to date. Replication of 
mammalian mtDNA has long ben recognized as unusual. The identification of 
intermediates containing long stretches of partially single stranded DNA led to the 
proposal of a strand asynchronous asymmetrical model (75 Clayton 1982), which 
stipulates two sites of initiation of DNA synthesis, one for each strand, which lie far 
apart. Synthesis of the leading H-strand starts at a point Oh in the major non-coding 
region, and proceeds two thirds of the way around the molecule, displacing the original fj 
strand, and then exposes the origin point of replication of the light strand Ol. DNA 
synthesis of the L strand then commences (77 Wong 1985).
More recently, an alternative synchronous model has been proposed (78 Holt 2000). In 
this model replication starts from a single poion at or near O h ,  and proceeds 
unidirectionally (5’—>3’) with the formation of short Okazaki fragments on the lagging 
strand (79 Kurosawa 1975). These two models may represent the two extremes of a 
single system, with the prevelant system depending upon the cellular environment (78 
Holt 2000).
DNA triplex moieties exist at the displacement or D-loop region. The third strand is 
approximately 0.5 kb long and arises from Oh (75 Clayton 1982). D-loop DNA synthesis 
appears to be preceded by the formation of an RNA primeroriginating at the L strand 
promotor (82 Kandg 1997 (81 Gillum 1978). D loops are thought to represent aborted 
replication intermediates, and most if not all are degraded. Termination of leading strand 
DNA synthesis is poorly understood, but may involve Termination Associated Sequences 
(TAS) in the major non-coding region (80 Doda 1981). The continuation of H strand 
synthesis beyond TAS is thought to mark a dedicated replication event.
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1.3.2 MtDNA transcription
The light and heavy mtDNA strands each have one major site for the initiation of 
transcription (ITLand IThi) located approximately 150 bp apart within the D-loop. These 
sites are embedded within a promoter element (HSP and LSP) that, with their upstream 
cis-acting enhancer elements, are critical for transcription. ITl and IThi function 
independently. A second initiation site for H strand transcription (ITH2) located at np 638 
in the tRNAphe gene may exist15.
Two /nms-acting proteins are known to be involved in transcription initiation. 
Mitochondrial transcription factor A (mtTFA) is a 25 kDa protein that confers selectivity 
on the binding of the second factor, an RNA polymerase, to the HSP and LSP 16. The 
major part of mtTFA consists of two DNA binding motifs that bind to the upstream
17enhancer regions to ensure that transcription proceeds in the correct direction . MtTFA 
may also induce conformational changes in the DNA that influence the access of RNA 
polymerase to the DNA 18, and be involved in the maintenance of mtDNA levels. 
Homozygous mtTFA knock-out mice are non-viable, and heterozygotes exhibit mtDNA
depletion, a quantitative defect of mtDNA 19. A further factor, mtTFB, with similarities to
20known RNA modifying enzymes, has been identified . Further trans-acting factors 
probably remain to be discovered.
The L strand is transcribed as a single polycistronic precursor 21. A dual H strand 
transcription initiation model has been proposed to explain the observation that the rate of 
transcription of rRNAs is greater than that of the mRNAs encoded on the H strand l5. 
This proposes that transcription is initiated infrequently from ITh2 resulting in 
transcription of the whole H strand, whereas IThi more frequently initiates transcription 
but is terminated at the 3’ end of the 16S rRNA gene. The latter results in transcription of 
both rRNA genes, plus tRNAphe and tRNAVal. A mitochondrial transcription termination 
factor (mtTERM) has been identified that has specificity for a tridecamer sequence within 
the tRNALeu(UUR) gene, and is the mechanism by which transcription of this shorter 
transcript is terminated 22. The DNA binding capacity of mtTERM is mediated by its
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three leucine zipper motifs and two basic domains 23. The exact mechanism of mtTERM 
is unclear. There is evidence that an additional factor may be necessary for termination 
activity. MtTERM may also inhibit L strand replication, but its role here is again unclear, 
because no L strand encoded genes are present downstream of this site 24. 
Polyadenylation of mitochondrial mRNAs and rRNAs, by an as yet unidentified enzyme, 
serves to stabilize the transcripts 25. This is achieved despite the lack of upstream 
polyadenylation signals like those found in nuclear mRNAs.
1.3.3 Mitochondrial DNA translation
The majority of mitochondrial genes are separated by tRNA genes, and their secondary 
structure is believed to provide punctuation marks for the transcription of mtDNA 14. 
Excision of tRNAs is achieved by a 5’ mtRNaseP and a 3’ tRNA precursor processing 
endonuclease 26. Some tRNA genes overlap, and may therefore be transcribed in a
77shortened form, with missing residues added later . Various other tRNA post- 
transcriptional modifications are required to ensure cloverleaf folding , and proper 
codon recognition 29. Efficient aminoacylation of tRNAs is dependent upon the 3’ 
addition of CCA by a nuclear encoded ATP(CTP)tRNA specific nucleotidyltransferase 
(mtCCA) located on chromosome 3p25.1 30. Other nuclear encoded enzymes, the 
aminoacyl tRNA synthetases, are responsible for charging mitochondrial tRNAs and their 
related amino acids. This group of enzymes catalyses the activation of amino acids and 
their subsequent linkage to tRNA molecules. At least one enzyme exists for each amino 
acid, and the reactions with both the tRNA and the amino acid are highly specific 31. In­
built mechanisms ensure a low error rate, for instance the enzyme for isoleucine will 
hydrolyse valine, which differs by only one methylene group, if it is bound inadvertently. 
Interaction with the tRNA is via the anticodon itself for some aminoacyl-tRNA 
synthetases, for others the recognition site resides in the 3’ acceptor stem, and for others 
recognition is via multiple determinants. ATP drives the reaction. Carboxyl group of 
amino acid is joined to the 3-hydroxyl terminus of the tRNA.
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The attachment of amino acids to tRNA molecules achieves two objectives. Firstly, the 
amino acids by themselves are not able to recognise the mRNA codons, and secondly this 
reaction activates the carboxyl group of the amino acid thus enabling the otherwise 
thermodynamically unfavorable reaction of peptide bond formation between the carboxly 
group of one amono acid and the hydroxyl group of another. The mitochondrial genome 
contains two tRNAScr (tRNASer<AGY) and tRNASer(UCN)), and two tRNAu " (tRNAUu<CUN) 
and tRNAUu(UUR)). A single enzyme performs sery lation of both tRNA species. This is 
despite the fact that they share no sequence motifs and differ structurally, with the 
tRNASer(AGY) lacking the entire dihydrouridine loop containing arm 2.
Protein synthesis is initiated by N-formyl methionyl, formed by the post-transcriptiona) 
action of methionyl-tRNA transformylase on methionyl-tRNA. Mitochondrial protein 
synthesis is considered to follow the classical model of protein synthesis as first described 
for E.coli. Thus during the first step this initiato tRNA will bind to the ribosomal P 
(peptidyl) site, while the other two sites for tRNA molecules, the aminoacyl (A) site and 
the exit (E) site, remain empty. Protein synthesis then proceeds in an amino to carboxyl 
direction by the sequential addition of amino acids to the carboxyl end of the growing 
peptidyl chain. One mitochondrial translation initiation factor has been identified (mtIF-
T92) on chromosome 2pl6-pl4 . It belongs to a family of GTPases that are molecular 
switches capable of alternating between an active (mtIF-2.GTP) and inactive (mtlF- 
2.GDP) conformation. It promotes the binding of N-formylmethionyl tRNA to the small 
ribosomal subunit in a GTP and mRNA-dependent reaction 33.
Mitochondrial ribosomes inhabit the matrix, and half of the population is attached to the 
inner mitochondrial membrane 34. They differ from ribosomes in the cytosol, but share a 
number of features with prokaryotic ribosomes. They have a low RNA, and high protein 
content. There are 29 mitochondrial ribosomal proteins (MRPs) in the small ribosomal 
subunit, and 48 in the large 35,36. Some are homologous to those found in E.coli. Others 
are apparently unique proteins, and some of these have previously been identified as pro- 
apoptotic proteins (death associated protein-3, and PDCD9), thus implicating 
mitochondria in cellular apoptotic signaling pathways 37 38. Some MRPs exist as several
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isoforms that may influence the decoding properties of the ribosome. The ribosomal 
population is therefore heterogeneous 38.
Mitochondrial mRNAs have limited ribosomal binding abilities, lacking the mechanisms 
used for this in the cytosol and in prokaryotes. Mitochondrial translational efficiency is 
low and may be a consequence of this 39. The small ribosomal unit binds mRNA tightly. 
This involves approximately 400 nucleotides but is a sequence independent process. This 
may explain why the shortest open reading frames of human mtDNA (ATPase 8 and 
NDL4) are both part of overlapping genes.
After initiation, elongation begins with the binding of an aminoacyl tRNA to thq 
ribosomal A (aminoacyl) site. Elongation of the mRNA product is facilitated by a number 
of elongation factors. The genes for several of these have been identified in humans (EF- 
Tu on chromosome 16pl 1.2, EF-Ts on chromosome 12q 13-q 14, EFG1 on chromosome 
3q35.1-q26.2 and EFG2 on chromosome 5ql3) 40'42. The process of translation 
elongation in E.coli is better established, and the human system is believed to be 
essentially similar. At the ribosomal A site mtEF-Tu forms a ternary complex with the 
correct amino-acyl-tRNA as determined by the codon. GTP is then hydrolysed, and EF- 
Tu.GDP leaves the ribosome. EF-Ts, the nucleotide exchange factor, replaces the GTP on 
EF-Tu to allow elongation to continue. Peptide bond formation is catalysed by the large 
ribosomal subunit, and the EF-G (like EF-Tu a GTPase), promotes the translocation of 
the tRNAs at the A and P sites to the P and E sites respectively. The mRNA is moved to 
expose the next codon to the A site. The deacylated tRNA is released from the site 43.
The initiator moves to the ribosomal E (exit) site before leaving the ribosome. The 
process is repeated as a new aminoacyl-tRNA binds to the now vacant A site. The whole 
process is powered by the hydolysis of GTP. Termination of translation requires several 
release factors (RF) that recognise and bind to stop codons at the A site, resulting in 
hydrolysis of the bond between the polypeptide chain and the tRNA at the P site. Other 
RFs serve to release the mRNA. The two ribosomal subunits then dissociate 44. A single
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putative human mitochondrial RF has been identified on chromosome 13q 14.1-q 14.3
45,46
1.3.4 Transfer RNA molecules
tRNAs are small ribonucleic acids, present in all organisms to ensure ribosome- 
dependent protein biosynthesis. More than 4300 sequences are documented including 
prokaryotic, eukaryotic-cytosolic, eukaryotic-chloroplastic, and eukaryotic-mitochondrial 
molecules 47. It is primarily the canonical tRNAs (bacterial and eukaryotic cytosolic 
tRNAs) that have been studied in most detail. Current knowledge encompasses structural 
features (including their cloverleaf secondary structure, conserved sets of primary 
elements, tertiary interactions, and L-shaped three dimensional structure), and functional 
aspects (including recognition of aminoacyl tRNA synthetases, translation initiation or 
elongation factors, and ribosomal proteins). In contrast, mitochondrial tRNAs are 
structurally and functionally more diverse, and less well understood than the canonical 
tRNAs 48’49.
The mitochondrial genetic code differs from the standard code in a number of ways. As a 
result mitochondria need only 22 tRNAs instead of the predicted 32 tRNAs to translate 
all codons. All known tRNA molecules are single chains of between 73 and 93 
ribonucleotides and molecular weight of approximately 25 kD. Other common features 
are that the 5’ end is always phosphorylated and the terminal residue is usually pG. At the 
3’ end the final residues are CCA, with the relevant amino acid attaching to the 3’ 
hydroxyl group of the terminal Adenosine. Approximately half of the nucleotides are 
base paired to form double helices. In this way all tRNA sequences can be written in a 
cloverleaf pattern. This uniform structure allows them all to interact with the same 
ribosomes, mRNAs and elongation factors. There are five groups of bases that are not 
base paired. The 3’ CCA terminal region, the TPC (ribothymidine, pseudouricil, 
cytosine) loop, the DHU loop containing several dihydrouracil residues, the anticodon 
loop, and an extra arm that contains a variable number of residues. Most bases in non­
helical regions participate in unusual hydrogen-bonding interactions, usually between
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non-complementary bases. The anticodon loop consists of seven bases that conform to 
the pattern: - 5’ pyrimidine - pyrimidine - X - Y - Z -  modified uridine -  variable base -  
3’. The tRNALeu(UUR) molecule is shown in figure 1.5.
Each tRNAs contain between 7 and 15 unusual bases. These are formed by enzymatic 
modification of A U C and G, and include Inosine (I), pseudouridine (VF), dihydrouridine 
(UH2), ribothymidine (T), and methylated derivatives of Guanosine and Inosine. 
Methylation inhibits the formation of certain base pairings and thus makes the base 
available for alternative interactions that may be of importance to the stability of the 
molecule. Methylation can also alter the hydrophobicity of regions of the tRNA and 
thereby alter the interaction with synthetases, ribosomal proteins, and folding and otheif 
mechanisms. Other modifications can have an effect on codon recognition.
The first tRNA base sequence was established by Holley in 1965 50. This was the yeast 
alanine tRNA, a 76 ribonucleotide chain. The three dimensional structure of yeast 
tRNAphe was established in 1974 by x-ray crystallography 51. They were shown to be “L” 
shaped structures with the two arms of the “L” formed by two double helix segments. 
This structure places the CCA terminus at one end of the “L”, and the anticodon loop 
approximately 80 A0 away at the other end of the “L”. This large distance may be 
functionally important to allow the molecule to accomplish its two separate tasks of 
recognising both the correct mRNA codon, and the correct aminoacyl tRNA synthetase. 
The DHU and TT'C loops lie at the comer of the “L”.
Codon recognition is achieved by base pairing with the tRNA anticodon. The amino acid 
in the aminoacyl-tRNA does not play a role in this. Some tRNAs are able to recognise 
more than one codon. The yeast tRNAAIa investigated by Holley can recognise GCU, 
GCC, and GCA. Models of various base pairs to determine the distance and angle 
between the glycosidic bonds. If some steric freedom or “wobble” is allowed certain base 
pairings are allowed at the third base pair position. These are C:G, A:U, U:A or G, G: U 
or C, I: U or C or A, (codomanticodon). The number of codons read by an anticodon is 
determined by its first base. Those beginning G or C will read 1 codon, those beginning U
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or G two, and those that start with Inosine, formed by the post transcriptional 
deamination of adenosine, read three codons. Therefore part of the degeneracy of the 
genetic code arises from wobble in the pairing of the third position of the codon and the 
first position of the anticodon.
Mitochondrial tRNAs show a number if differences from cytosolic tRNAs. Cloverleaf 
folding occurs in all but the tRNA Ser(AGY) group, but exhibits large size variations 
especially within the T-loops. This aspect of tRNA structure is highly conserved in the 
canonical tRNAs. Furthermore all mt tRNAs have a variable region restricted to 3 to 5 
nucleotides, as opposed to the standard 23 nucleotides variable region in canonical 
tRNAs 47. The degree of conservation of nucleotides in the primary sequence also differ^ 
greatly from non-mitochondrial tRNAs. These are often nucleotides involved in tertiary 
folding, implying that mt tRNAs probably have their own set of folding rules.
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Figure 1.5
The mitochondrial tRNALue(UUR) molecule, showing its nucleotide sequence, amino acid 
acceptor stem, dihydrouridine loop, TT'C loop, anticodon, and sites of common 
mutations, (from 115)
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1.4 MITOCHONDRIAL IMPORT
Nuclear genes encode the vast majority of mitochondrial proteins. Therefore, in order to 
reach their target organelle these nuclear encoded mitochondrial proteins rely upon 
transport mechanisms to reach their intended target. Protein translocation across and into 
the mitochondrial membranes involves at least four specialised translocation systems. A 
single general translocase (the TOM complex) is present in the outer membrane and is 
responsible for the transfer of all nuclear encoded mitochondrial proteins through the 
outer membrane 52. The inner membrane however contains three distinct translocases, 
each for different classes of preproteins. Some mitochondrial preproteins, transcribed on 
cytosolic ribosomes, contain an N-terminal mitochondrial targeting sequence. Th^ 
preprotein interacts with the inner membrane surface and then inserts into the preprotein 
translocase of the inner membrane (TIM 23 complex). Hydrophobic preproteins with 
internal targeting signals rely on the TIM 22 complex for insertion into the inner 
membrane. The OXA translocase controls the insertion of preproteins and 
mitochondrially encoded proteins from the mitochondrial matrix into the mitochondrial 
inner membrane 53. Translocation through the outer and inner membrane is completed by 
the mitochondrial HSP 70-ATP dependent driving system associated with the TIM 
complex. The preproteins also undergo proteolytic processing in the mitochondrial 
matrix. Protein folding is achieved by molecular chaperone systems, mtHSP70, HSP60, 
and associated co-chaperones 54. Successful translocation across the inner membrane 
requires ATP and the presence of the mitochondrial membrane potential. Insertion into 
the membrane requires the membrane potential only.
1.5 CYBRID TECHNOLOGY
The ability to deplete cells of their mtDNA whilst maintaining their viability has allowed 
the development of cybrid technology. This has proved a powerful tool in the 
investigation of mitochondrial disorders. MtDNA replication can be inhibited by 
ethidium bromide. This intercalates with DNA and at low concentrations (0.1-2jig/ml)
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inhibits mtDNA replication without affecting nuclear DNA 55,56. Dideoxycytosine and 
azidothymidine also result in depletion of mtDNA levels but achieve this effect by the 
inhibition of mtDNA polymerase y 57,58. Cells lacking mtDNA are termed rho-zero (p°).
Rho-zero yeast cells remains viable if supplemented with a fermentable energy source. 
Human cells however cannot survive even in a high glucose environment 59. Pyrimidine 
synthesis is also deficient in these cells because dihydrooratate dehydrogenase, an 
enzyme of the pyrimidine synthesis pathway located on the mitochondrial inner 
membrane requires mitochondrial electron transport for normal function 60. Uridine 
supplementation is therefore necessary for cell survival. The addition of pyruvate to the 
culture medium is also required. The reason for this requirement is uncertain but probably 
relates to the need for excess cytoplasmic NADH to be oxidised to NAD in order for 
glycolysis to proceed. This is achieved by the conversion of pyruvate to lactate via lactate 
dehydrogenase. Additional pyruvate is therefore required to provide sufficient levels for 
entry into the tricarboxylic acid cycle 61.
The generation of cytoplasts, by the enucleation of mammalian cells provides a source of 
mitochondrial DNA devoid of nuclear DNA. Their subsequent fusion with p° cells 
(containing nuclear DNA but devoid of mitochondrial DNA) to generate cybrids allows 
the mixing of mtDNA with novel nuclear backgrounds 62'64. After its initial development 
this technique also proved applicable to human cells 61. Repopulated cybrids with 
functioning mitochondria are able to grow in the absence of uridine and pyruvate 59. 
Nuclear markers are also required to exclude the presence of nucleated donor cells, 
because most enucleation procedures will leave some residual intact nucleated cells 59. 
“206” osteosarcoma cells are thmidine kinase deficient and therefore able to survive in 
the presence of bromodeoxy Uridine since toxic products are not generated. A549 lung 
carcinoma cell lines are resistant to Geneticin. Alternatively, platelets can be used to 
provide an easily obtainable, naturally enucleated source of mitochondria 65.
Cybrid technology therefore allows the study of specific mtDNA genotypes containing 
mutations and nuclear-mitochondrial genomic interactions at the cellular, molecular, and
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biochemical level. The persistence of a biochemical defect after transfer of mtDNA to a 
new nuclear environment is considered proof of a mtDNA aetiology of the defect 66. If 
the defect is complemented then a nuclear origin for the defect is implicated. Cybrid 
technology also allows the generation of clones containing a range of mutant loads from 
0 to 100%. This is an important resource in the investigation of molecular mechanisms 
underlying mtDNA mutations. The persistence of altered protein synthesis and 
respiratory chain deficiencies after the introduction of mtDNA harbouring the A3243G 
mutation into 206 p° cells was the first functional proof of the pathogenicity of this 
common MELAS mutation. A threshold value of 6% wild type mtDNA, sufficient to
67 68restore the normal biochemical parameters, was also established by this technique ’ . 
The same technique revealed that mutant levels above 60% resulted in the synthesis of 
little or no ND6 complex I subunit, and impaired complex I activity. Clones of similar 
mutant load showed markedly different levels of O2 consumption with pyruvate. Mutant 
levels above 95% showed a consistently reduced complex I, III, and IV activities with a 
marked generalised reduction in levels of mitochondrial translation products 69. In a 
similar way platelet fusion experiments proved the mtDNA genotype containing the 
common MERRF A8344G mutation to be causal 65.
Cybrid technology was also used to demonstrate the nuclear origin of mtDNA depletion 
syndromes. Patient fibroblasts with mtDNA levels below 2% and impairment of all 
respiratory chain enzymes, were enucleated and fused with A549 p° cells. This led to the 
restoration of mtDNA levels and MRC function confirming that nuclear genes were 
responsible for this disorder70. The nuclear origin of COX deficient Leigh syndrome was 
shown in a similar manner71.
1.6 THE GENETICS OF MITOCHONDRIAL RESPIRATORY CHAIN 
DYSFUNCTION.
In the 1.5 billion years since the incorporation of mitochondria into eukaryotic cells, a 
complex symbiotic relationship has developed. Mitochondria are no longer self
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supporting. Nuclear genes encode 72 of the 85 subunits that make up the MRC. All other 
non-respiratory chain proteins within a fully functioning mitochondrion, numbering in 
excess of 1000, are also nuclear encoded. The human genome contains an estimated 
30,000 genes, and thus 3% of the nuclear genome is devoted to the function of a single 
organelle, the mitochondrion n . Therefore, the majority of mitochondrial proteins are 
encoded by nuclear genes, translated in the cytoplasm usually as precursors with an N- 
terminal mitochondrial targeting sequence, and then transported across one or both of the 
mitochondrial membranes. Once inside the mitochondrion they may require cleavage of 
the targeting sequence and further modification by assembly and other factors n . 
Furthermore, although mtDNA encodes all the tRNAs required for mitochondrial 
translation, these tRNAs need to be charged by aminoacyl-tRNA synthases that are; 
nuclear encoded. In addition although mtDNA encodes two rRNAs, all the associated 
mammalian mitochondrial ribosomal proteins are the products of nuclear genes that also 
require importation to the mitochondrion from the cytosol.
In the short history of mitochondrial medicine innumerable rearrangements and over 130
79point mutations have been described . The mutation rate of mtDNA is estimated to be 5 
to 100 times that of nuclear DNA, due to the oxidative environment, and poor repair 
mechanisms of mtDNA 73,74. However, in children with an isolated or combined 
OXPHOS enzyme deficiency, a mtDNA mutation is identifiable in only 5-10% of cases
75,76
MRC dysfunction can be a consequence of mutations within either mitochondrial or 
nuclear DNA. MtDNA mutations can be either rearrangements or point mutations. 
Rearrangements are usually deletions, but also include duplications. MtDNA deletions 
result in the loss of protein coding genes, tRNAs or rRNAs, but can also generate novel 
fusion products. Point mutations can involve protein coding genes, rRNAs or tRNAs. Of 
all point mutations a third are located in mtDNA encoded polypeptides (18 in complex I 
mtDNA subunits, 14 in cytochrome b subunits of complex III, 11 in complex IV subunits, 
and 5 in complex V all of which lie within the ATPase 6 subunit gene).
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The first nuclear gene mutation causing a mitochondrial respiratory chain defect in 
humans was reported by Bourgeron in 1995 11. In two siblings with complex II deficiency 
presenting as Leigh syndrome, an Arg554Trp substitution was detected in a conserved 
domain of the nuclear-encoded flavoprotein subunit gene of succinate dehydrogenase 
(SDH). The mutation was shown to have a deleterious effect on the catalytic activity of 
SDH (complex II) in an SDH- yeast strain transformed with mutant Fp cDNA.
To date, mutations in nuclear encoded OXPHOS subunits have been identified in 
complex I subunits (NDUFS4 in four patients with Leigh syndrome (LS), NDUFS7 in 
two siblings with LS, NDUFS8 in a singleton with LS, and NDUFV1 in two infants with 
leukodystrophy and myoclonic epilepsy, and three LS patients, NDUFS2 in three familiesj 
affected by cardiomyopathy and encephalomyopathy, and NDUFS1 in three unrelated LS 
patients) 78-85. Mutations in the FP subunit of complex II were responsible for late onset 
neurodegenerative disease in two sisters with optic atrophy, ataxia, and proximal 
myopathy 86. Two families have also been described with mutations of complex II 
associated with LS 77,87. Three different families with hereditary paragangliomas have 
been linked to the PGL1, PGL2, and PGL3 loci. Mutations in SDHD and SDHC are 
responsible for PGL1 and PGL3 respectively. These are the smallest subunits of complex 
II and are responsible for anchoring the enzyme to the inner mitochondrial membrane 
88,89. Mutations in the region of SDHD have also been identified in non-familial 
phaeochromocytoma 90 (Table 1.4). In a few unrelated families a syndrome of muscle 
coenzyme Qi0 deficiency causing recurrent myoglobinuria, seizures, ataxia and mental 
retardation, with ragged red fibres, the histological hallmark of mitochondrial 
myopathies, and lipid storage in muscle is described 91. Cases lacking myoglobinuria and 
with mild myopathic signs are also seen. These are attributed to defects in coenzyme Qi0 
synthesis and respond to coenzyme Qio supplementation 91-94. To date, mutations in 
nuclear encoded complex III or IV subunits have not been described.
Our knowledge of the 70 human nuclear genes that encode the subunit building blocks of 
the OXPHOS system has grown. Mutation identification has focused on those nuclear 
subunits with a high degree of evolutionary conservation, and established functional
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significance. It has subsequently become apparent that most nuclear gene mutations 
resulting in mitochondrial disease lie not in these genes, but in genes for proteins 
involved in the regulation of transcription, translation, post-transcriptional modification, 
mitochondrial signaling, folding and assembly, or the transport of nucleotides and 
metabolites 72. Approximately 340 of these genes are known to be involved in 
mitochondrial maintenance and assembly in Saccharomyces cerevisiae 95. A number of 
these genes are now identified in humans and those associated with the archetypal 
mitochondrial encephalomyopathies are discussed under the relevant sections below. 
Mutations in the dystonia deafness protein, a human homologue of the yeast 
mitochondrial import protein Tim8p, are responsible for Mohr-Tranebjaerg syndrome 96. 
This is the first example of defective mitochondrial import in human disease and i^  
discussed further in Chapter 5. Future efforts using human expressed sequence tag 
databases and known genes of lower species to identify candidate genes should expand 
this area of mitochondrial biology.
1.7 GENETIC FEATURES OF MITOCHONDRIAL DNA DISEASES.
Diseases associated with mtDNA mutations are characterised by their diverse 
manifestations. They have a predilection for the neuromuscular system and can manifest 
with disease affecting any part of the neuraxis. Their presenting features are often 
commonly occurring neurological symptoms such as stroke, epilepsy, neuropathy, 
movement disorders, dementia, ocular disease and deafness. Mitochondrial disorders 
often cause multi-system disease with endocrine, heamatological, gastrointestinal, 
hepatic, renal, dermatological, psychiatric, ophthalmological, and cardiovascular 
manifestations. Age of onset can cover a wide range even for specific disease entities. 
The relationship between phenotype and genotype is notoriously poor. A single 
phenotype can invariably result from multiple mtDNA mutations, and a single mutation 
may result in a wide range of phenotypes. Phenotypic variability may be marked even 
within a single family. A reported family with the A8344G common myoclonic epilepsy 
and ragged red fibres (MERRF) mutation illustrates this point. Within the family different
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members presented with Leigh syndrome, spinocerebellar degeneration, or atypical 
Charcot-Marie-Tooth disease. Even within those presenting with a phenotype of 
spinocerebellar degeneration cases varied from age of onset in late childhood with death 
aged 73 years, to onset aged 20 years and death at 40. This family illustrated another 
common finding in mitochondrial disease in that when they were first reported they were 
classified as an unknown neurological disease of autosomal dominant inheritance. When 
they were re-reported the ascertainment of oligosymptomatic subclinical cases revealed 
the maternal pattern of inheritance.
A number of genetic features peculiar to mitochondrial DNA that distinguish it from 
Mendelian genetics may underlie the clinical diversity of these conditions. j
1.7.1 Maternal inheritance
The ovum contains several hundred mitochondria and these, each containing several 
copies of mtDNA, contribute to the zygote. The sperm in contrast, despite containing 
mitochondria to power its motility, have been believed to contribute no mtDNA material 
to their offspring 97. Paternal mtDNA may be excluded from the zygote simply because 
sperm mitochondria fail to gain access to the interior of the oocyte. Alternatively, if 
sperm mitochondria do gain access they may be lost from the zygote due to a dilutional 
effect. Other mechanisms, including molecular surveillance mechanisms have also been
QO
proposed . Therefore, if inheritance is purely maternal, a mother harbouring a mtDNA 
mutation would pass it on to all her offspring, but only her daughters would pass it on to 
subsequent generations " .  Recent evidence however has proposed that paternal mtDNA 
inheritance does in fact occur. Schwartz and Vissing described a patient with exercise 
intolerance, lactic acidosis after minimal exertion, and RRFs. MtDNA sequencing 
revealed a 2 bp deletion in the ND2 gene in 90% of muscle mtDNA, but absent from 
lymphocyte mtDNA. Sequencing of the parents mtDNA revealed a paternal haplotype 
that matched the patients muscle mtDNA, but a maternal haplotype that matched the 
patients lymphocyte mtDNA. The 2 bp deletion was not present in either parent and is 
assumed to have arisen as a new mutation in the paternal germ line or during
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embryogenesis. In embryogenesis metabolic needs are met by glycolysis and there is 
therefore no selection against mutant mtDNA 10°. Paternal mtDNA transmission has 
previously been reported only as a very rare event that occurs in crosses of different 
strains of laboratory mice 101. Its occurrence in humans has not previously been reported, 
although detection methods may have been sub optimal.
Alternatively, mitochondrial disease caused by nuclear gene mutations may exhibit X- 
linked, autosomal dominant or autosomal recessive patterns of inheritance (table 1.1).
j
Table 1.1 Inheritance of Genetically Determined OXPHOS Disorders
Nuclear Gene Defects Inheritance
Structural OXPHOS genes AR
Non-structural OXPHOS genes
Assembly defects AR
Import defects XR
nDNA-mtDNA communication AR
Mitochondrial DNA defects
Point mutations Maternal
Single deletions Sporadic
Multiple deletions AR/ AD
Depletion AR
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1.7.2 Heteroplasmv
Each cell contains two alleles of each nuclear gene, one paternally, and one maternally 
derived. Each cell however contains several hundred to several thousands mitochondria, 
each of which contains several mtDNA molecules 102. Each cell therefore contains several 
thousand copies of each mtDNA genome. Silent polymorphisms in mtDNA usually affect 
all mtDNA molecules in a given individual, a state known as homoplasmy. In contrast, 
pathogenic mtDNA mutations usually affect a proportion of these molecules in each state. 
They therefore coexist with wild type molecules, a state known as heteroplasmy. The 
ratio of mutant to wild type can vary from cell to cell, and tissue to tissue. This mutant 
load can also vary over time if one population expands more rapidly than the other, or if a 
certain cell with a particularly high or low mutant load proliferates faster than other cells. 
This segregation may occur as a random event or due to selection advantages of 
particular cells.
MtDNA pathogenic mutations may exist in the homoplasmic state contrary to the above 
rule. For some time this has been known to be true for mutations causing Leber’s 
Hereditary Optic Neuropathy 103, but more recently further evidence has accumulated 
regarding pathogenic homoplasmic mtDNA mutations 104. A 35 year old woman was 
described who in ten pregnancies from four partners, had had one therapeutic 
termination, one live child with Leigh syndrome, and eight infant deaths, usually from 
cardiac failure and lactic acidosis at a maximum of 85 hours. Three of her siblings had 
died in early infancy. She herself had a past history of migraine, and a proximal 
myopathy was evident on examination. Muscle biopsy revealed a uniform decrease in 
COX activity, instead of the usual mosaic pattern seen as a consequence of heteroplasmic 
mutations. MtDNA sequencing revealed a C1624T tRNAVal mutation in the highly 
conserved dihydrouridine loop. The explanation for the mother’s relatively asymptomatic 
survival remains a mystery 104.
1.7.3 The Threshold Effect
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MtDNA mutations need to be present above a specific level before biochemical 
impairment and clinical features occur. This level or threshold varies between mutations 
and tissue types. In general the threshold is lower for more aerobically dependant tissues. 
In vitro studies have shown that both the A3243G and A8344G mutations cause a 
mitochondrial respiratory chain defect and impair intramitochondrial protein synthesis 
once the level of mutant mtDNA exceeds about 85% 66’105‘107. The extent to which this 
single factor accounts for phenotypical variation remains to be established. A high level 
of correlation between mutation load and clinical phenotype has been found in some 
studies 108' 110? but not in others 107’11M14. Other unidentified factors, environmental or 
genetic, have also been suggested to determine phenotype via modulation of the primary 
mtDNA defect115116’117.
1.7.4 Mitotic segregation
At cell division wild-type and mutant mtDNA molecules may segregate to the daughter 
cells unevenly. The level of heteroplasmy can therefore shift between passages of cells. 
Thus during embryogenesis larger amounts of mutant mtDNA can move into different 
cell lineages. This process of shift also means that thresholds can be exceeded at any 
point in time. The tissue distribution of different mtDNA mutations differs. Deletions, 
unlike point mutations are rarely present in peripheral blood samples. The variable 
segregation to different cell lineages could be an important factor in determining 
phenotype. If this theory were correct it would imply that the passing of deletions into all 
three germ layers would result in the Keam Sayre syndrome (KSS),segregation into the 
haematopoietic lineage would cause Pearson marrow-pancreas syndrome, and 
segregation to muscle alone would result in chronic progressive external ophthalmoplegia 
(CPEO) " 8.
1.7.5 The Bottleneck Phenomenon
A fertilised oocyte contains approximately 100,000 mtDNA molecules 119. However only 
about 1000 of these will eventually repopulate the foetus. This dramatic reduction is
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thought to take place in early oogenesis and is referred to as the bottleneck. This 
phenomenon was first observed in Holstein cows when heteroplasmy at position 346
1 on •shifted towards homoplasmy within a single generation . Neutral mitochondrial 
genotypes were shown to segregate in different directions in the offspring of the same 
female. Heteroplasmy was shown to return to homoplasmy within only two or three 
generations. Previous insect studies had suggested much slower rates of mtDNA 
segregation. Fundamental differences are believed to exist in the mechanisms of 
mitochondrial gene transmission between different taxa. As a consequence of the 
bottleneck phenomenon the evolution of a polymorphism through generations is difficult 
to predict.
!
1.7.6 Secondary MtDNA mutations
There is evidence that secondary mutations, mitochondrial or nuclear, may influence the 
clinical or biochemical effect of primary mtDNA mutations. For example the A3243G 
common MELAS mutation has been shown to be 2.7 times more likely to cause stroke­
like episodes if an A12308G nucleotide change is also present 1 2 This secondary 
mutation exists as a neutral polymorphism in 16% of the population. Also in vitro studies 
have shown that the biochemical effects of the A3243G mutation are ameliorated by the 
presence of a G12300A mutation in the tRNA Leu(CUN) gene 122. This was identified from 
a cell line containing 99% A3243G mutant mtDNA and exhibiting a severe defect in 
mitochondrial respiratory metabolism. A spontaneous derivative was isolated that, whilst 
still containing 99% mutant mtDNA levels, had reverted to the wild type phenotype as 
determined by normal respiration, growth characteristics in selective media, 
mitochondrial protein synthesis, and biogenesis of mitochondrial membrane complexes. 
The secondary G12300A heteroplasmic mutation within the tRNA Leu(CUN) gene was 
detected in this clone, and accounted for approximately 10% of its total mtDNA. The 
secondary mutation was predicted to generate a suppressor tRNA with the ability to 
decode UUR leucine codons, thus bypassing the deleterious effects of the A3243G tRNA 
Leu(UUR) mutation.
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1.7.7 Immunological and Environmental factors
Evidence also exists for a role of immunological and environmental factors. The effects 
of ageing on the mitochondrial genome and the fact that some subunits show tissue 
specificity (such as 2 of the 13 complex IV subunits) may also be of importance in 
determining phenotypic expression.
1.8 MITOCHONDRIAL DISEASE
As our knowledge of the genetic mechanisms underlying mitochondrial disease has
expanded, the need has arisen for a revised classification of these disorders 123’124. They
are now classified as class I (primary), and class II (secondary) OXPHOS defects to
incorporate the concept of disease originating from either mitochondrial or nuclear
1 2genome defects (see table 1.2) ’ . The former represents the archetypal mitochondrial 
encephalomyopathies. Class II disorders are predominantly neurodegenerative disorders.
1.8.1 THE ARCHETYPAL MITOCHONDRIAL ENCEPHALOMYOPATHIES
The mitochondrial encephalomyopathies are a clinically diverse group of disorders. This 
diversity combined with their multi-system nature demands a high index of suspicion in 
order to ensure the detection of these progressive and potentially fatal disorders. The 
situation is further complicated by the complexities of mtDNA genetics, the limitations of 
investigation modalities including genetic analysis, uncertainties regarding potential 
therapeutic agents, and further limitations regarding prognostication.
The incidence of the mitochondrial encephalomyopathies is undoubtedly higher than 
often appreciated. An epidemiological study in Finland covered a population of 245,201 
and identified 615 individuals with any of the symptoms reported to occur in the 
mitochondrial encephalomyopathy, lactic acidosis and stroke like episodes syndrome 
(MELAS). 480 of these were analysed for the common A3243G MELAS mtDNA point 
mutation. A mutation frequency of above 16.3/100,000 of the adult population was
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Table 1.2
MITOCHONDRIAL DISORDERS 
(Classification according to Leonard + Schapira 2001)
Class I: Primary OXPHOS defects
a. MtDNA mutations
i. large scale deletions, duplications involving protein coding genes and tRNA 
genes
ii. mutations of protein coding genes e.g. point mutations, small rearrangements.
iii. mutations of tRNA and rRNA genes.
b. Mutations of nuclear encoding OXPHOS subunits
including mutations affecting the gene promoter, mature protein or its mitochondrial 
targeting sequence.
Class II: Secondary OXPHOS defects
a. Genetic
i. abnormalities of mtDNA induced by nuclear gene defects affecting mtDNA 
transcription, translation, or replication.
e.g. autosomal dominant or recessive multiple deletions, or mtDNA depletion.
ii. direct damage to mtDNA or defects of mtDNA repair
e.g. frataxin deficiency and oxidative damage in Friedreich’s ataxia
iii. defects of the import pathway of nuclear encoded OXPHOSsubunits 
e.g. membrane receptors, protein processing, etc
iv. defects of the assembly of OXPHOS
e.g. chaperone mutations, defects of heme synthesis
b. Toxic
i. endogenous
e.g. free radicals including superoxide, nitric oxide, peroxynitrite
ii. exogenous
e.g. 1 -methyl-4-phenyl 1,2,3,6 tetrahydropyridine, 3-nitropropionic acid, malonic 
acid, isoquinolines
established 125. The high prevalence of the common MELAS mutation in the adult 
population suggests that mitochondrial disorders constitute one of the largest diagnostic 
categories of neurogenetic disease. A study in the northeast of England estimated a 
minimum point prevalence of 7.59/100,000 in those under the age of sixty-five years. 
12.48/100,000 either had mtDNA disease or were at risk of developing it. This would 
make mtDNA disease as common as amyotrophic lateral sclerosis (point prevelance 
6:100,000, annual incidence 1:50,000) or Huntington’s chorea (point prevelance 
5:100,000; annual incidence 0.4:100,000), and more common than Duchenne muscular 
dystrophy(prevelance 3:100,000, incidence among live bom males 20-30:100,000) or 
myotonic dystrophy (1:8000 live births) 126. Furthermore, the A3243G mutation has been 
found in 0.9% of unselected patients with diabetes mellitus (DM), and in 1.6% of those; 
with matrilineal DM 127.
The first report of disease resulting from mitochondrial respiratory chain dysfunction was 
published in 1962. A 35 year old woman developed severe euthyroid hypermetabolism 
and a mitochondrial respiratory chain defect resulting in the uncoupling of oxidation and 
phosphorylation in muscle mitochondria129. Further cases were reported 13°, and these 
cases also described heat intolerance, profuse sweating, polyphagia, and polydipsia 
without polyuria. Muscle weakness was mild. Ragged red fibres (RRFs) were found on 
skeletal muscle biopsy. This histological change, which came to be the defining feature of
i i i
mitochondrial myopathies , represents the peripheral and intermyofibrillar proliferation 
and accumulation of structurally abnormal mitochondria (Figure 1.5). RRFs were later 
noted to be associated with progressive external ophthalmoplegia 132 133 and with other 
myopathic syndromes lacking ophthalmolplegia. Subsequently, RRFs were also 
identified in patients with non-myopathic central nervous system manifestations of 
mitochondrial disease. This realisation led to the introduction of the term “mitochondrial 
encephalomyopathies”. Non-myopathic cases may present with any of a vast range of 
neurological symptoms including cognitive impairment manifesting as psychomotor 
retardation or dementia, movement disorders and ataxia, stroke, seizures, retinopathy or 
deafness, or peripheral neuropathy in various combinations and permutations, leading to 
the identification of the archetypal encephalomyopathies 134'136.
52
A number of mitochondrial encephalomyopathy syndromes have subsequently been 
delineated. Common to all is the phenotypic and genotypic diversity. The correlation 
between phenotype and genotype is poor and a complete explanation for this remains 
elusive. In the majority of these conditions, a wide range of potential clinical 
manifestations are described in addition to the core clinical features, and a wide range of 
disease causing mutations have been described, in addition to the commonest mutation.
1.8.1.1 Chronic Progressive External Ophthalmoplegia / Kearns Savre Syndrome 
(CPEO / KSSI
Chronic progressive external ophthalmoplegia is one of the commonest manifestations of 
mitochondrial myopathy. Presentation is with slowly progressive ptosis, and 
multidirectional limitation of eye movements, affecting upgaze maximally. In Kearns 
Sayre syndrome CPEO is accompanied by pigmentary retinopathy, and one or more of
1 ^ 7complete heart block, a CSF protein level of above 1 g/1, and ataxia
In 1988 Ian Holt made the seminal discovery of single large scale deletions on mtDNA in 
patients with mitochondrial myopathies 145. The following year Zeviani showed that these 
deletions were consistently associated with KSS 146. This mtDNA abnormality is 
detectable in DNA extracted from muscle samples of CPEO/KSS, but blood mtDNA 
analysis is normal. Deletions lack segments of DNA in the major arc between Oh and Ol 
and most are flanked by direct sequence repeats 147>148. These deletions are found in 80% 
of those with KSS, and 70% of those with CPEO 149. MtDNA duplications are also 
occasionally found 149. Conversely, all patients with single mtDNA deletions and 
neurological disease have CPEO, with only two exceptions to this rule described 150151. 
Histological examination of muscle reveals RRFs and a mosaic pattern of COX negative 
fibres. Patients with mtDNA deletions present as sporadic cases 152. Other CPEO patients 
show a maternal pattern of inheritance and in these cases mtDNA point mutations are 
detectable. This is most commonly the A3243G MELAS mutation, although several other 
point mutations have also been detected 153. Autosomal dominant and recessive pedigrees
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also occur. In contrast to sporadic cases, these are associated with multiple mtDNA 
deletions that arise secondary to nuclear gene defects 146’154. Three loci have been 
associated with adPEO, 4q34-35, chromosome 10q24, and 15q22-q26 155'158. Mutations 
in the genes encoding adenine nucleotide translocator (ANT-1), DNA polymerase y (Pol 
y), and Twinkle have been identified 159'161. ANT-1 forms a homodimeric inner 
mitochondrial membrane channel for the exchange of ADP into and ATP out of the 
mitochondrial matrix. In addition ANT is a component of the mitochondrial permeabiliy 
transition pore that has a pivotal role in mitochondrially-mediated apoptosis 159. Twinkle 
has homology to bacteriophage helicases, and mutations identified to date are believed to
1 ff)alter its dNTPase activity with consequent mitochondrial nucleotide pool imbalance 
Mutations of the catalytic unit of POLy have been identified, but their functional) 
significance is as yet undetermined 158. This finding suggests that disorders of mtDNA 
replication can also be responsible for mtDNA deletions. Models for the generation of 
deletions have been proposed and include “slip-replication” and “illegitimate-elongation”
163,164
The size of the deletion does not correlate with the clinical phenotype, in the same way 
that although a wide variety of deletions have been described, each removing a different 
set of mitochondrial genes, all KSS patients have fundamentally the same phenotype. 
This is thought to occur brcause mtDNA that remains and is transcribed, will still not be 
able to be translated due tot the fact that tRNAs, scattered around the genome are also 
removed by the deletion. Every documented pathogenic mutation in KSS or PEO 
removes at least 1 tRNA gene. If wild type mtDNA co-exists at a high enough level 
though, it can compliment this deficiency.
1.8.1.2 Mitochondrial Encephalomvopathv, Lactic Acidosis, and Stroke Like Episodes 
(MELAS)
In 1984, MELAS was described by Pavlakis as a distinct clinical syndrome within the 
spectrum of mitochondrial disorders171. This original report described two cases and nine 
other similar cases from the literature. Normal early development was later complicated 
by stunted growth, the development of focal and generalised seizures, and recurrent
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neurological deficits resembling strokes. Additional clinical features have been described 
in association with the core features of MELAS 172. The phenotypic consequences of this 
mutation and the common MERRF mutation have been compared (Table 1.3).
Of all cases meeting the clinical criteria for MELAS, 80 % are positive for an A to G 
transition at base pair 3243 within the tRNA LeuUUR gene 199’200. A large number of 
different mutations have also been found to result in the MELAS phenotype. A G13513A 
mutation in the ND5 gene was also associated with recurrent focal cortical brain 
hematomas in a child with MELAS 201. Conversely, of all cases with the 3243 mutation 
from an unselected population of 17 patients with mitochondrial myopathy, 50% were 
found to fulfil the criteria for MELAS at the time of clinical assessment140. Theoretically 
further cases could develop these clinical features with the passage of time. Mutations in 
protein coding genes (ND5 and COX III) have also been reported in patients with 
clinically typical MELAS 202'204.
1.8.1.2.1_____Pathogenesis of the A3243G common MELAS mutation:
Disease associated mutations have been identified in 20 of the 22 mt tRNA genes, and it 
seems likely that the two remaining tRNAs (tRNAArg and tRNAHls) will be added to this 
list in the future. Certain tRNAs such as tRNA1^ 171^ ,  tRNALys and tRNAIle appear to be 
hot spots for mutations whilst other tRNA genes are less often affected. Most pathogenic 
mutations affect highly conserved nucleotides whereas most polymorphic mutations 
affect rather non-conserved nucleotides. However exceptions to this rule do exist. 
Furthermore, the type of mutation (transition or transversion), the distribution on the 
secondary structural domains, and their structural effect in stems also fail to completely 
distinguish polymorphic and disease associated mt tRNA mutations.
Despite the identification of the A3243G common MELAS mutationin in 1990 199, an 
accepted explanation of how this mutation causes disease, and in particular how it causes 
such a diverse spectrum of phenotypes was slow to appear. This hampered the 
development of therapeutic interventions or preventative strategies which had to rely on
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educated guesses alone. A body of literature has focused on the relationship between 
mutant load, and tissue distribution of mutations and the severity of the clinical 
phenotype. Whilst there is a lot of evidence to support the threshold theory, it is also 
apparent that other factors must be involved in the pathway from mutation to disease.
Much of the initial investigations into the mechanism of the A3243G mutation focused on 
the fact that the mutation lies within the mtDNA binding site for mTERF, a protein factor 
that promotes termination of transcription at the 16S rRNA / tRNALeu(UUR) boundary. In 
vitro assays revealed a marked decrease in affinity of purified mTERF for the mutant 
target sequence. By contrast, in transformants carrying the MELAS mutation, despite 
severe protein synthesis and respiration defects, RNA transfer hybridisation experiment^ 
failed to show any significant change in the steady-state amounts of the two rRNA 
species encoded upstream of the termination site, and of the mRNAs encoded 
downstream 68’574. in addition the reduction in labelling of the various mitochondrial 
translation products in defective transformants is not correlated to their UIUR-encoded 
leucine content, thus arguing against an effect of the MELAS mutation on the function or 
stability of the tRNALeu(UUR) 575. Altered RNA processing has also been implicated in the 
pathogenesis of the A3243G mutation, after the identification of the accumulation of a 
novel RNA transcripts, termed RNA 19, in immortalised cell lines and patient tissue 
samples. This abnormal transcript corresponds to 16S rRNA plus tRNALeu(UUR) plus 
subunit 1 of the NADH-coenzyme Q-oxidoreductase gene 576.
Cybrid analysis has been a cornerstone of this field of research. This in vitro scenario has 
many potential limitations. Studies in osteosarcoma and lung carcinoma cell lines have 
suggested that the mutant tRNA is functionally deficient and thus less able to decode Leu 
UUR codons. Impaired aminoacylation 711’581j low levels of base modification within the 
D-stem 712, and low steady state levels in some cell lines122 but not others713 have all been 
observed. This loss of function mechanism would be consistent with the observed 
threshold effect that results in impaired MRC function and loss of mitochondrial protein 
synthesis.
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Other cybrid studies, predominantly those using Hela cells, have given conflicting results. 
Despite lower levels of the mutant tRNA aminoacylation is minimally affected . The 
mutant tRNA lacks the wobble base U hypermodification. This feature normally confers 
specificity of codon recognition, and without it phenylalanine UUY codons may also be 
translated by tRNALeu(UUR). This mechanism would confer a gain of function that would 
result in an impairment of mitochondrial protein synthesis.
The picture is complicated further by studies in patient derived lymphoblastoid cell lines 
that have shown no effect of the mutation on tRNALeu(UUR) levels or the level of 
mitochondrial protein synthesis. There was however reduction of the relative amounts of
CHQ
incorporation of leucine into some mitochondrial translation products . The inference 
was that the mutant tRNA may be mischarged with incorrect amino acids or that the 
affinity of the mutant tRNA for the codon is impaired allowing other tRNAs to 
incorporate the wrong amino acid at UUR codons. In this setting mutant levels as low as 
70% significantly reduced complex IV activity. Gain of function mechanisms would 
explain the presence of the disease in patients with mutant levels below the threshold 
levels found in cybrid studies. Other potential gain of function mechanisms have been 
proposed, and include a role for precursor-like RNA molecules that are believed to
1 7 7  C 7Qaccumulate in mutant cells and interfere with ribosome function ’ .
In vivo protein synthesis studies may clarify the picture but are currently lacking. 
However, it may be that these apparently conflicting views are in fact both correct. 
Studies in A549 cells support the loss of function hypothesis. A heteroplasmic anticodon 
mutation within tRNALeu(CUN) generates a novel tRNA capable of reading UUR. This 
suppresses the protein synthesis defect and respiratory impairment of cells with high 
A3243G mutant loads 122. This phenotype suppression effect is transmitted along with the 
“suppressor mtDNA” to successive generations 58°. In the 143B nuclear background 
abnormal translation products are present at mutant loads below the threshold levels 
normally accepted to cause total loss of mitochondrial translation 69. As in lymphoblasts 
respiratory deficiency occurs at levels at which protein synthesis appears normal 69,581. 
Despite proteins appearing to be synthesised at normal rates, the proteins generated may
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not be totally normal. Low but functionally significant levels of amino acid 
misincorporation have been reported 58°. High mutant A3243G levels have also been 
associated with as yet unidentified structural modification of tRNALeu*CUN* 122. This may 
represent a compensatory or partial suppressor mechanism allowing a proportion of 
tRNALeu(CUN) to read UUR codons.
The question will always remains as to whether all of these in vitro changes represent 
primary or secondary effects of the mutation. Cybrid studies utilise immortalised, usually 
tumour derived, cell lines. The nuclear material of these cells is not normal with high 
rates of aneuploidy that vary even within a single cell line and within a single culture.
i
In vivo studies of mutant tRNALeu(UUR) levels and aminoacylation efficiency in muscle 
biopsies from A3243G patients have shown defects of both in most patients. In some 
however, one parameter was low and the other normal, and in one patient no abnormality 
was apparent. Four different patterns were therefore seen. The patients studied however 
all had similar phenotypes at the far end of the spectrum of disease associated with this 
pathogenic mtDNA mutation 582.
The role of nuclear genes, mitochondrial haplotype, developmental background, and 
epigenetic factors remains unestablished. The primary effect of the mutation on tRNA 
function has also not been fully explored. Potential mechanisms of interest include the 
level of expression of other tRNAs, such as tRNAphe. Incorrect modification of normally 
aminoacylated mutant tRNALeu(UUR) may result in frequent misreading of the Phe codon. 
The Leu(UUR) and Phe tRNAs would then compete for the UUY codon and the 
generation of abnormal translation products would then depend upon the relative levels of 
these two tRNAs. TRNAphe synthesis is almost entirely dependent upon not the full 
length overlapping H strand, but the rRNA transcription unit, the termination of which is 
inhibited by the 3243 mutation 583. In a different background aminoacylation of the 
mutant tRNA may be the limiting factor. The relationship between mutant load and 
phenotype would therefore differ due to this loss of function mechanism. Recent studies 
have focused on wobble modification deficiency in mutant tRNAs in patients with
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mitochondrial diseases. Mt tRNALeu(UUR) containing the A3243G mutation has previously 
been shown to be deficient in a normal taurine containing modification (taum5U;5- 
taurinomethyluridine) at the anticodon wobble position. This is believed to result in a 
UUG codon specific translational defect (A5). This has been demonstrated in cybrid cells 
with different nuclear backgrounds as well as from patient tissues (Al). Correlation with 
clinical phenotype has also been shown by comparing tR N A ^ 00^  mutations known to 
cause a MELAS phenotype and those causing milder disease (A2).
Nuclear factors may influence the expression of mtDNA mutations. In yeast, a mutation 
in the initiation codon of the mitochondrial COX III was suppressed by a reduction in the 
level of cytoplasmic ribosomal protein SI8 584. This effect was believed to be mediatecj 
by changes in cytoplasmic translation accuracy or by products that affect mitochondrial 
protein synthesis. Suppression of mutated tRNA function has also been reported. Again 
in yeast, a mutated tRNAAsn causing impaired maturation could be compensated for by 
the presence of additional copies of the mitochondrial Ef-Tu and aspartyl-tRNA 
synthetase 585. In humans, a secondary mutation in tRNALeu(CUN) has been shown to 
suppress the effects of the archetypal MELAS A3243G tRNALeu(UUR) mutation. This
occurs because the secondary mutation enables the tRNA1^ 01^  to recognise UUR
122codons . Recently a G5703A mutation that causes a severe mitochondrial protein 
defect and a reduction in the steady state levels of tRNAAsn, has been shown to generate 
revertant lines due to presumed nuclear gene factors. These revertant clones contained 
homoplasmic levels of the mutation, but did not exhibit the biochemical defects and had 
normal OXPHOS activity. When the mitochondria were transferred to a novel nuclear 
background the original defective phenotype was restored 586.
The effect of mtRNA mutations on the pattern of mitochondrial proteins at a broader 
level has been assessed using comparative proteomics as a tool to evaluate several 
hundred mitochondrial proteins. In cybrid cell lines carrying the A3243G MELAS or the 
A8344G MERRF mutations, large quantitative decreases were apparent for COX Va and 
COX Via, two nuclear encoded subunits of cytochrome c oxidase. This finding opens yet
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another avenue through which to explore the pathogenic mechanisms of mitochondrial 
tRNA mutations.
1.8.1.3 Myoclonic Epilepsy and Ragged-Red Fibres (MERRF)
The syndrome of myoclonic epilepsy and red ragged fibres (MERRF) was first described 
in 1980 135, although the association between progressive myoclonic epilepsy and ragged 
red fibres had been described seven years previously 205. Subsequently the role of 
mtDNA mutations in the pathogenesis of MERRF was documented 206. The core clinical 
features are of myoclonus, ataxia, and seizures.
The most commonly detected mutation, found in approximately 80% of cases fulfilling 
the clinical criteria for MERRF, is at position 8344 within the tRNA Lys, and was first 
reported by Shoffner in 1990 206. The relationship between mutant load and phenotype 
has revealed a positive correlation in some reports 140>206’210 but not others 21 Other 
mutations within the same tRNA gene (T8356C and G8363C) are also described in 
association with MERRF 209>212. Insertion of a C nucleotide at position 7472 in the tRNA 
Serine UCN gene results in a syndrome of hearing loss, ataxia, and myoclonus that is 
very similar to MERRF 2I3. MERRF has also been reported in patients harbouring 
multiple mtDNA deletions 166, and overlap syndromes with features of both MERRF and 
MELAS have been reported for the T7572C and T8356C tRNA Serine(UCN) mutations.
MELAS and MERRF are thus both phenotypically highly variable, in terms of age of 
onset, organs involved and severity of symptoms 115’200 2,1> Both mutations in vitro cause 
mitochondrial respiratory chain defects, and impaired intramitochondrial protein 
synthesis, above a specific threshold of about 85% 210>216. it is generally accepted that 
variation in the percentage mutation load is the principle factor responsible for the varied 
clinical presentation of mtDNA defects 216)217 however previous studies have only found a 
weak correlation between the mutation load and the clinical phenotype 107’110’112-114 This 
may be explained by intercellular heteroplasmy but secondary factors as discussed above 
may also be aetiologically significant.
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Analysis of 245 individuals with the A3243G of A8344G mutation showed a strong 
correlation between the frequency of the more common clinical features and mutant load
I 8Ain muscle however no relationship with mutant load in blood was shown . Thus 
percentage mutant mitochondrial DNA in muscle has been proposed, but not yet widely 
accepted, as a useful prognostic indicator.
The relationship between maternal mutation load and the frequency of clinically affected 
offspring has also been examined in an attempt to guide genetic counseling . These 
studies concluded that the higher the level of mutant load in mother’s blood the higher the 
frequency of affected offspring, and at any one level of mutant load, the number of 
affected offspring was found to be always greater for the A3243G mutation than for the 
A8344G MERRF mutation. These two mutations both involve tRNA genes and have
136similar effects on respiratory chain function in vivo . The reason for different 
inheritance patterns is therefore unclear. Mothers with A3243G have a high (>25%) 
frequency of affected offspring what ever their mutant load. Women with less than 40%
918A8344G have a relatively low frequency of having an affected child . Prospective 
studies are required to provide sufficient information for predictive genetic counselling 
purposes.
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Table 1.3
Clinical features of the A8344G MERRF and A3243G MELAS mutations 
(from 186)
Clinical feature A3243G A8344G
Recurrent stroke 48% 1 %
CPEO 28 6
Diabetes mellitus 15 3
Pigmentary retinopathy 15 0
Deafness 44 39
Dementia 27 25
Epilepsy 50 43
Myopathy 53 70
Short stature 15 13
Lipomata 1 8
Optic atrophy 1 13
Neuropathy 5 24
Ataxia 24 50
Myoclonus 8 61
1.8.1.4 Neurogenic Muscle Weakness. Ataxia, and Retinitis Pigmentosa fNARP)
First described by Holt et al in 1990, the key features are peripheral neuropathy, ataxia, 
retinitis pigmentosa, seizures and dementia 219Inheritance is maternal. The commonest 
mutation is a T to G transversion at nucleotide position 8993. This causes a change from 
the highly conserved leucine to arginine within subunit 6 of the mitochondrial F0Fi ATP 
synthase. This mutation has also been identified in several cases of maternally inherited 
Leigh syndrome (MILS) 220, and both LS and MILS have been reported within the same
62
family 221. A T8993C transition replacing leucine with proline has been reported in one 
NARP/MILS family 222 and also in one patient with LS 223. Both of these mutations 
involve a conserved charged region of ATP synthase which is associated with the proton 
channel of this enzyme complex 224. These changes may interfere with the utilisation of 
the electrochemical gradient to produce ATP 10.
Patients with NARP usually have above 80% mutant mtDNA levels. With mutant 
mtDNA levels below 75% patients usually suffer from pigmentary retinopathy alone, or 
suffer migraines, or are asymptomatic 225. This illustrates the good correlation between 
mutant load and disease severity that is not present in the majority of the other 
mitochondrial encephalomyopathies.
1.8.1.5 Leigh Syndrome (LS)
This subacute necrotising encephalomyelopathy was first described in 195 1 228. Its 
characteristic neuropathology is of bilateral symmetrical focal necrotic lesions within the 
thalamus, extending into the pons, inferior olives and spinal cord. The clinical features of 
LS are of psychomotor retardation, hypotonia, failure to thrive, respiratory abnormalities, 
oculomotor disturbances, optic atrophy, seizures and lactic acidosis. Biochemical 
abnormalities include defects of oxidative phosphorylation (in particular complex I 229 or 
complex IV 23°, and deficiency of the pyruvate dehydrogenase complex 231 and 
biotinidase deficiency 232. Ragged-Red fibres are absent.
The majority of LS cases are believed to result from nuclear gene defects 233>234. This has 
been confirmed for cases of LS with deficiency of the PDH complex 233, complex I 80,
77and II . The majority of children with complex IV deficient LS harbour mutations in the 
surfeit-1 housekeeping gene 235>236. This gene is involved in the complex process of 
complex IV assembly 237’239. Mutations in other complex IV assembly genes have been 
identified. These include SC02 (Synthesis of Cytochrome Oxidase gene) mutations in 
three unrelated infants with fatal cardio-encephalomyopathy and isolated complex IV 
deficiency 240. All were compound heterozygotes and all had an E140K mutation on one
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allele. SCO 10 (heme A famesyltransferase) mutations have been identified in complex 
IV deficient patients with LS and DeToni-Fanconi-Debre syndrome 24 *. This enzyme 
catalyses the first step in the conversion of protoheme to the heme A prosthetic groups of 
cytochrome oxidase. SCOl mutations have also recently been reported in a single family 
with multiple cases of neonatal ketoacidotic coma and isolated COX deficiency 242. 
Deficiency of heat shock protein (Hsp) 60, a mitochondrial matrix protein involved in the 
assembly and folding of polypeptides into many complex mitochondrial enzymes, is also 
known to result in multiple mitochondrial inner membrane enzyme deficiencies, and a 
fatal systemic mitochondria disease 243,244. The underlying genetic defect is not 
established.
The BCS1 gene is involved in complex III assembly, and mutations within this gene have 
been detected in six patients from 4 unrelated families with neonatal proximal 
tubulopathy and hepatopathy 245. This gene may be a frequent cause of complex III 
deficiency.
Nuclear gene defects are also presumed to be causal for cases of LS with biotinidase 
deficiency. Mutations in the E la  subunit of PDH have been identified in X-linked and 
sporadic cases. Up to 20% of LS patients have the T to G, or T to C, mtDNA mutation at 
position 8993 within the ATPase 6 gene of complex V 234. Mutant loads are above 90%, 
and lower levels of this mutation are associated with the neurogenic muscle weakness, 
ataxia, and retinitis pigmentosa (NARP) syndrome. High levels of the A3243G MELAS 
mutation and the A8344G MERRF mutation have also been reported in LS 234. Other 
mtDNA mutations described include G1644T within the tRNA Val gene 246, and 
deletions 247 and depletion of mtDNA levels 248. The ATPase 6 mutations T8851C and 
T9176C are also associated with bilateral striatal necrosis and with maternally inherited
L g  249,250
1.8.1.6 Mitochondrial DNA Depletion Syndrome
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This quantitative disorder of mtDNA was first described in 1991 251. More than 30 cases 
of this severe (up to 99%) tissue specific reduction in total mtDNA copy number have 
now been described 252, and this syndrome thus represents a relatively common cause of 
lactic acidosis in infancy. Clinical heterogeneity is marked, but typically neonatal or 
infantile fatal lactic acidosis is associated with severe hypotonia, and progressive liver 
failure. Seizures, ophthalmoplegia, Fanconi syndrome, congestive cardiac failure, and 
cataracts are also described. The clinical course is often rapidly fatal with death before 
the first year.
There has been no evidence of maternal transmission. Some cases are sporadic, and some 
autosomal families are also described. In vitro complementation studies concluded a 
nuclear gene defect to be responsible for this syndrome 70. This syndrome is both 
clinically and genetically heterogeneous. Mutations in the deoxyguanosine kinase gene 
(DGUOK - chromosome 2p), and mitochondrial thymidine kinase gene (TK - 
chromosome 16q) have been identified in kindreds of Druze Israeli descent 254’255. Both 
of these enzymes are responsible for the salvage of nucleotides within mitochondria. 
There is no de novo synthesis of nucleotides within mitochondria, and their only other 
source is from the import of cytosolic nucleotides. In non replicating cells cytosolic 
dNTP synthesis is down regulated, forcing mitochondria to rely on these nucleotide 
scavenging pathways.
Depletion of mtDNA can also be secondary, occuring in inclusion body myositis, or 
iatrogenic, as occurs in patients receiving nucleoside analogues. MtDNA is also reported 
in Alpers’ syndrome and Navajo hepatopathy 256>257} but it is unclear whether it represents 
a primary or secondary event in these conditions.
1.8.1.7 Mvoneurogastrointestinal Encephalopathy (MNGIE')
This recessively inherited syndrome was first described in 198 7 258 and the term MNGIE 
was proposed in 1994 259. Diagnostic criteria include peripheral neuropathy, CPEO, 
gastrointestinal dysmotility, in combination with histological features, namely RRFs,
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259increased SDH staining or ultrastructurally abnormal mitochondria . A variety of 
oxidative phosphorylation enzyme defects have been reported in these patients including 
isolated partial complex IV defects and combined enzyme defects. Molecular defects are 
usually of multiple mtDNA deletions. MtDNA depletion is also described 
Homozygous and compound heterozygous mutations within the thymidine phosphorylase 
gene (chromosome 22ql3.32-ter) have been identified 261. The mechanism by which 
these mutations result in multiple deletions is uncertain.
1.8.2 THE NON-ENCEPHALOMYOPATHIC ARCHETYPAL MITOCHONDRIAL 
DISORDERS: i
Leber Hereditary Optic Neuropathy (LHON) is a maternally inherited bilateral acute or 
subacute painless optic neuropathy. 90% of patients present before the age of 45, with 
mean age of onset of 23 years. 85% of patients are male. The majority of cases result in 
severe and permanent visual loss. Acuity may deteriorate to less than 6/60 over a period 
of a few weeks 262.
Three mtDNA point mutations, all lying within the complex I genes, account for the vast 
majority of cases. The G11778A mutation in the ND4 gene is found in 50-70% of LHON 
cases, the G3460A mutation in ND1 in 15-25%. A mutation at nucleotide 14484, within 
the ND6 gene, is associated with a better prognosis with some visual recovery in 70% of 
those affected . The mutations are detectable in blood, and are often homoplasmic, in 
contrast to the point mutations found in the other mitochondrial encephalomyopathies.
Complex I deficiency has been demonstrated in the muscle and platelets of some patients
265 266’ . Only 15% of females carrying one of the primary mutations are clinically affected.
This led to the hypothesis of an X-linked susceptibility locus 267, but linkage analysis has 
not supported this 268.
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Pearson marrow-pancreas syndrome was described in four unrelated children in 1979. 
These infants presented with refractory sideroblastic anaemia, vacuolation of erythroid 
and myeloid precursors within the marrow, and exocrine pancreatic failure 295. All
• • 9Q f\reported cases harbour mtDNA rearrangements (deletion, duplication, or both) . Cases
907are usually sporadic, although maternal inheritance has been reported . Mortality in 
Pearson syndrome is high. Occasional cases show spontaneous improvement of the 
anaemia, reflecting the clearance of mutant mtDNA from rapidly dividing haematopoietic 
tissue. In slowly dividing tissues however mutant mtDNA may accumulate. In this way
9qo
multisystem features, including KSS, may gradually develop . The spectrum of 
mtDNA re-arrangements is similar in both KSS and Pearson syndrome, suggesting that 
they may both be part of the same disease entity although KSS is less clinically severe). 
There is no correlation between the type, size, or location of the mtDNA arrangements 
and clinical course.
1.8.3 BIOCHEMICAL CLASSIFICATION OF MITOCHONDRIAL DISEASE
Mitochondrial respiratory chain activity can be analysed in any tissue, but most 
commonly muscle or platelets. Whole, fresh or frozen muscle samples can be used, or 
mitochondrial preparations can be fractionated from tissue samples. Analysis can be 
performed by polarography or spectrophotometric methodologies. In this way 
deficiencies of each of the mitochondrial respiratory chain complexes can be identified. 
Complex I deficiency is associated with a wide spectrum of mitochondrial disorders,
9^ 4most commonly as LS . It is probably the commonest respiratory chain defect 
associated with MELAS and MERRF, and occurs in isolation or with complex III and/or 
IV defects 310'312. Complex I deficiency has also been found in CPEO and mtDNA
• 313 •deletions . The deleted region in these cases encompassed only complex I genes and 
the intervening tRNAs. These are the only examples where the deleted mtDNA genes 
correspond exactly with the biochemical defect. LHON is also associated with complex I 
defects.
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Complex II deficiencies are less common, but again are associated with a wide clinical 
spectrum. Complex III deficiency is usually not an isolated defect 314. Complex IV 
defects may result from mutations of mtDNA encoded subunits, or from mutations of 
assembly genes (Table 1.4). The clinical spectrum is again diverse, and includes LS, 
benign and fatal infantile myopathies and cardiomyopathies, adult onset myopathies, 
MNGIE, MERRF, and MELAS.
Table 1.4
NUCLEAR GENE DEFECTS RELATED TO 
MITOCHONDRIAL DISORDERS
1 Structural components of RC complexes
Protein Function Phenotvoe
NDUFS4 Cxi Atypical LS
NDUFS8 Cxi LS
NDUFV1 Cxi LS, leukodystrophy, myoclonus
NDUFS1 Cxi LS
NDUFS7 Cxi LS
Flavoprotein CxII LS
SDHD, SDHC Cx II Hereditary paraganglioma
CoQIO synthesis Cx III III Ataxia, myopathy, epilepsy
2 Factors controlling OXPHOS or mtDNA metabolism
Protein Function Phenotype
SURF1 COX assembly LS
SCOl COX assembly, Copper metabolism IE
SC02 COX assembly, Copper metabolism Infantile CM
COX 10 COX assembly, heme A synthesis IE
BCS1 Complex III assembly IE, tubulopathy, hepatopathy
ANTI Nucleotide pool adPEO
Twinkle Helicase adPEO
Thy phos Nucleoside pool MNGIE
Mt proteins indirectly related to OXPHOS
Protein Function
Tim 8/9 transporter
ABC7 iron exporter
Frataxin iron storage
Paraplegin metalloprotease
OPA1 dynamin-related protein
Phenotype
X dystonia deafness 
X ataxia/ sidero anaemia 
Friedreich’s ataxia 
HSP
AD Optic Atrophy
1.9 PATHOGENIC MECHANISMS OF MtDNA MUTATIONS
The pathogenesis of mitochondrial DNA mutations is only partly explained by the rules 
of mitochondrial genetics. The influence of heteroplasmy, the bottleneck effect, 
threshold, and mitotic segregation on the phenotypic consequences of mtDNA genotypes 
has been discussed above. However, despite these theories, the poor genotype-phenotype 
correlation typical of the mitochondrial encephalomyopathies remains to a great extent 
unexplained.
Mutations in tRNA genes are usually associated with multisystem disease. In cases of 
isolated myopathy a family history is usually lacking, the inference being that the 
mutations arise spontaneously. In most patients the mtDNA mutation is also detectable iii 
blood and fibroblasts suggesting that the phenotype is a consequence of “skewed
T1 Sheteroplasmy” with preferential accumulation of the mutation in skeletal muscle
As the spectrum of mitochondrial disorders widens other phenotype-genotype 
correlations have proved invalid. Protein coding gene mutations, as in LHON and 
NARP/MILS, were thought to always cause multisystem, maternally inherited, disease 
and to be inconsistently accompanied by lactic acidosis and never associated with RRFs 
. The evaluation of patients with exercise intolerance, with or without myalgia and 
myoglobinuria due to ND4, ND1, cytochrome b, COX III, and COX I mutations 
disproved these rules 316-321.
Our understanding of the phenotypic consequences of mtDNA mutations will be 
enhanced by the recent development of several animal models of mitochondrial disease 
(see chapter 4). Until now reliance has been on the use of cybrid cell technology. Human 
cell lines are depleted of mtDNA using a variety of agents. These mtDNA-less (p°) cells 
can then be repopulated with heteroplasmic mtDNA to generate clones of varying 
degrees of heteroplasmy. This in vitro system has a number of potential limitations. 
Cybrid cells require a high percentage of A3243G mutant mtDNA to be present before 
OXPHOS is impeded. In vivo studies suggest a much lower threshold effect. Calf muscle 
magnetic resonance spectroscopy from an oligosymptomatic patient revealed markedly
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decreased maximal ATP production despite the fact that the mutant load was very low in 
muscle 322. Proton MRS has shown elevated lactate in the brain of A3243G carriers, and 
that the relationship to the proportion of mutant mtDNA was linear as opposed to the
323exponential pattern usually seen for the threshold effect
1.10 MODELS OF MITOCHONDRIAL DISEASE
The pathogenesis of mitochondrial disease remains obscure. There is still little 
understanding of the causes of clinical heterogeneity and progression of symptoms, and 
this lack of knowledge has hindered the development of directed therapies. The quest for 
a greater understanding of the pathogenesis of human mitochondrial diseases and thp 
desire for systems in which to evaluate potential therapeutic agents have stimulated 
attempts to develop both in vivo and in vitro models of mitochondrial diseases. A number 
of strategies have been developed based on cellular and animal models.
Primary myoblast or fibroblast cultures, established from muscle or skin biopsies of 
patients with mitochondrial disease, have been used as cellular models of mitochondrial 
disease 587. Transformed cell lines rendered p°, transmitochondrial hybrids (cybrids), and 
xenocybrids have also been employed to this end. The latter is a technique unique to 
mitochondrial biology. Cloning provides cell lines of varying mutant load. The lifespan 
of these cell lines in culture is limited, but they have been used for the investigation of 
transcription, translation, threshold effects, and segregation of mtDNA mutations 106. Cell 
lines devoid of mtDNA (p° cells) can be generated in a number of ways. From these p° 
cells transmitochondrial cybrids can be generated by fusion with platelets or enucleated 
cells. This technique allows the study of the effect of different levels of mutant mtDNA 
on transcription, translation, and respiratory chain function in a constant nuclear 
background.
The generation of inter-specific (xenomitochondrial) cybrids, as first suggested by
588Kenyon and Moraes , has provided both an alternative approach to generating 
OXPHOS defects in mouse cells, and also provided opportunities to explore cross-species
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nuclear-mitochondrial interactions. MtDNA divergence is about 5-13 times more rapid 
than in nuclear DNA (nDNA) 589. Therefore as species evolve a general incompatibility 
between nuclear and mitochondrial encoded gene products would be expected. This is 
predicted to occur between pairs of even recently diverged taxa 59°. The complete 
mtDNA sequence for mouse, rat, and a number of non-human apes have been determined 
(Bibb 1981) 591, and provides a very clear picture of the evolution of mtDNA in these 
species. Despite a relatively high number of sequence variations, once non-coding and 
synonymous mutations are ignored, a high level of functional homology is revealed 591. 
Even between human and orang-utan this homology exceeds 95%. The co-evolution of 
the nuclear and mitochondrial genomes in vertebrates, and how these interactions evolved 
to optimise OXPHOS are poorly understood.
Prior to the work on Kenyon and Moraes the maintenance of mitochondrial genomes in 
interspecies somatic hybrids had been dependent upon the presence of a complete set of 
cognate chromosomes 592'594 595. It has subsequently been shown that OXPHOS function 
in human p° cell lines can be restored by the insertion of mtDNA from other humanoid 
primates including the common chimpanzee {Pan troglodytes), pigmy chimpanzee {Pan 
paniscus), and gorilla {Gorilla gorilla). These results suggest that in primates 
mitochondrial nuclear compatibility had been preserved over approximately 5-12 million 
years (myr). MtDNA from orang-utan {Pongo pygmaeus) however, a species that 
diverged from other humanoids 12-18 million years ago, is unable to functionally replace 
human mtDNA implying an increase in failed mitochondrial nuclear interactions at this 
degree of evolutionary distance. The critical nNDA-mtDNA interactions that have been 
affected in unsuccessful xenomitochondrial cybrids are not known. Potential candidates 
include primate promotor recognition by the nuclear-coded human mitochondrial RNA 
polymerase 596. Further studies on human-chimpanzee or human-gorilla xenocybrids 
revealed a 20-30% reduction in oxygen consumption and a 40% decrease in complex I 
activity, attributable to defective interactions between nDNA and mtDNA encoded 
complex I subunits 591. These cybrids also exhibited an increased sensitivity to 
programmed cell death when treated with complex I inhibitors 324.
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Transmitochondrial mouse cells have been created using mus musculus p° cells and
589 • •mtDNA from rattus norvegicus or mus spretus . Evolutionary distances are 
controversial but believed to be 10-12 myr and 1 myr respectively 598. Both fusions 
generated viable cybrids. The mouse-mouse xenocybrid product exhibited normal 
OXPHOS function. The mouse-rat xenocybrid showed normal replication, transcription, 
and translation (as determined by S35 methionine labelling) but complex I activity was 
46%, complex III 37%, and complex IV 78% of control values. The maximal rate of 
respiration, analysed polarographically, was 12-31% of control and mus spretus-mus 
musculus xenocybrids. It is anticipated that the generation of other mouse xenocybrids 
with less severe OXPHOS phenotypes will provide models of a broader spectrum of 
human mtDNA diseases. j
The retention of both species of mtDNA in mouse-rat and mouse-hamster xenocybrids 
has also been reported. However it is not known whether both species of mtDNA are 
expressed or whether one set is selectively repressed 5" . The uniparental loss of mtDNA 
has been shown to occur in parallel with chromosomal loss 595’600’602# Human cells will 
preferentially replicate defective human mtDNA over foreign normal primate mtDNA 
suggesting that mtDNA determinants for trans-acting factors may be of greater 
significance than OXPHOS functionality 603.
MRC defects of primate xenocybrids differ from those of mouse-rodent xenocybrids, 
both in terms of which complexes are affected, and the evolutionary distance that can be 
tolerated. These findings provide new insights into the interactions of nuclear DNA and 
mitochondrial DNA by showing that predictions regarding viability and phenotype of 
xenomitochondrial cells do not correlate strictly with evolutionary divergence or the 
overall number of amino acid or nucleotide differences and will vary depending on the 
species used. By comparative studies of the species used it will be possible to gain 
important insights into the nuclear mitochondrial interactions that determine efficient 
mitochondrial function, and may provide useful mouse models of human mtDNA disease.
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Figure 1.6 Brief phylogeny of the Muridae showing divergence times estimated from
molecular studies. Time is shown by the scale below the phenogram and expressed as
con
millions of years before present (m.y.b.p.). (from ).
mt gene product Identity Number of amino acids No. of amino 
acid differencesRat Mouse
NADI 90% 318 315 32
NAD2 74 345 345 88
COXI 97 514 514 14
COXII 99 227 227 3
ATP8 79 67 67 14
ATP6 95 226 226 12
COXIII 97 261 261 9
NAD3 87 115 114 15
NAD4L 86 98 97 14
NAD4 87 459 459 59
NAD5 78 610 607 133
NAD6 80 172 172 34
Cytochrome b 93 380 381 26
Table 1.5 Comparison of M. musculus and R. novegicus mitochondrial translation 
products.
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1.10.1 Animal Models
The high cellular mtDNA copy number and the lack of demonstrated mechanisms of 
recombination have presented technical barriers to the generation of mtDNA “knockout” 
mice or animal models of mtDNA mutations. Several mechanisms have been explored to 
overcome this 604. Some approaches may be limited by the lack of available mtDNA 
mutants in cultured mouse cells.
Using available vectors the stable introduction of mutant mtDNA into the mitochondria 
of mammalian cells is problematic. Attempts have been made to use a transfection 
approach using a DNA construct linked to a mitochondrial target peptide leader sequencp 
504,605 c ommoniy usecj vectors are retroviruses that require active DNA replication to 
enable their insertion into genomic DNA. This technique is therefore precluded in 
myoblasts, which like neurons cease DNA synthesis before fusion 606. An alternative 
approach was developed using transformed cybrid technology to generate a mouse model
f\(YJof mitochondrial disease, termed mito-mouse . Synaptosomes were isolated from 
healthy aged mouse brains and fused with p° cells. Aging tissue accumulates mtDNA 
deletions 608, and these are referred to as low abundance rearranged molecules or 
“sublimons”. The resultant cybrids containing such deletions were identified, and these 
cells were enucleated and electro-fused with zygotes before implantation into 
pseudopregnant female mice. Previously mtDNA had been shown to be eliminated from 
zygotes, depending upon its tissue origin, inter or intra species barriers, and whether it is 
implanted into sperm or oocytes 609. These findings implied the existence of imprinting 
factors 6I0. The mtDNA deletion was passed not only into somatic cells but also into the 
germ line, a rare event for human pathologically rearranged mtDNA other than partial 
duplications. It accumulated in successive generations, and when a threshold of 90% was 
reached mitochondrial dysfunction become apparent in various tissues.
In humans, the presence of deleted or partially duplicated mtDNA above a threshold of 
50% causes multisystem disease of variable phenotype. The phenotype is determined by 
both the tissue distribution of the rearranged mtDNA, and the type of rearranged
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molecule present, and probably other, as yet unidentified, factors. Duplications tend to 
cause more widespread disease. Red ragged fibres and weakness are almost always 
present. Mito-mouse exhibited no RRFs, there was a mosaicism of respiratory 
impairment in cardiac and skeletal muscle, and death occurred at 200 days due to renal 
failure and anaemia, rare manifestations of disease in humans. Furthermore, in contrast to 
human mtDNA disease, the mouse levels of mutant mtDNA showed little variation 
between different tissues. In addition to the deleted mtDNA, partially duplicated mtDNA 
molecules were detectable in the mice. It was deduced that in early development donor 
deleted mtDNA must have recombined with wild type mtDNA to generate these partially 
duplicated species. Inter molecular recombination of this type has not been observed in 
human cybrids heteroplasmic for deleted mtDNA. Mito-mouse has therefore provided  ^
disease model for human mtDNA rearrangement diseases. However the dissimilarities 
from human mtDNA biology, also rather than detracting from this model, serve to 
provide us with new insights into a number of aspects of mtDNA biology, including the 
maintenance of mtDNA during development, tissue expression, and transmission.
An A2379T mutation within the 16S rRNA mtDNA gene confers resistance to 
chloramphenicol (CAP) in mouse 3T3 cells. The introduction of this “(CAP)-resistant” 
mtDNA mutation into mouse embryonic stem cells has provided another animal model of 
mtDNA disease. Embryonic stem cells were obtained, and CAP-sensitive mtDNAs 
selected against. Chimeric mice were then generated by fusing these cells with enucleated 
CAP-resistant 3T3 mouse cells. The resulting cell lines had a mutant load of 90% and 
reduced cytochrome oxidase activity 61 \  Chimeric heteroplasmic (transmitochondrial) 
mice were generated by the injection of these cells into blastocysts. The mutant mtDNA 
load in tissues analysed varied from 0% to 50% 611,612. The mice developed cataracts, 
retinopathy, cardiomyopathy and myopathy 612>613. Parallels can be drawn to human 
mitochondrial disease because sensorineural deafness may also result from mutations of 
rRNA genes, the A3243G MELAS mutation results in a similar translational defect, and 
the NARP T8993G ATPase6 mutation causes a similar alteration in retinal function 
611>613. The variable segregation of wild and mutant type mtDNA into different tissues 
also mirrors human mtDNA disease 61 \  The lack of a technique for site directed
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mutagenesis of the mitochondrial genome means that this method may be of use in the 
generation of mouse mutants for different mtDNA mutations. Severe combined 
immunodeficiency (SCID) mice have been used to generate animal models of human 
mtDNA disease. Myoblasts obtained from patients with NARP and MERRF are able to 
regenerate and express their mtDNA after injection into the tibialis anterior muscle of 
SCID mice 6'4.
Three different classes of nuclear DNA encoded mitochondrial gene mutations have been 
reported in the mouse. These include mutations in a biosynthetic apparatus gene (Tfam), 
mutations in the mitochondrial bioenergetics genes ANTI and UCP1-3, and mutations in 
the mitochondrial antioxidant genes GPxl and SOD2 (MnSOD). Knockout gene? 
technology has been used to generate mouse models of mitochondrial disease due to 
nuclear DNA defects. Mitochondrial transcription factor A (mtTFA) is a nuclear-encoded 
protein that binds upstream of the light and heavy chain mtDNA promoters, promotes 
transcription and may also regulate mtDNA replication 615. Knockout of the mouse 
homologue Tfam causes severe mtDNA depletion and embryonic lethality in the 
homozygous state. Mitochondria are enlarged, of abnormal morphology, and are 
deficient in COX but not SDH. Heterozygous mice have a 34% reduction in mtDNA 
copy number, a 22% reduction in mitochondrial transcripts, and a partial reduction of the 
COI protein in heart but not in liver 19. Tissues vary in their sensitivity to changes in the 
levels of mtTFA. A gene-dosage effect may therefore contribute to tissue-specific 
differences in respiratory chain capacity in humans 19. A similar model has been 
developed with Tfam inactivation confined to cardiac and skeletal muscle 616. This caused 
postnatal lethality due to dilated cardiomyopathy. Cardiac conduction defects were also 
present. There was a reduction of complexes I and IV, but not II. Tfam inactivation in the 
pancreatic |3 cells has been used to examine the importance of mtDNA depletion in 
diabetes 617.
Inactivation of the mouse nDNA adenine nucleotide translocase (ANTI) gene provides a 
model of mtDNA multiple deletion syndrome 159’294s but also provides insight into the 
role of depleting cellular ATP, inhibition of the electron transport chain, and increasing
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mitochondrial ROS production in the pathophysiology of mitochondrial disease 159. 
ANTI mutants exhibit exercise intolerance and cardiac hypertrophy, a dramatic 
proliferation of mitochondria, and the presence of ragged-red muscle fibers 294. There are 
elevated levels of serum lactate, alanine, succinate, and citrate, consistent with inhibition 
of the TCA cycle and the ETC 294. Inhibition of ETC causes electrons to be redirected to 
0 2 to generate 0 2'. There is increased production of reactive oxygen species (ROS) in the 
ANTI deficient mice, with a six to eight-fold increase in levels of hydrogen peroxide 
(H202). The respiratory defect is complete in skeletal muscle, and partial in cardiac 
muscle. The levels of antioxidant defence enzymes induced are consequently higher in 
skeletal muscle than the heart, and the accumulation of mtDNA damage is lower in 
skeletal muscle 329. The ANTI -/- mouse therefore provides a model of AD-PEO, but one 
important difference is that ANTI mutations in human are dominant, but in mice are 
recessive.
Mutations in the genes for superoxide dismutase (SOD), an enzyme that reduces
superoxide anions generated during the OXPHOS process to H202, result in reduced ATP
£10
synthesis and increased oxidative stress . There are three genes for SOD and their 
effects have been examined in knockout mice 486. Inactivation of SOD2 gene causes the 
most deleterious phenotype, with cardiomyopathy, lactic acidosis and hepatic fat 
accumulation 619 Biochemical analysis revealed severe deficiencies in MRC complexes I 
and II and the tricarboxylic acid cycle enzymes. A severe inhibition of ATP synthesis and 
the accumulation of oxidative mtDNA damage result 485’486’620t The SOD mimetic and 
synthetic antioxidant manganese 5, 10, 15, 20-tetrakis (4-benzoic acid) porphyrin 
(MnTBAP) may prevent the development of cardiomyopathy and the accumulation of 
lipid in the liver 620. Therefore, the SOD2 knockout mice constitute a good model to 
examine the efficacy of antioxidants and to study the mechanisms of oxidative damage 
that may be associated with mitochondrial disease.
Glutathione peroxidase 1 deficient mice have increased levels of mitochondrial H20 2 
production. Their phenotype is determined by the inter-tissue (high expression in liver, 
brain, and renal cortex) and intra-cellular (cytosol and mitochondria of liver and kidney,
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and cytosol of heart) distribution of GPxl. GPxl mice have chronic growth retardation, 
increased H2O2 production in the liver, but this has only a mild deleterious effect on 
respiration 621.
Uncoupling proteins (UCP) increase the mitochondrial inner membrane permeability to 
protons. This short circuits the Aij/ (membrane potential) and activates the ETC to rapidly 
bum brown fat to generate heat. Mice lacking either UCP2 or 3 (the more widely 
expressed isoforms) exhibit increased mitochondrial ROS production 622623 
Mitochondrial function was assayed by determining the resistance of mice to infection 
with toxoplasma gondii
1.11 CLASS II NON-ARCHETYPAL SECONDARY OXPHOS DEFECTS
A growing number of neurodegenerative disorders without overt primary OXPHOS 
defects are now linked to mutations in mitochondrial proteins that are indirectly linked to 
the processes of cellular respiration and energy production. The breadth of mitochondrial 
disorders is therefore expanding to include more common neurological disorders. It may 
be that mitochondrial biology underlies an even greater number of disorders both 
neurological and others. (Table 1.5)
OXPHOS defects have consequences beyond impairment of ATP production. In vitro 
drug induced complex I deficiency results in alterations in cellular respiration, growth, 
free radical production, lipid peroxidation, mitochondrial membrane potential, and 
apoptosis. The degree of complex I inhibition correlates with the extent of these defects 
324. Mechanisms of free radical production and oxidative damage have been proposed in 
the pathogenesis of both the class I archetypal mitochondrial encephalomyopathies and 
the class II neurodegenerative conditions.
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Table 1.6
Genetic causes of bioenergetic defects in neurodegenerative diseases
Diseases with nuclear DNA-encoded mitochondrial defects
Friedreich’s ataxia 
Wilson’s disease 
Hereditary spastic paraparesis 
Deafness-dystonia 
Leigh’s disease
Diseases with nuclear DNA mutations with secondary mitochondrial dysfunction
Huntington’s disease 
Cerebellar degenerations
Diseases with mitochondrial DNA-encoded mitochondrial defects e.g.
LHON 
KSS/CPEO 
MELAS 
MERRF 
Leigh’s disease
Diseases with some evidence of mitochondrial dysfunction
Amyotrophic lateral sclerosis 
Parkinson’s disease 
Alzheimer’s disease 
Progressive supranuclear palsy
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1.12 Reactive Oxygen Species and Oxidative damage as a pathogenic mechanism 
in class I and class II mitochondrial disorders.
O c  '2 ')£L
Over 85% of the oxygen used by a cell is consumed by its mitochondria ’ . If free
electrons are released during this process, or if the oxygen is incompletely processed, 
oxygen radicals are generated that are damaging to lipids, protein, and DNA. 
Mitochondria have therefore evolved a number of ROS scavenging mechanisms both 
enzymatic and non-enzymatic. Their capacity is however usually exceeded by the rate of 
production of ROS 327>328. The degree of damage to mtDNA is inversely proportional to 
the levels of these antioxidant defences 329.
The major ROS are superoxide (0 2'), hydrogen peroxide (H2O2), and the hydroxyl 
radical (OH ). Superoxide is formed by the transfer of a free electron to molecular 
oxygen. This reaction occurs at a number of specific sites within the electron transport 
chain. Production is maximal from complex I and III. Superoxide is highly reactive and 
diffuses poorly throughout the cell. Damage is therefore maximal at the site of 
production, the mitochondrial inner membrane. The mitochondrial scavenging enzyme 
manganese superoxide dismutase converts superoxide to H2 O2 , which is, by contrast, 
highly diffusible. H20 2 in turn is converted to H20  by glutathione peroxidase. This 
reaction requires reduced glutathione as a coenzyme. However, in the presence of 
reduced transition metals, H2O2 reacts via the Fenton reaction to generate OH a highly 
reactive ROS that lacks any known scavenging mechanism.. This will react with virtually 
any molecule in close proximity.
Other important radicals include nitric oxide (NO) and peroxynitrite (ONOO'). These can 
be produced endogenously by mitochondrial NO synthetase 330'332. NO can have both 
beneficial and detrimental effects, with its influence on the mitochondrial permeability 
transition pore being dependent on the prevailing NO concentration 333. Mitochondrial 
NO decays via ubiquinol oxidation, reversible binding to cytochrome c oxidase, and by 
interaction with superoxide resulting in the formation of ONOO' 334. Peroxynitrite causes 
modification of proteins by nitration of tyrosine residues to form dityrosine, and oxidizes
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tryptophan to cysteine 335. These effects culminate in mitochondrial swelling,
336depolarization, calcium release, and permeability transition
Mitochondria thus play the role of both assailant and victim in ROS induced cellular 
damage. These roles have been proposed to be of pathological significance in a number 
of archetypal mitochondrial encephalomyopathies and other neurodegenerative 
conditions, and are thought to result in a vicious cycle of cellular damage. In this way an 
initial MRC defect causes generation of ROS, which, by induction of secondary mtDNA 
mutations further exacerbates the ROS production rate and MRC defect.
Oxidative stress causes greater damage to mtDNA than nuclear DNA due to the lack of 
histones, repair mechanisms, non-coding sequences from mtDNA, and due to its location 
near the site of ROS production 33?. However in patients with pathogenic mtDNA 
mutations PCR based techniques failed to show an increased level of mtDNA deletions in 
muscle arguing against this vicious cycle theory . ROS production and oxidative 
damage are increased in MELAS and MERRF fibroblasts . Hydroxyl radical damage 
of mtDNA is reported in MELAS and can be accelerated by specific genotypes 34°. ROS 
associated telomere shortening has been reported in both MELAS and LHON 341. These 
hypotheses have been strengthened by the findings in xenomitochondrial cybrids, where 
the degree of complex I deficiency correlates with the rates of cellular respiration and 
growth, ROS production, lipid peroxidation and other markers of ROS induced damage 
324. Partial MRC deficiencies may therefore precipitate cellular degeneration via ROS 
related pathways.
1.13 The role of mitochondrial dysfunction in neurodegeneration
Mitochondrial dysfunction has been implicated in the pathogenesis of a range of 
neurodegenerative conditions. Hereditary spastic paraparesis (HSP) is a clinically and 
genetically heterogeneous group of disorders. Incidence is estimated at 1:10000 342>343. it 
occurs as complicated and pure forms and can be inherited as autosomal recessive or
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dominant, or X-linked traits 344. The unifying feature is of progressive spasticity and less 
evident weakness of the lower limbs. Seven loci for AD HSP, three autosomal recessive 
loci and two X chromosome loci have been identified. Chromosome 16 linked families 
with AR complicated and pure HSP (SPG7), have been found to harbour mutations in the 
gene encoding paraplegin a protein of 795 amino acids 346. Muscle biopsies from these 
patients revealed typical mitochondrial pathology 346,347. Paraplegin shows high sequence 
homology to three yeast proteins (Afg3p, Ymelp, and Rcalp), suggesting that it also is a 
mitochondrial ATP-dependent zinc metalloprotease of the triple ‘A’ protease family 
(^4TPases associated with a variety of cellular activities). These proteins act as 
chaperones and are involved in the ATP dependent degradation of mitochondrial 
translation products. AD HSP Linked to 2p (SPG4) is caused by mutations in spastin. 
This is also a member of the AAA family 348, but does not localize to the mitochondrion. 
Evidence of mitochondrial dysfunction has been reported in HSP patients not linked to 
chromosome 16 349>35°. Spastic paraparesis secondary to the ingestion of chick peas 
(lathyrism) is also linked to mitochondrial dysfunction 351.
Hepato-lenticular degeneration (Wilson’s disease WD) is an autosomal recessive disorder 
that causes the accumulation of copper, maximal in the brain and liver. It affects 
approximately 1:30,000, and is the consequence of mutations in the ATP7B gene on 
chromosome 13. The WD protein localizes to mitochondria 352. The ATPase is expressed 
predominantly in the liver and transports copper into the hepatocyte secretory pathway 
for subsequent incorporation into caeruloplasmin and excretion into bile 353. This is the 
only significant pathway for copper removal. Mitochondrial morphology is abnormal in 
WD . Impaired activities of mitochondrial respiratory chain complex I, II/III, IV and 
aconitase are found in WD liver 358. The level of oxidative stress has been shown to 
correlate negatively with the copper concentration 359. Copper is an important component 
of complex IV, and it may act as a substitute for iron in redox reactions resulting in the 
generation of free radicals 360’361.
Dystonia is a disorder of movement caused by sustained involuntary muscle contractions 
affecting one or more body sites. This frequently causes twisting and repetitive
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movements, or abnormal postures 631,632. The prevalence of dystonia is not accurately 
known, und estimates vary between 127 to 329 per million 633>634. The aetiology of 
dystonia remains uncertain in the majority of cases. Furthermore in those cases with 
an identified gene, the pathogenic mechanisms remain to be elucidated. Mitochondrial 
dysfunction, either as a primary or secondary phenomenon, has been implicated by a 
number of studies.
Among the many clinical manifestations of the primary mitochondrial diseases, 
disorders of movement, especially dystonia, occur at a greater frequency than 
expected. In 85 consecutive patients with mitochondrial myopathy 10.5% had a 
movement disorder, which included dystonia, chorea, Parkinsonism and myoclonus 
142. In a number of families with Leber’s hereditary optic neuropoathy (LHON) 
dystonia is also present. A missense mutation in the mtDNA encoded ND6 complex I 
subunit gene was identified in one family 272. Cells from patients containing this 
G14459A mutation showed a 55% reduction in complex I activity 669. In a Dutch 
family a heteroplasmic A11696G in the ND4 gene, and a homoplasmic T14596A 
mutation in ND6 were identified. Biochemical analysis of a muscle biopsy revealed a
9 7 1severe deficiency of complex I
Further support for the role of mitochondrial dysfunction in the aetiology of dystonia 
came with the identification of the causative gene for Mohr-Tranebjaerg syndrome/X- 
linked deafness-dystonia-optic atrophy syndrome . This condition is characterised 
by X-linked recessive sensorineural hearing loss, dystonia, dementia, psychotic 
features and optic atrophy. The DFN1/MTS locus was linked to Xq21.3-22 673 and a 
mutation identified in a novel gene DDP (deafness-dystonia peptide) 67°. The DDP 
gene generates a 1167 bp cDNA which encodes a 97 amino acid, 1 lkDa polypeptide, 
named DDP1 96. This protein is homologous to a family of yeast proteins known as 
the ‘Tiny Tims’, which are part of a complex of proteins known as inner membrane 
translocases. Via yeast homolgy studies the DDP1 protein was identified as TIMM8a 
675. TIMM8a assembles with TIMM13 in a 70kDa complex in the mitochondrial 
intermembrane space. This complex is responsible for the import, at low membrane 
potentials, of Tim23 an essential component of the import machinery for matrix- 
targeted proteins. Impairment of this mechanism would therefore lead to a significant 
reduction of many mitochondrial functions 677.
Mitochondrial involvement in the pathogenesis of dystonia is further supported by 
studies of the systemic administration of subacute doses of 3NP, a mitochondrial 
toxin, in cebus apella monkeys. This led to the developed of dyskinesia at 5-6 weeks 
after discontinuation of 3NP. After this time period chorea lessened as dystonia
/ n o
worsened in severity and intensity . Biochemical evidence of mitochondrial
A 7Qdysfunction in primary dystonia first came in 1992 . Decreased complex I activity
was demonstrated in the platelets of patients with focal (37% mean reduction), and 
segmental or generalised (62% mean reduction) primary dystonia. In a separate study 
a complex I defect was confirmed in platelets from patients with sporadic focal 
dystonia (mean reduction 21%). However for patients with generalised dystonia 
(linked or unlinked to chromosome 9q34) the difference from controls was not 
significant 680. Biochemical analysis of cybrids from these patients with sporadic focal 
dystonia, showed that the defect was complemented in mixed and clonal cybrid lines 
681 suggesting that the complex I defect in dystonia is caused by a nuclear mutation or 
a circulating toxin.
Huntington’s disease (HD) is caused by an expanded CAG repeat on chromosome 4p. 
This causes a polyglutamine repeat in the N-terminal region of the widely expressed 
Huntingtin protein. Roles in glutamate homeostasis, endocytosis and vesicle 
trafficking have been proposed for Huntingtin ’ . Post mortem, in vivo and in vitro
studies have implicated mitochondria in the pathogenesis of HD. OXPHOS defects of 
complexes II, III, and to a lesser extent complex IV, have been reported in HD 
caudate nucleus 371>372. Huntingtin does not localize to mitochondria, and OXPHOS 
function is normal in cybrid studies . Mitochondrial dysfunction is thought to be a 
secondary consequence of excitotoxicity mechanisms and/or oxidative stress. Other 
evidence pointing to a disturbance of cellular energy metabolism includes the findings 
of elevated lactate levels in the occipital cortex and basal ganglia 374, abnormalities on 
muscle 31P MR spectroscopy 375, and that mitochondrial toxins can create animal
376 377models of HD ’ . Studies of transgenic HD mice also implicate secondary
mitochondrial dysfunction as a consequence of the gene mutation 378,379.
l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP), a contaminant of synthetic 
opiates, led to an outbreak of young-onset parkinsonism 38°. MPTP is metabolized to
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MPP+ a complex I inhibitor 381. In the substantia nigra of patients with idiopathic
382Parkinson’s disease there is a 30-40% decrease in complex I activity , and reduced 
immunohistochemical subunit staining for complex I, with sparing of the other MRC 
complexes 383. Cybrid studies imply a mtDNA-encoded defect 384,385. Both the 
susceptibility to MPP+ and free radical production are increased, and mitochondrial
n o /
calcium buffering is impaired . The 11778 mtDNA mutation has been associated
007
with multisystem degeneration, parkinsonism, and a complex I defect . MtDNA 
mutations have however not been identified in idiopathic PD, implying that the 
bioenergetic defect may be the result of unidentified mtDNA mutations or
388polymorphisms, or the interaction of genetic and environmental factors
TQQ
Alzheimer’s disease (AD) postmortem tissues show complex IV defects 
Immunostaining shows reduced subunit levels maximal for mtDNA encoded subunits 
390. The biochemical defect persists in cybrids generated from AD platelets. Results 
are conflicting however and a study of cybrids generated from synaptosomes and 
platelets failed to find a MRC defect391. Initial results suggesting a mtDNA mutation 
to be responsible for the defect, were withdrawn when a nuclear pseudogene was later 
found to be responsible for this spurious result . Further mtDNA polymorphisms of
'IQ'l
proposed aetiological significance have been reported .Oxidative damage to 
mtDNA is increased threefold in AD post-mortem tissue 394. Other parameters of 
oxidative damage also imply that this is an important mechanism in the pathogenesis 
of AD.
The role of mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is 
supported by a large body of literature. Mitochondria are histologically abnormal in 
liver and anterior horn cells 395’396. In skeletal muscle complex I activity is reduced by 
50% 397, and mitochondrial volume and calcium concentrations are increased 398. 
There is also evidence of increased oxidative damage 3" .  A COX subunit I mutation 
has been reported in an individual with sporadic ALS 400Mutations in copper-zinc 
superoxide dismutase (SOD) are found in a proportion of patients with familial ALS 
40 \  These mutations have been shown to impair mitochondrial function in vivo 402, 
and transgenic studies show mitochondrial morphological changes to be an early 
feature preceding motor weakness and loss of motor neurons 403.
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1.13.1 Friedreich’s ataxia:
This ataxic disorder was first described by Nicholaus Friedreich in a series of five 
papers published between 1863 and 1877 404'408. He reported nine members of three 
families who had onset in puberty of ataxia, dysarthria, sensory loss, muscle 
weakness, scoliosis, foot deformity, and cardiac symptoms. Areflexia was only 
described in the final two reports, but was later adopted as one of the clinical 
diagnostic criteria. In the intervening 133 years until the elucidation of the molecular 
mechanism of FRDA there was much debate about the clinical features and the 
phenotypic spectrum of this disorder 409.
FRDA is now recognised as the commonest inherited ataxia. Prevalence studies 
performed after the introduction of genetic testing have suggested that it is commoner 
than previously recognised with values up to 1:29,000 410. Carrier prevalence is 
estimated at between 1:60 to 1:90 4n. The disease is rare in Asia and Africa. 
Autosomal recessive inheritance was established by segregation analysis 409, although 
this had also been suggested by the high rate of consanguinity 412. Due to the high 
carrier frequency pseudo-dominant inheritance had also been reported 4I3,414.
Prior to the introduction of genetic testing various diagnostic criteria were proposed to 
enable natural history studies and the investigations of molecular mechanisms 409)415. 
Subsequently a number of these have proved invalid, most noticeably with the 
recognition of onset over the age of 25 years (late-onset Friedreich’s ataxia -  LOFA), 
and the preservation of lower limb reflexes (Friedreich’s ataxia with retained reflexes 
-  FARR). These patient groups, and others such as the Acadian form of FRDA and 
Acadian spastic ataxia have all been found to be due to the same genetic mutation 416' 
424. Other atypical forms include the presentation of FRDA as a pure spastic 
paraparesis 425)426. Presentation as a pure sensory ataxia or as chorea is also recognised
427,428
The core clinical features of gait and lower limb ataxia are reported in virtually 100% 
of all reported studies. The frequency of other features varies depending on: 1) 
whether the patients were identified by clinical or genetic criteria 2 ) potential racial 
variations, 3) the range of age and disease duration in the patients studied and 4) the
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criteria used to define the presence of certain features. The latter are illustrated by 
variations between studies in the criteria used to define for example diabetes (defined 
by patient history, blood glucose values, or oral glucose tolerance tests), 
cardiomyopathy (defined by ECG alone in some studies, and by echocardiography in 
others), impaired visual and auditory acuity, and skeletal abnormalities including 
scoliosis and pes cavus (Table 1.6).
There is a paucity of natural history data for FRDA, a common feature of slowly 
progressive disorders. Onset ranges from 1.5 years to 51 in reported series. Loss of 
ambulation has been reported to occur at a mean of 15.5 ± 7.4 years after disease 
onset but ranges between 3 and 44 years. Death is most commonly as a consequence 
of cardiomyopathy and is at a mean age of 37.5 ± 14.4 years 429. Retrospective 
analysis of disease progression has reported a mean time to wheelchair confinement 
of 1 1  years 429.
Pathological studies of FRDA report changes maximal in dorsal root ganglia, dorsal 
columns, corticospinal tracts, and heart. Macroscopically the spinal cord is atrophic 
with the posterior and lateral columns particularly affected 43°. Changes within the 
nervous system are thought to be the consequence of a dying back process from the 
periphery affecting the longest and largest myelinated fibres that show changes of an 
axonopathy 43 !’432. Demyelination is seen in the dorsal columns. The cerebellar cortex 
shows only mild neuronal loss 433, but the dentate nucleus, and Clarke’s column in the 
cord show marked changes. The cerebellar, and occipital cortex, show reduced 
phospholipids levels in the absence of neuronal loss 434. A hypertrophic 
cardiomyopathy develops in a significant proportion o f patients. Studies of the cardiac 
phenotype report variable left ventricular hypertrophy (concentric, asymmetric, or 
both, left ventricular outflow tract obstruction, and thickening of the papillary muscles 
435,436 Yhe presence of cardiac hypertrophy is non concordant with the presence of 
ECG abnormalities or the neurological features of the condition. The mechanism of 
cardiac hypertrophy is unclear. Histology reveals cellular hypertrophy, diffuse 
fibrosis, and focal myocardial necrosis 437. The susceptibility of the heart in FRDA 
may be a reflection of the relatively high cardiac expression of frataxin 438, and the 
low antioxidant defences of cardiac tissue 329.
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Table 1.7
Clinical, genetic, and neurophysiological parameters in Friedreich’s ataxia, according 
to the studies of Harding 1981, Durr 1996, Dalatycki 1999, and Hart 2003 
(unpublished data) 409,418,439. Ages are given in years,other values are percentages of 
total patient group. (NA= not available)
Harding 1981 Durr 1996 Dalatycki 1999 Hart 2003
Number of patients 115 140 51 77
(families) (90) (114) (43) (67)
Definition of case clinical genetic genetic genetic
Mean age 32.3±13.8 31±13 NA 24.1±10
(range) (10-73) (7-77) (10-57)
Mean age onset 10.52±7.4 15.5±8 10.5±6.4 11.75±6.3
(range) (1.5-27) (2-51) (1-26) (2-27)
Onset to w/c NA 1 0 .8 ± 6 10.1± 4.4 1 1 . 2
confinement
Mean GAA repeat NA 630±230 739±191 730±225
(range) (120-1700) (300-1345) (130-1080)
Gait ataxia 1 0 0 1 0 0 1 0 0 1 0 0 e
Limb ataxia 99 99 1 0 0 1 0 0
Dysarthria 97 91 95 95*
LL reflexes 0.9 1 2 2 13
extensor plantars 89 79 74 87
Impaired vibration 73 78 8 8 56
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Impaired visual 
acuity
18 13 NA 3d
Sphincter
disturbance
NA 23 41 45g
Pes cavus 55 55 74 64
Scoliosis 79 60 78 76
cardiomyopathy 6 6 a 63 65 47*1
Diabetes mellitus 1 0 b 32 8 5C
Median NCV 52.2±7.63
(n=2 2 )
NA NA 50.6±3.45
Peroneal NCV 44.96±7.2
(n=2 2 )
NA NA 40.5±7.4
At least 1 SAP 
absent
92
(n=26)
NA NA 83
a cardiomyopathy defined by ECG alone
b 10% of patients known to be diabetic. No other patients found to have
glycosuria
c patients known to be diabetic, including one unknown case detected on
random serum glucose and HbAlc analysis 
d patients previously investigated for optic atrophy
e Gait ataxia defined as unable to walk more than 4 steps in tandem
f any modification of fluency or suggestion of slurring.
g Minimum criteria: patients reporting mild urinary hesitancy, urgency or
retention < once per month 
h Defined as an interventricular septal thickness of greater than 11 mm.
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Clinical parameters also correlate with the repeat length size. The size of GAA1 
accounts for between 33 and 73% of the variation in the age of onset in various 
studies. GAA2 accounts for les than 20% of this variability 4 1 8 ,4 1 9 ,440 ,44 Indeed 
GAA1 correlated better than GAA2 for several disease parameters and complications, 
including cardiomyopathy, in all studies 4 1 8 >4 1 9 ’4 3 9 ’4 4 1 >442 except one 423. Diabetes 
mellitus by contrast correlated in only one study 441.
Further variation may result from other factors. The GAA repeat length may vary in a 
tissue specific pattern due to mitotic instability, and peripheral blood samples may be 
a poor indicator of repeat lengths in pathologically affected tissues. GAA1 has been 
shown to differ in different brain regions 443 and in various tissues 443'446. Cis acting 
factors may also influence the phenotype. Potential mechanisms would include effects 
upon the stability of the trihelix structure by sequence alterations within or flanking 
the GAA expansion 447. Other genetic or environmental factors may also exert an 
influence on the phenotype. This is illustrated by the finding that the age of onset in 
sibs correlates strongly regardless of the degree of difference between their repeat 
lengths 440’448.
Our level of understanding of mitochondrial involvement in FRDA is perhaps greater 
than for any other neurodegenerative condition. Subsequently mitochondrially 
targeted therapies have been trialed in FRDA. This issue, and in particular the 
measurement of the efficacy of potential therapies for FRDA are the subject of 
chapter 6 . At this point the clinical and molecular features of FRDA and the evidence 
to date for therapeutic benefit will be discussed.
In 1988 the FRDA gene was mapped to chromosome 9 449. The gene was linked to 
9q 13-21.1 in 1990 and cloned in 1996 450’451. 9 5 % of cases are now known to be the 
result of a homozygous GAA triplet repeat expansions in intron 1 of the FRDA gene 
on chromosome 9 452. This is a unique trinucleotide repeat disorder in that its 
inheritance is autosomal recessive, its location is intronic, and it involves a GAA 
trinucleotide. The repeat length is normal individuals is 6  to 34, but is expanded in 
patients and carriers to between 67 and 1700 4l8’453. The remaining 5% of patients are 
compound heterozygotes harbouring an expanded repeat on one allele and a point 
mutation on the other. Twenty-three different point mutations are described to date
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and include missense, frameshift, splice site, initiation codon, and nonsense 
mutations. The former are found only in the C-terminal suggesting that functional 
domains reside in this part of the protein 454. The location of these mutations in highly 
or poorly conserved amino acids correlates with the severity of the phenotype and the 
presence of atypical features 455_458. No cases resulting from homozygous point 
mutations have been described, although the population incidence of such individuals 
has been calculated to be l:100xl06 459. Clinically typical FRDA may occur in 
individuals in the absence of linkage to chromosome 9 suggesting that a second locus
~  • .4 6 0may exist
The FRDA gene contains seven exons (l-5a, 5b, and the non-coding exon 6 ) within 
80 kb of nuclear DNA. Transcription most commonly generates a 1.3 kb product 
representing exons 1 to 5a 452. This is translated into a 210 amino acid protein named 
frataxin. Alternative splicing, with the transcription of exon 5b instead of 5a, 
generates a 171 amino acid protein of uncertain significance 452. Frataxin and mRNA 
levels are maximal in tissues of high mitochondrial content (heart, pancreas, liver and 
skeletal muscle) 438. Not all of these exhibit obvious clinical involvement in FRDA. 
Within the CNS mRNA levels are highest in the cord, low in the cerebellum, and very 
low in the cerebral cortex 452. Frataxin appears to play a role in development; its 
homozygous knockout is embryonically lethal 461. Frataxin mRNA levels are high in 
fetal spinal cord, dorsal root ganglion, heart, liver, skeletal muscle, and skin 462’463. 
Lymphocytes from patients with homozygous expansions contain low levels of 
frataxin, and this level, and that of the mRNA, are inversely related to the size of the 
smaller repeat 438,464,465. The block is thought to occur at the level of transcript 
elongation 465, and the mechanism for this is believed to be through the formation of 
unusual DNA structures, such as DNA triplexes, by the GAA/TTC repeats 466. Several 
point mutations (I145F, G130V) appear to alter the secondary structure of the protein 
and thus influence mitochondrial uptake or cleavage 467.
The function of frataxin is incompletely understood. The amino acid sequence shows 
no strong homology to any proteins of known function. It has however been shown to 
contain an N-terminal mitochondrial targeting sequence in it’s first 55 amino acids 
and a sequence of highly conserved amino acids in exons 4 and 5a 468. The predicted 
mitochondrial location was confirmed when tagged expressed frataxin was shown to
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co-localise with mitochondrial markers in HeLa and COS cells 463,469,470. An inner 
membrane and a matrix location within the mitochondrion have both been proposed 
438,471 x-ray crystallography studies reveal similarities to ferritin, a site for protein- 
protein interaction, and the ability to bind one molecule of iron 468. An oligomer 
structure may be required for this latter attribute. Point mutations in the protein core 
cause more severe phenotypes than those within the ferritin-like anionic patch, or flat 
external protein interaction surface.
Repeat lengths are unstable. Paternal transmission is associated with a reduction in 
repeat length, an effect that increases with increasing paternal age. Maternal 
transmission can cause an increase or decrease in repeat length, and expansions are 
greater with increasing maternal age 445. The repeat length is less in an individual’s 
sperm than in their blood, suggesting post-zygotic mechanisms. Repeat length can 
vary between and within tissues, somatic mozaicism has been demonstrated in 
different CNS tissues 443. The effects of these factors on frataxin levels and clinical 
phenotype are uncertain.
A number of models of FRDA have aided our understanding of the pathogenesis of 
FRDA. Ataxia with vitamin E deficiency (AVED), caused by mutations in the a  
tocopherol transfer protein on chromosome 8 , causes a phenocopy of FRDA. This fact 
provided the first evidence that an increased susceptibility to oxidative stress could be 
involved in the pathogenesis of FRDA472. The yeast homologue of frataxin (yfhlp) 
was identified as a suppressor which rescued a mutant yeast strain unable to grow on 
iron limited medium 469. Loss of the yeast frataxin homologue (YFH1) causes poor 
growth on non-fermentable substrates, a two-fold increase in cellular and a ten-fold 
increase in mitochondrial iron content, defects of complexes I, IV, and V of the MRC, 
reduced mtDNA levels, and increased susceptibility to hydrogen peroxide induced 
oxidative stress 460>469’473i However, these findings may simply be a consequence of 
excess cellular iron causing oxidative damage by promoting the conversion of H2 O2 to 
the hydroxyl radical. Analysis of patient tissues has also shown iron deposits in the 
hearts of some but not all patients 433>474. Post-mortem human cardiac and skeletal 
muscle shows reduced activity of aconitase, an enzyme particularly susceptible to free 
radical damage 475, and this may be further evidence of increased oxidative damage in
93
FRDA 474>476. Cardiac muscle also exhibited severe defects of complexes I and II/III 
with a milder defect detectable in skeletal muscle 474,476. These four enzymes all 
contain iron-sulphur centers. Magnetic resonance imaging has shown increased iron 
content in the dentate nucleus of the cerebellum 47?, and iron levels are mildly
A H Q
increased in FRDA fibroblasts . Yeast, mouse, and human studies suggest that 
frataxin assembles as multimers of approximately 60 subunits and binds over 3000 
atoms of iron 479’480. Frataxin may therefore have roles in the storage, uptake or efflux, 
or bioavailability of mitochondrial iron. A mitochondrial ferritin has been identified
4 0 1
that may also serve this role but it has a severely limited tissue distribution 
Despite this evidence there is to date no evidence of MRC defects in cells cultured 
from FRDA patients 482. The role o f oxidative damage in the pathogenesis of FRDA is 
supported by the finding of elevated levels of urinary 8  hydroxy 2 ’ deoxyguanosine, a 
surrogate markers of oxidative damage 483, reduced blood free glutathione levels 35°, 
and elevated plasma malondialdehyde, a marker of lipid peroxidation 484. The 2-6 fold 
elevations of urinary 80H2’dG, shown in a study of 33 FRDA patients, was not 
related to GAA1 size or disease duration. The level of plasma DHBA 
(dihydroxybenzoic acid) a marker of hydroxyl radical attack was not elevated in this 
group of FRDA patients. MRC defects may be secondary to loss of mtDNA which 
itself may be the result of increased oxidative damage. MtDNA deficiency has been 
shown to be present but to a degree insufficient to explain the biochemical defect seen 
. The pattern of biochemical defect is similar to that seen in response to oxidative 
stress, as occurs in the manganese SOD knockout transgenic mouse 486, and in 
Huntington’s disease 372.
Evidence suggests a role for frataxin in mitochondrial iron-sulphur (Fe-S) centre 
synthesis. Loss of this function will affect the assembly of MRC complexes and many 
other intra and extra-mitochondrial proteins. Reduced MRC and aconitase function 
would lead to increased mitochondrial iron. Further evidence comes from phylogenic 
profiles that describe the distribution of genes within multiple genomes. This 
technique relies upon the fact that genes of similar function are often located in close 
proximity within the genome. These studies have revealed that Frataxin, or its 
homologues, are closely located to the numerous proteins already known to be 
involved pathways of iron-sulphur (Fe-S) centre assembly 487_489. Furthermore, 
similarities exist between FRDA and the X-linked sideroblastic anaemia with ataxia
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syndrome (XLSA/A), a condition as described above, caused by mutations in hABC7,
367another Ee-S cluster synthesis protein
3 Phosphorous magnetic resonance spectroscopy (31P MRS) provides an in vivo 
technique for the measurement of high-energy phosphorous compounds 
(phosphocreatine (PCr) and ATP). The rate of PCr recovery following exercise 
(Vmax) in skeletal muscle is a measure of the efficiency of OXPHOS. In cardiac 
muscle the PCr/ATP ratio is a good measure of energy availability 490. This technique 
reveals abnormalities in FRDA heart and skeletal muscle, the latter correlating to the 
GAA repeat size 490-492.
The addition of iron chelators to the culture medium in the YFH1 model prevents iron 
accumulation and improves MRC activities, but aconitase activity remains low 493. 
Frataxin also shows homology with the cyaY protein of y-purple bacteria. Its 
knockout in E.coli had no effect on viability, iron content, or susceptibility to 
oxidative stress 494. FRDA knockout mice die in utero. In mouse embryo studies 
frataxin expression increases from day 10 to 14 462>463. Conditional knockouts have 
been generated using a ere recombinase transgene under the control of muscle 
creatine kinase (MCK) or neurone specific enolase (NSE). This causes tissue specific 
deletion of exon 4 flanked by loxP sites. These mice died prematurely with features 
similar to FRDA 495. Cardiac muscle showed abnormal mitochondria, reduced SDH 
staining, and impaired complex I, II/III, and aconitase activities a pattern similar to 
that found in human tissues. Skeletal muscle was unaffected. Iron deposition was seen 
in MCK mice only, and at a later stage than the bioenergetic defects. Similarly, the 
mutation of several yeast proteins involved in the synthesis of iron-sulphur clusters 
also results in late secondary mitochondrial iron accumulation 496. Knock-in 
techniques have been used to generate double heterozygous knock-in mice, or knock- 
in/knock-out mice. Frataxin levels were reduced to 75% in the former, and 30% in the 
latter but the mice were clinically normal up to one year, and increased cardiac iron 
levels and fibrosis were found in only one mouse 497. Lower frataxin levels may be 
necessary for phenotypic consequences.
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The precise relationship between frataxin levels, impaired MRC function, oxidative 
stress, and anti oxidant defence levels in FRDA remains incompletely understood.
1.14 Therapeutic intervention in Class I and Class II mitochondrial disorders.
The evidence of disturbed bioenergetics in both the archetypal mitochondrial 
encephalomyopathies and other neurodegenerative disorders has provided therapeutic 
avenues for exploration.
The treatment of the archetypal encephalomyopathies includes the specific treatment 
of disease complications. This includes the use of beta-blockers for the treatment of 
cardiomyopathy, the avoidance of aminoglycoside antibiotics, and pacemakers for 
cardiac conduction defects. Various pharmacological agents have been trialed in these 
disorders but hard evidence of efficacy is lacking. This includes the use of quinone 
derivatives, vitamins Bi, B 12, C and K3 , metabolic supplements (succinate, creatine, 
and carnitine), dichloroacetate, and corticosteroids (for review see 498). Antioxidants 
appear to delay clinical progression in various mouse models of mitochondrial disease 
499. A further target for therapeutic intervention has been the apoptotic pathway, in 
view of the pivotal role of mitochondria within it 50°. Drugs, such as cyclosporin A, 
that inhibit the mitochondrial permeability transition pore have been proposed but not 
yet evaluated in mitochondrial disorders or models 501. Gene therapy to enable the 
expression of mtDNA protein encoding genes within the nucleus have succeeded in
fAA _
yeast models but failed in mammalian cells in vitro . To date the only success 
has been with the delivery of self-replicating plasmids to isolated mitochondria 504. 
Mechanisms have been identified within yeast for the transport of tRNAs into 
mitochondria 505 and these may provide pathways for the delivery of gene therapy. 
Other potential therapies have been designed to alter the level of heteroplasmy in 
favour of wild type molecules. These techniques include the selective inhibition of the 
replication of mutant molecules by sequence specific peptide nucleic acids 506; the use 
of oligomycin to inhibit mitochondrial ATP synthesis thus leading to an increase in
• 507wild type mtDNA ; and the use of bupivicaine or concentric exercise to induce the 
proliferation of satellite cells that usually contain lower levels of mutant mtDNA 508. 
Effective patient therapies remain elusive.
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Mitochondrially targeted therapies have also been employed in the class II disorders. 
Administration of vitamin E to AD patients has been shown to slow the rate of 
progression 509, and vitamin E and C to reduce the risk of AD 51°. Coenzyme Qio, an 
important antioxidant in mitochondrial and lipid membranes 511 ,512 and a MRC
c  1 i
enhancer, has been shown to increase ATP production in vitro . It has shown 
benefit in animal models of mitochondrial disease and transgenic ALS mice 514,515. 
Two clinical trials have suggested benefit from coenzyme Qio therapy in Parkinson’s 
disease 516,517. Creatine and phosphocreatine have important roles in brain energy
C I O
metabolism and the maintenance of membrane potentials . Creatine increases brain 
energy stores and compensates for an energetic defect, and has also been shown to 
stabilise the transition pore and to promote glutamate reuptake 519. Benefit has been 
shown in 3-nitropropionic acid and MPTP induced neurotoxic models of
520 523mitochondrial disease, and in transgenic ALS and HD mice
A wide range of agents has been proposed for the treatment of FRDA and other ataxic 
disorders. These include phosphatidylcholine, acetazolamide, serotonin and 
carbidopa, amantadine, lecithin and linoleic acid, choline chloride, gamma vinyl 
GABA ' . These trials were highly variable in their design and the outcome
measures utilised. Their unifying feature was that they assessed small numbers of 
patients for short periods of time and showed no, or equivocal, benefit. Modem 
therapeutic trials, designed in response to the evidence of mitochondrial iron 
accumulation, oxidative damage, and MRC abnormalities, therapeutic strategies have 
been developed for FRDA. Iron chelation restores mitochondrial iron levels and 
prevents MRC dysfunction in the yeast model 493. In vivo use has been problematic 
because desferrioxamine the most commonly used iron chelator is relatively 
hydrophilic with poor permeability across the plasma membrane 533,534. In vitro 
studies have shown that desferrioxamine can protect respiratory chain complex II 
activity and lipids from oxidation by iron, but reduces aconitase activity. Iron 
chelators may therefore simply displace the toxic effects of ferrous iron rather than 
protect against it 535. Other iron chelators that are able to mobilise mitochondrial iron 
stores have been developed and include 2 -pyridylcarboxyaldehyde isonicotinoyl 
hydrazone (PCIH) 534. Iron chelation therapy has not yet been evaluated in FRDA and 
several potential problems exist with this proposed method of treatment. Serum 
ferritin and iron levels are normal in FRDA 536 and iron accumulation may be only a
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secondary event in the pathogenesis of FRDA 495. Despite this the reduction of 
mitochondrial iron levels may still help prevent secondary oxidative damage, however 
other physiological consequences may ensue since iron still needs to be available for 
roles such as it’s incorporation into iron-sulphur centers.
Antioxidant agents employed in the treatment of FRDA include idebenone 483,537,538, 
coenzyme Qio and vitamin E 539, N-acetyl cysteine and selenium 
(http: //intemaf. or g/ataxia/nacupd. htmO.
Coenzyme Qio (2,3,dimethoxy-5-methyl-6-decaprenil-l,4-benzoquinone) is a 
naturally occurring antioxidant 540541. In 1957 it was isolated from beef heart 
mitochondria 542. It is a lipid of the quinonic group. Its name is derived from the fact 
that it has 10 isoprenoid units in its sidechain. Due to its ubiquitous distribution it is 
also referred to as ubiquinone. It acts as an electron carrier in the MRC and therefore 
part of its mechanism of action may be to enhance cellular ATP synthesis. Although 
Qio is at high concentrations within mitochondria it does not saturate enzymes that it 
interacts with. Changes in its availability can therefore directly affect the respiratory 
rate 543. An average daily diet contains 5 mg. After ingestion it is readily taken up into 
blood 544, brain 515, heart and liver. Idebenone, a short chain analogue of coenzyme 
Qio is well tolerated, and is known to cross the blood brain barrier 545.
Vitamin E was discovered in 1922 as a factor required to prevent reproductive failure 
in rats. It is a naturally occurring lipid soluble anti-oxidant. Its concentration is 
maximal in the mitochondria. Its structure was elucidated in 1937. It consists of 
tocopherols (a, p, y and 8 ), the former being the most metabolically active form, and 
tocotrienols that have an unsaturated side chain. Vitamin E is involved in intercepting 
the production of secondary radicals from lipid hydroperoxide. It achieves this in 
conjunction with the actions of glutathione and selenium. Vitamin E donates 
hydrogen from its phenolic group to the peroxyl radical, so reducing it to 
hydroperoxide and forming the poorly reactive tocopheryl radical. In rats, oral 
administration of vitamin E increases tissue levels, in particular those of heart, 
skeletal muscle, and brain 546. It has been used with varying results in cardiovascular 
disease, Parkinsons disease, and malignancies 547'549. In AVED, vitamin E therapy can
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lead to a mild improvement in cerebellar ataxia especially in those patients in the 
early stages of the disease 55°.
Vitamin E and coenzyme Qio may act synergistically. Qio regenerates a-tocopherol, 
the active form of vitamin E, by reducing the a-tocopheryl radical 551. In addition, 
vitamin E has been shown in vitro to reduce the formation of the bisemiquinonelO
552radical, thus increasing the lipophilicity of Qio
Following the in vitro demonstration that in control heart homoigenates, idebenone 
protects against Fe2+ induced complex II deficiency and lipoperoxidation, the effect of 
idebenone (5 mg/kg/day for 4 to 9 months) was assessed in three FRDA patients. The 
in vitro studies had also shown that iron chelators and antioxidants worsen some of 
the biochemical defects, and that the protective effects of idebenone were dependent 
upon the presence of succinate to reduce it. The in vivo studies revealed a substantial 
decreases in cardiac septal thickness, and left ventricular wall thickness in the three 
patients. Left ventricular mass index was reduced by 20% to 30%, and the shortening 
fraction was substantially improved. In one patient left ventricular outflow tract 
obstruction decreased from 40 to 10 mmHg pressure gradient, allowing the 
discontinuation of beta blocker therapy. Intra-rater variability of echocardiographic 
findings was not addressed in this small study. There were subjective reports of 
improved hand strength and fine movements, but no objective evidence of 
improvement in ataxia. Subsequently the same group have reported the results of an 
open trial of the same treatment in 40 FRDA patients. After 6  months treatment a 20% 
reduction in left ventricular mass was seen 48% of patients. Six patients had a reduced 
shortening fraction pre-treatment, and in 5 this improved 553’554.
Idebenone, used for 8  weeks at a dose of 5 mg/kg/day in 8  patients, has also been 
shown to significantly reduce, by 20%, the levels of 80H 2’dG (a marker of oxidative
483damage to DNA) but in another study, only a small non significant reduction in 
MDA (a product of lipid peroxidation) was seen 484.
A placebo controlled cross over trial of idebenone ( 120 mg tds) in 9 ambulant FRDA 
patients showed no echocardiographic changes. Treatment blocks were 6  weeks long
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with a three-week wash out period. 3 IP MRS and clinical parameters, as assessed by 
the international clinical ataxia rating scale (ICARS) 555 also showed no significant 
change 538.
Our own experience with the combined therapy of Coenzyme QIO (400 mg/day) and 
vitamin E (2100 IU/day) in 10 patients with FRDA is discussed in detail in chapter 6 . 
In summary, after 3 months treatment 31P MRS showed an increase of 178% in the 
PCr:ATP ratio of cardiac muscle, and a 139% increase in the skeletal muscle 
maximum rate of ATP production. The effect was related to GAA1 length for the 
latter but not the former. Furthermore these increases were greater in pre-hypertrophic 
hearts. Four years follow up has now been completed and these effects are 
maintained.
A recent open-labelled trial of one years treatment with idebenone in 9 FRDA patients 
aged 11-19 used ICARS, echocardiography, and neurophysiology to evaluate 
response. There was a significant reduction in ICARS score at 3 months. Cardiac
539parameters did not change
Future therapeutic trials in FRDA may make use of antioxidants or other agents 
coupled to the triphenylphosphonium cation, which facilitates mitochondrial targeting 
of the agent. In this way intra-mitochondrial vitamin E levels can be increased 80 fold
556. Potentials for gene therapy are also being explored, and may utilise drugs that 
interfere with the “sticky DNA” structures that are thought to be the cause of the 
transcription blockade that occurs in FRDA. Gene therapy would need to overcome a 
large number of hurdles before being a therapeutic option in FRDA. Not least of these 
would be the systemic manifestations of frataxin deficiency.
Therapeutic trials in FRDA are also hampered by the lack of natural history data, 
making it difficult to evaluate treatments that may only serve to slow down the rate of 
disease progression. Furthermore, there is a dearth of information regarding the 
suitability of the vast range of measurement tools that have been proposed for the 
evaluation of ataxia it treatment trials. These issues and the results of our own trial of 
combined Co Qio and vitamin E therapy in FRDA are the subject of chapter 6 .
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
The following equipment was used unless otherwise stated.
Tissue culture and human tissue handling equipment
ICN-Flow Automatic CO2 Incubator model 320 (ICN-Flow Ltd, High Wycombe, 
Bucks, UK); Gelaire (ICN-Flow) for tissue culture; Class 1 ICN Flow hood. 
Centrifuges
Beckman GPR bench-top centrifuge with GH-3.7 horizantal rotor (Beckman Ltd, 
High Wycombe, Bucks, UK), Kontron T-124 high speed centrifuge with 8.24 8x50ml 
fixed angle rotor (Kontron Instruments, Watford, Herts, UK), Biofuge 13 with 
18x 1.5ml fixed angle rotor (Haraeus, Germany), Fresco Microentrifuge (Heraeus). 
Electrophoresis equipment
Biorad 200/2.0 constant voltage power packs (BioRad Lab. Ltd., Hemel Hempstead, 
Herts, UK), BRL horizontal system for agarose gel electrophoresis (Bethseda Res 
Lab, Life Tech Inc., Gaithsburg, MD20887, USA) UV transilluminator (GRI Ltd., 
Dunmow. Essex, UK) and Polaroid camera.
Cell and Tissue homogenisers
Uni-form 5ml and 10ml glass/Teflon homogeniser (Jecons Ltd., Leighton Buzzard, 
Bedfordshire, UK), 5ml glass homogeniser and Glass-Col stirrer (CamLab Ltd., 
Cambridge, UK)
Spectrophotometers
Hitachi U-3210 (Hitachi Scientific Instrumants, Wokingham, Berks, UK) and 
Kontron Uvikon 940 (Kontron Instruments, Watford, Herts, UK) split beam 
spectrophotometers.
Microscopy and photography
Zeiss axiophot fluorescence microscope with FITC and rhodamine filters (Carl Zeiss 
Microscope Division, Oberkochen, Germany), Kodak ektachrome 400 for 
immunofluorescence.
Chemicals
Unless otherwise stated all chemicals were purchased from Sigma, Poole, Dorset, UK 
or Merck Ltd, Dagenham, Essex, UK.
101
2.2 Cell Culture
2.2.1 Cell lines
Myoblasts
Primary myoblast cultures were set up from 16 week old foetal skeletal muscle with 
ethical approval of Imperial College Medical School Ethics Committee.
A549 B2 Neo o° cells
These cells were a gift from Dr Ian Holt, Ninewells Hospital Dundee. A549 cells are 
an immortal cell line derived from a human male lung carcinoma. Depletion of 
mtDNA had been achieved by prolonged exposure to ethidium bromide at 50 ng/ml
557. This cell line had also been transfected with a gene conferring resistance to G418. 
206 p° cells
These cells were a gift from Dr G Attardi (CalTech, San Francisco, USA). This is an 
immortal cell line derived from the osteosarcoma line 143B.TK and rendered p° by 
the same technique as described for A549 cells. These cells are resistant to 
bromodeoxyuridine (BrdU).
NT2 cells fNtera2/Dl) fStratagene. UK)
NT2 cells are neuronal precursor stem cells derived from a human teratocarcinoma. 
Following treatment with retinoic acid these cells form post-mitotic mature neurones 
(hNT neurones) 558>559.
SHSY-5Y cells
SHSY-5Y are a human neuroblastoma cell line that can be differentiated with retinoic 
acid to produce a neuronal phenotype. This phenotype involves both morphological 
changes such as growth arrest and neuritic sprouting as well as biochemical changes 
such as the production of dopamine receptors 560.
IB3RN cells tECACC)
The IB3RN cell line is an SV40 transformed normal male human fibroblast line 
resistant to geneticin (G418)
STOG o° cells
STOG mouse fibroblasts cells were a kind gift from Dr P Simons, Dept of Anatomy, 
Royal Free Campus, UCL medical School. They were rendered p° by prolonged 
exposure to ethidium bromide. They are derived from Sim-1 cells (Sandos Inbred 
Mice) 561
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2.2.2 Cell growth conditions
All chemicals and plates were obtained from Life Technologies Ltd (Paisley, UK) 
except DMSO, pyruvate and BrdU which were from Sigma chemicals Co. (Poole, 
UK).
2.2.3 Cell culture maintenance and harvesting
Unless otherwise stated cells were grown on 10 cm plastic culture dishes. Myoblasts 
were grown in 10 cm pre coated plates (Sarstedt).
Fibroblasts, STOG, A549, IB3RN and NT2 cells were grown in standard growth 
medium, consisting of Dulbeco’s modified Eagles medium (DMEM) containing 
glucose (4.5g/litre) and glutamine (5mM), penicillin 50units/ml, streptomycin 50mg/l, 
10% (v/v) fetal calf serum, 0.2mM uridine and ImM sodium pyruvate. Myoblasts 
were grown in standard medium but with 20% (v/v) fetal calf serum. SHSY-5Y cells 
were grown in standard growth medium except that a 50:50 mix o f Eagle’s modified 
essential medium and Ham’s F I2 replaced the DMEM, with 15% (v/v) fetal calf 
serum, and 1% non-essential amino acids. Selection medium was made using the 
above ingredients, but omitting uridine and pyruvate, and using dialysed fetal calf 
serum (Labtech international). Growth medium was changed twice weekly. Cells 
were washed whenever medium was changed with sterile phosphate buffered saline 
(PBS, Sigma UK), consisting of 137mM NaCl, 2.7mM KC1, lOmM Na2 HPC>4 , and 
1.8mM KH2PO4 pH 7.4. When cells reached confluency they were subcultured by 
harvesting. To harvest, cells were first washed twice with PBS, then 1ml of 10% (v/v) 
trypsin (2.5%) in Versene was added for 1-2 minutes at 37°C until the cells were 
easily dislodged by gently tapping the plate. Trypsin was inactivated by the addition 
of 5 mis of fresh standard growth medium. Cells were then split onto 2-6 fresh plates, 
depending on their anticipated rate of growth, and total volume of medium on each 
plate was made up to 10 mis. Unless stated otherwise cells were grown at 37°C and 
8 % C 02.
Foetal myoblasts were cultured by placing the foetal limb in a bacterial petri dish, 
covering it with fungizone solution (5ml PBS, 0.1ml penicillin 50units/ml, 
streptomycin 50mg/l, and 0.5 ml Fungizone250pg/ml), and removing the skin. The 
muscle was isolated and minced with scissors. Erythrocytes were washed away with
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small volumes of PBS. The muscle was transferred to a 10ml of enzyme solution 
(Hams F10 with 2% L-glutamine and 1% penicillin 50units/ml, streptomycin 50mg/l, 
plus 0.1% (w/v) collagenase type I, 0.1% (w/v) bovine serum albumin, 0.15-0.2% 
(w/v) trypsin in DMEM. The enzyme solution was filter sterilized through a 0.2 
millipore filter. The muscle in enzyme solution was incubated at 37°C for 15 minutes 
with constant agitation. The enzyme solution was then neutralized with an equal 
volume of growth medium. The solution was trituated in a 10ml pipette for 1 minute 
to generate a smooth cell suspension. The solution was filtered through a sterile 40pm 
cell strainer (Fulcon). The filtrate was centrifuged at 350g/1000 rpm for 10 minutes at 
room temperature. The supernatant was removed and the pellet was resuspended in 
10ml of culture medium. The digestion process was repeated a further two times. The 
combined supernatants were placed onto 35 mm tissue culture dishes precoated with 
0.1% gelatin. The dishes were incubated at 37°C and 5% CO2 . The medium was
562changed every three to four days
2.2.4 Culture conditions for the generation of p° cell lines
Cells were grown in the presence of ethidium bromide (EtBr) (Sigma chemicals) at a 
final concentration of 5, 0.5, 0.05, 0.04, 0.025, 0.01, or 0.005 pg/ml, or in the 
presence of dideoxycytidine (ddC) (Sigma chemicals) at a final concentration of 1, 2, 
or 3 pM. The ethidium bromide or ddC were refreshed with each change of culture 
medium.
2.2.5 Cell freezing and defrosting
A confluent plate of cells was harvested and centrifuged at 350g for 10 mins at RT. 
The pellet was resuspended in sterile freezing medium. Freezing medium consisted of 
90% growth medium and 10% DMSO filter sterilised for all cells except NT2 and 
SHSY5Y for which 90% fetal calf serum and 10% DMSO was used. All cells were 
frozen in 1ml cryotubes and frozen slowly in polystyrene boxes at -70°C overnight 
before long term storage in liquid nitrogen.
Frozen cells were defrosted by rapidly thawing the vial in a water bath at 37°C. The 
contents of the vial were added to lOmls of pre-warmed growth medium and then 
centrifuged at 350g for 10 minutes. The supernatant was removed and the resultant
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pellet was resuspended in lOmls of fresh medium. The following day cells were 
washed with PBS and fed with fresh medium.
2.3 Cell fusion methods
Enucleations, and construction of A3243G/P0 and control cvbrids.
Fibroblasts for enucleation were grown until nearly confluent on collagen coated 2cm 
plastic discs cut from the bottom of 10cm culture dishes. These were sterilised by 15 
mins of exposure to UV light and then coated with 0.1% gelatin. The discs with 
fibroblasts attached were inverted in sterile centrifuge tubes containing 5mis of pre­
warmed DMEM containing 1 Opg/ml of cytochalasin B. Centrifugation at 12000g for 
20 mins achieved enucleation of >50% of fibroblasts as judged by direct visualisation 
under light microscopy. The cytoplasts (enucleated fibroblasts) were incubated with 
3x105 p° cells for 3 hours at 37°C. Fusion was then achieved by agitating the cells 
upon their coverslips for 1 minute in polyethylene glycol (PEG) 50%w/v and DMSO 
(10%w/v) in DMEM. Coverslips were then washed three times in DMEM / 
10%DMSO with a final wash in standard growth medium. 24 hours later cells were 
plated at very low density in selection medium. Growing colonies were identified and 
isolated 3-6 weeks later.
Platelet fusions
30 ml of venous blood was taken using a 19G butterfly and no tourniquet. The blood 
was mixed with 3ml of 3.8% (w/v) tri-sodium citrate to prevent clotting. The platelet 
rich plasma (PRP) was separated by centrifugation at 200g for 20 mins. The 
supernatant containing PRP was taken off and prostaglandin h  (fc 3.5nM) added to 
prevent platelet aggregation. The PRP was then centrifuged at lOOOg for 30 mins. The 
resultant PRP pellet was then resuspended in 15mls of modified Tyrodes buffer (see 
appendix) centrifuged at lOOOg for 10 minutes. This Tyrodes wash was repeated twice 
more.
p° cells were prepared for fusion by harvesting, counting using a haemocytometer, 
and resuspending in Ca2+ free DMEM to a concentration on 5x10s cells /ml. 2 mis of 
this was added to the PRP pellet, and the mixture then centrifuged at 200g for 5 mins. 
The supernatant was aspirated and the pellet containing platelets and p° cells was 
resuspended in 100pl of PEG/DMEM mixture (5g PEG 1500 in 4ml Ca2+ free DMEM
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and 1ml DMSO). The suspension was incubated for exactly 1 minute by agitation by 
pipetting. 1 0  ml of standard growth medium was then added and cells transferred to a 
10cm culture dish. The next day cells were washed 3 times with PBS to remove debris 
and fed with standard growth medium. 24 hours later medium was replaced by 
selection growth medium. Growing colonies were identified and isolated 3-6 weeks 
later.
2.4 Isolation of clones
Two different techniques were used. 1) Plastic rings were cut from the tops of 0.5ml 
eppendorfs and autoclaved. Growth medium was removed from the culture duishes 
containing mature colonies, and two PBS washes were performed. The sterile plastic 
rings were dipped in UV sterilised high vacuum silicone grease and then placed so as 
to surround the individual clones. lOOpl of trypsin was added to each well and the 
clone harvested with lOOpl of standard growth medium. The cells were them 
transferred to 35mm culture dishes for further growth and grown in non-selection 
medium from this point onwards. 2) Sterile lOOpl pipette tips were used to draw up 
50pl of growth medium followed by 50pl of air so as to leave the bottom half of the 
tip empty, with medium above this air space. The tip could then be used to scrape 
over an individual colony, causing the cells of the colony to impact into the air space 
of the tip. The medium in the upper part of the tip could then be used to flush out the 
cells onto a fresh 35mm culture dish for further growth. Cells were grown in non­
selection medium from this point onwards.
2.5 DNA extraction
DNA was extracted from 1-I0xl06 cells or 2-5mls of whole blood using the Nucleon 
1 DNA extraction kit (Scotlab, UK) according to the manufacturer’s instructions. The 
extracted DNA was stored in 50pl sterile TE at -20°C. The yield was approximately 
5pg DNA per 106 cells.
2.6 Estimation of DNA concentration and purity
5pi of DNA solution was added to 995pi ddH20  in a 1ml silica quartz cuvette and 
mixed by inversion. The solution was scanned by measuring the absorbance pattern 
between 210nm and 310nm. The DNA concentration (pg/pl) was calculated assuming
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that a 1 mg/ml DNA solution has an absorbance of 20 at 260nm (Maniatis). The purity 
of DNA was accepted when the A2 60/A280 ratio was between 1.7 and 2.0.
2.7 Polymerase Chain Reaction (PCR)
DNA primers, dATP, dGTP, dCTP, dTTP, Taq polymerase, polymerase buffer, and 
MgCh were obtained from Perkin-Elmer Ltd (Bucks, UK). The standard PCR 
mixture, total volume 50pl, contained DNA (1 pg), forward and reverse primers (25 
pmol, see relevant chapters for primer sequences), 0.2mM of each dNTP, 1.5mM 
MgCh, and 5 units of Taq polymerase, and polymerase buffer (20mM Tris-HCl, 
lOOmM KC1 pH7.5). The reaction was either carried out in 0.5 ml eppendorf tubes, 
with sterile paraffin overlayed, or in 0.3ml thin walled PCR tubes using a Perkin- 
Elmer 2400 thermal cycler.
Standard reaction conditions were an initial denaturation of 94°C for 4 mins. Taq 
polymerase was added at 72°C if the reaction required a “hot start”. This was followed 
by 1 minute of denaturation at 94°C, 1 minute of primer annealing (see relevant 
chapters for annealing temperatures), and 1 minute of primer extension at 72°C 
repeated for 25-35 cycles. Finally the reaction was completed with lOmins of 
extension at 72°C. Variations of these standard conditions were used, and are 
described in the relevant chapters.
2.8 Semi-quantitative PCR detection of mtDNA levels
PCR amplification of a 630bp fragment of mtDNA (2928-3 558bp) was performed. 
Standard PCR conditions were used (section 2.7) with an annealing temperature of 
60°C. The forward primer at nt 2928mtDNA:5’-CCT AGG GAT AAC AGC GCA 
AT-3’ and the reverse primer at nt 3558mtDNA:5’-TAG AAG AGC GAT GGT GAG 
AG-3’ were used to amplify the mtDNA fragment. The PCR products were visualised 
on a 1.2% agarose gel. Comparisons were made with normal controls and a standard 
curve constructed with a dilution series of cellular DNA starting with 50jiig. Known p° 
cell lines were also used as positive controls. This allowed for a semi-quantitative 
analysis of mtDNA levels.
A lkb PCR was also performed on occasions to exclude the presence of a nuclear 
pseudogene mimicking the persistence of mtDNA after attempted depletion. The 
forward primer at nt 8765 mtDNA:5’-CCA CAA CTA ACC TCC TCG GA and the
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reverse primer at nt 9765 mtDNA:5’-TGA AGG GAG ACT CGA AGT AC were 
used to amplify the mtDNA fragment, using standard PCR conditions and an 
annealing temperature of 59°C.
2.9 Restriction enzyme digests of DNA
All enzymes and buffers were obtained from Promega (Chilworth Science Park, 
Southampton). Conditions for individual restriction digests are given in the relevant 
chapters.
2.10 Detection of PCR DNA products
All PCR reaction products and restriction digest products were separated on agarose 
gels using the BRL horizontal system for agarose gel electrophoresis (Bethseda Res 
Lab., Life Technologies Inc.). 0.8-1.2% (w/v) agarose gels (Sigma) were prepared in 
lxTAE buffer containing lpg/ml ethidium bromide. To facilitate loading onto the gel, 
PCR products, restriction digest products, and DNA size markers (Smartladder 
(containing fragments of 200bp to 10 kb, Eurogentec, Belgium), or lkb ladder were 
all diluted in 6x loading buffer (Promega UK Ltd, Hants). Electrophoresis was 
performed in lxTAE buffer at 40-100 Volts for 1-3 hours. The sample was visualised 
using an ultraviolet transilluminator and then photographed with a Polaroid camera.
2.11 Determination of mutant load
Apa I digest
1 jllI  of Apal restriction enzyme (Promega, Chilworth Science Park, Southampton), 
was added to 2.3 pi of restriction enzyme buffer and 20pl of sample. The mixture was 
incubated at 37°C for 1 hour. The products of the reaction were run on an agarsoe gel.
Polymerase chain reaction with fluorescent dUTPs
lpl of fluorescently labelled deoxynucleotides (dUTPs) (R6G IX 3nmol; ABI 
PRISM) that had been diluted 5 times in water, was added prior to the last cycle of the 
PCR. The PCR products were purified and subjected to restriction fragment length 
polymorphism analysis.
Automated capillary electrophoresis (ABI PRISM® 373A, Perkin Elmer) was used for 
the quantitation of the heteroplasmic proportions for the specific mtDNA mutation in
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different patient samples. The digested sample was precipitated using 4 volumes of 
ethanol per volume pf product. The pellet was mixed with 0.5 loading dye, 2 j l i 1 of 
water and 0.5pl of GeneScan-400HD size standard that contains 21 DNA fragments 
ranging in size from 50 to 400 bp. The run was executed with the ABI PRISM® 373A 
Data Collection Software (version 1.2). The capillary was filled with the Performance 
Optimized Polymer 4 (POP4) that achieves size separation of DNA fragments.
After completion of the run (approximately 40 minutes per sample), analysis was 
accomplished with the GeneScan® Analysis software (version 3.0) that uses the size 
standard to determine the size of unknown DNA fragments. The GeneScan Analysis 
software calculates the size of the unknown DNA sample fragments by generating a 
calibration or sizing curve based upon the migration times of the fragments in the 
standard. The unknown fragments are mapped onto the curve and converted from 
migration times to sizes.
Calculation of the percentage of heteroplasmy was achieved by dividing the peak area 
to data point ratio of the undigested product over the sum of the peak areas to data 
point ratios of the digested and undigested products.
2.12 Enzyme Analyses
All assays were performed on either Hitachi U3210 or Kontron 940 dual-beam 
spectrophotometers at 30°C in a final volume of 1 ml. Each enzyme was assayed in 
triplicate and values accepted if they were within 15% of each other. All chemicals 
were from Sigma Chemical Company and Boehringer Mannheim.
2.12.1 Citrate Synthase (CS)
CS is a mitochondrial matrix enzyme which was used as an indicator of mitochondrial 
mass in preparations as it has not known to be altered in disease states (Cooper JM 
personal communication). Respiratory chain activities were expressed as CS ratios to 
correct for variation in the purity of mitochondrial preparations or to correct for 
variation in the mitochondrial mass in tissue homogenates. The assay is based on the 
method of Coore et al 1971 563. The enzyme catalyses the condensation of acetyl-CoA 
and oxaloacetate to form citrate, producing CoA whose free thiol group combines 
with the 5-5’-dithiobis-nitrobenzoic acid (DTNB), resulting in an increase in the 
absorbance at 412nm.
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Two cuvettes were set up containing: lOOmM Tris-HCl buffer pH8.0, 200 pM Acetyl- 
CoA, 200 pM DTNB, 0.1% (v/v) Triton-X-100 and sample in a final volume of lml. 
The reaction was initiated by the addition of lOOpM oxaloacetate and the increase in 
absorbance at 412nm measured. Citrate synthase activity was calculated using the
a
molar extinction coefficient of 13.6 x 10 for the DTNB-CoA-SH complex and 
activity expressed as nmol/min/mg protein.
2.12.2 NADH-CoOi oxidoreductase (complex I activity)
The method of Ragan (1987) was used to measure the rotenone sensitive CoQi 
dependant oxidation of NADH at 340nm 564. CoQi was a gift from Eisai Chemical 
Co, Japan. A dilution of stock CoQi was made in ethanol and its absorbance at 275 
nm noted. Complete reduction of quinone to quinol was achieved by addition of 
excess sodium borohydride to the reference cuvette. The resultant absorbance change 
was used to calculate the CoQi concentration using a molar extinction coefficient of 
2.25x103 565.
Two identical cuvettes were set up containing 20mM potassium phosphate buffer 
pH7.2 with 8mM MgCl2, 150pM NADH, ImM KCN, 2.5 mg/ml BSA and sample. 
The reaction was initiated in the test cuvette by adding 50 pM CoQi. The rate of 
NADH oxidation was monitored by the change in absorbance at 340nm. After 10 
minutes 10 pM rotenone was added to the test cuvette and the rotenone insensitive 
rate measured for a further 10 minutes. The complex I activity was defined as the 
rotenone sensitive rate (i.e. the total rate minus the rotenone insensitive rate). 
Calculation of activity used a molar extinction coefficient of 6.81xl03 for NADH to 
allow for the contribution of reduced CoQi to the absorbance at 340nm. Enzyme 
activity was expressed as a ratio with citrate synthase (CS)
2.12.3 Succinate cytochrome c oxidoreductase (complex II/IIII
This assay, based on the method of King 566, determines the combined activity of 
complex II and III. It detects the antimycin A sensitive, succinate dependent, 
reduction of cytochrome c at 55nm.
0.1M potassium phosphate buffer pH 7.4, 0.3mM potassium (K2) EDTA, and O.lmM 
cytochrome c were added to two identical cuvettes. Into two eppendorfs was placed 
ImM KCN, 20mM succinate and sample. These were incubated at 30°C for 5 minutes
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to fully activate the enzyme. The contents of the eppendorfs were then added to the 
cuvettes to initiate the reaction. The change in absorbance at 550nm was monitored. 
After 10 minutes 20 pM antimycin A was added. The complex II/III activity was 
calculated as the rate which was sensitive to antimycin A using the molar extinction 
coefficient of cytochrome c (19.2x103). Enzyme activity was expressed as a ratio with 
citrate synthase (CS).
2.12.4 Succinate-ubiquinol oxidoreductase (complex II)
This assay, based on the method of Hatefi et al 567measures, at 660nm, the reduction 
a dye, 6,6-dichlorophenolindophenol (DCPIP) in the presence of succinate and 
ubiquinone-2 (C0 Q2). Enzyme activity is taken as the rate inhibited by 2- 
thenoyltrifluoroacetone (TTFA).
Two identical cuvettes were prepared containing 50mM potassium phosphate buffer 
pH7.4, O.lmM K2-EDTA, 20mM sodium succinate, 74 pM DCPIP, ImM KCN, 
lOpM rotenone and sample. 50pM of ubiquinol-2 was added to initiate the reaction. 
After 10 minutes ImM TTFA was added to inhibit the reaction. Activity was 
calculated using the molar extinction coefficient of DCPIP (2.1x10 ). Enzyme activity 
was expressed as a ratio with citrate synthase (CS).
2.12.5 Ubiquinol-cvtochrome c reductase (complex III1
• • c/:o #This assay is based on the method of Birch-Machin et al . Ubiquinol-cytochrome c 
reductase catalyses the oxidation of ubiquinol and the reduction of cytochrome c. This 
is measured at 550nm. The concentrations of ubiquinone-2 and cytochrome c 
influence the reaction rate. Their concentrations are therefore established prior to 
enzyme assay. To determine the cytochrome c concentration 15 pM of cytochrome c 
in ddFhO (final volume 1 ml) was added to two identical cuvettes. A few granules of 
ascorbate were added to the reference cuvette thus reducing the cytochrome c. The 
absorbance change was noted and the cytochrome c concentration calculated 
(extinction coefficient 19.2mM).
Ubiquinol-2 was prepared from ubiquinone -2  (lOmM) in ethanol acidified to pH2 
with HC1. After addition of ddlUO to a final volume of 1ml, a few granules of sodium 
borohydride were added to reduce quinone to quinol. The quinol was extracted into 
3ml of diethyl ether: cy c lohexane (2:1 v/v) and the upper phase collected. 1ml of 2M 
NaCl was added and the upper diethylether phase collected. This was evaporated to
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dryness under a stream of nitrogen gas. The resultant residue was dissolved in 1ml of 
ethanolr acidified to pH2 with HC1 and alliquoted and stored at -20°C under nitrogen 
gas to prevent oxidation.
To lOpl of ubiquinol-2 was added lOpl of 5M KOH and 980pl of ethanol. The 
subsequent oxidation of ubiquinol-2 to ubiquinone-2 led to an absorbance change at 
275nm from which the concentration of ubiquinol-2 was determined using the 
extinction coefficient of 12.25mM.
The rate of non-enzymatic reduction of cytochrome c, influenced by the 
concentrations of ubiquinone-2 and ubiquinol-2, that occurs in this reaction was 
determined and subtracted from the observed sample rate. Identical cuvettes were set 
up with all reaction ingredients (see below) except ubiquinol and sample. Ubiquinol-2 
was then added to the test cuvette and the rate of absorbance change at 550nm noted. 
The non-enzymatic activity was calculated as below.
To assay complex III activity the reaction contained 35mM potassium phosphate 
buffer pH7.2, ImM K2 EDTA, 5mM MgCU, 2mM KCN, 5pM rotenone and 15pM 
cytochrome c. 15pM ubiquinol-2 was added to the test cuvette to initiate the reaction 
which was followed at 550nm for 5 minutes.
Calculation of the pseudo first-order rate constant (k) is performed by extrapolation of 
the absorbance back to time=0 and determination of the change in absorbance at 
various time points up to two minutes. The non-enzymatic rate was calculated in the 
same way and subtracted from the sample rate. K/min/ml was calculated by: {lnO.288- 
ln(0.288-change in absorbance at time t) x 1000/sample volume(pl) x dilution factor}, 
where 0.288 represents the absorbance of fully reduced cytochrome c. The k/ml 
values for five time points were plotted against time and the gradient of the line was 
calculatedusing linear regression analysis (k/min/ml). Results were expressed as a 
ratio with citrate synthase (CS).
2.12.6 Cytochrome c oxidase (complex IV)
This assay is based on the method of Wharton et al 569 and monitors the oxidation of 
reduced cytochrome c at 550nm.
Reduced cytochrome c was prepared from 100 mis of a 1% (w/v) solution of horse 
heart cytochrome c in lOmM potassium phosphate buffer. This was reduced by adding 
an excess (13mg) of ascorbate. Complete reduction was confirmed by 
spectrophotometry at 550nm, using two cuvettes containing 50pl of the cytochrome c
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solution and 950pl of lOmM potassium phosphate buffer. lOpl of freshly made 
saturated ascorbate solution was added to the sample cuvette. A positive change in 
absorbance would indicate that the cytochrome c solution could be further reduced by 
the addition of ascorbate, and was therefore not yet fully reduced. When fully 
reduced, removal of the ascorbate from the cytochrome c solution was achieved by 
dialysis, using size 1 dialysis tubing (Medicell International Ltd., London) and 
dialysing against 51itres of lOmM potassium phosphate buffer pH7.0 at 4°C overnight. 
To confirm complete removal of ascorbate, oxidised cytochrome c was added to a 
sample of the dialysed reduced cytochrome c. No change in absorbance implied 
complete removal of ascorbate.
The concentration of reduced cytochrome c was calculated by placing lOOpl of 
lOOmM potassium phosphate buffer pH7.0, 850pl ddH20, and 50pi of reduced 
cytochrome c in two identical cuvettes. lOpl of 0.1 M K+ Ferricyanide was added to 
the reference cuvette to oxidise the reduced cytochrome c. The change in absorbance 
was noted and the concentration calculated by: 0.96/Absx50=volume of stock 
cytochrome c solution required for 50pM solution (where 50pM cytochrome c 
produces an absorbance of 0.96).
The enzyme assay was performed by adding lOmM potassium phosphate buffer and 
and 50pM cytochrome c to two identical cuvettes. lOpl of lOOmM K+ Ferricyanide 
was added to the reference cuvette to oxidise the cytochrome c. The initial absorbance 
was noted (0.96=50 pM cytochrome c) and the reaction initiated by the addition of 
sample to the test cuvette. The reaction was followed at 550nm. The pseudo first- 
order constant k was calculated as for the complex III assay. Complex IV activity 
(k/min/ml) was expressed as a ratio with citrate synthase (CS).
2.12.7 Aconitase
Aconitase catalyses the isomerisation of citrate to isocitrate. With the reduction of 
NADP this product then forms a-ketoglutarate. This assay measures this reduction of 
NADP at 340nm. Into two identical cuvettes are added 50mM Tris-HCl pH7.4, 
0.4mM NADP, 5mM sodium citrate, 0.6mM MgCL, \% (v/v) Triton X-100 and 2 units 
of isocitrate dehydrogenase. Sample was added to the test cuvette only, and both 
cuvettes were pre-incubated at 30°C for 30 minutes. The absorbance change at 340nm 
was then followed for 15 minutes. Aconitase activity was calculated using the molar 
extinction coefficient for NADP (6.22x103).
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2.13 Preparation of mitochondrial-enriched fractions (MEFs)
MEFs were prepared from twenty confluent 10cm plates of cells based on the method 
of Ragan et al 564. Harvested cells were washed three times in PBS and the resultant 
pellet frozen at -70°C overnight. The pellets were thawed and resuspended in 2ml of 
ice-cold homogenisation buffer (see appendix). Each sample was homogenised on ice 
using a Potter homogeniser for 20 strokes at 1000 rpm. The sample was spun at 1500g 
for 10 minutes at 4°C. The resultant post-nuclear supernatant (PNS) was collected into 
a fresh tube on ice. Homogenisation of the residual pellet in a further 2ml of 
homogenisation buffer and subsequent centrifugation was performed twice more. The 
combined PNS (6 mis) was subjected to a further centrifugation and any resudual 
pellet discarded. The final PNS was centrifuged at 10,000g for 12 minutes at 4°C on a 
Kontron Centrikon T-124. A small brown pellet, the mitochondrial enriched fraction, 
was generated. This was resuspended in 200-800pl of ice-cold homogenisation buffer, 
snap frozen in liquid nitrogen and stored at -70°C for a maximum of five days before 
assaying. All samples were freeze thawed in liquid nitrogen three times before 
assaying to maximise the mitochondrial enzyme activities.
2.14 Preparation of brain homogenates
Brain samples were stored at -70°C. Aliquots were removed, put in liquid nitrogen 
and weighed. Homogenisation was performed in nine volumes of ice-cold 
homogenisation buffer using a 5ml glass/Teflon homogeniser. Samples were freeze- 
thawed as above prior to immediate assaying.
2.15 Preparation of muscle homogenates
Muscle samples were stored at -70°C. Aliquots were removed, put in liquid nitrogen 
and weighed. Homogenisation was performed in ice-cold homogenisation buffer 
using a glass/glass homogeniser. Samples were freeze-thawed as above prior to 
immediate assaying.
2.16 Preparation of cell homogenates (for aconitase assavl
Three confluent plates of cells were harvested using a cell scraper (Lifetech Ltd). 
Cells were washed three times in PBS and the pellet was then resuspended in 1ml of 
ice-cold homogenisation buffer. Assays were performed immediately.
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2.17 Protein assay
All protein assays were performed using the Pierce-Warriner BCA™ Protein assay 
reagent. This system uses the reaction of protein with Cu2+ in an alkaline environment 
to form Cu1+ which is then detected by the reagent bicinchoninic acid (BCA). The 
purple reaction product of BCA and Cu1+ is water-soluble and exhibits a strong 
absorbance at 562nm. For each assay a set of protein standards, made to cover the 
range of protein concentrations expected for the samples being tested, was made using 
bovine serum albumin (BSA) in the same diluent as the samples. The assay was 
performed according to the manufacturers instructions. The protocol requiring thirty 
minutes incubation at room temperature was used. Each assay was performed in 
triplicate.
2.18 Immunofluorescence staining of cultured cells
Cultured cells were seeded onto coverslips. Coverslips were washed three times im 
PBS, and then fixed in pre-warmed 4% paraformaldehyde in PBS for 20 minutes. 
After a further three washes in PBS coverslips were immersed in methanol at -20°C 
for 15 minutes. After a further three washes in PBS coverslips were blocked with 10% 
normal goat serum in PBSfor 30 minutes at 37°C in a humidified atmosphere. Cells 
were then incubated with the primary antibody for 2 hours at 37°C, then washed, then 
incubated with goat anti-mouse IgG Alexa® 488 (molecular probes, Inc.) for 1 hour at 
37°C. After a final three washes in PBS coverslips were mounted on glass slides in 
Citifluor/PBS/glycerol (Agar) supplemented with 1 pg/ml of DAPI (Sigma).
2.19 Microscopy and photography
All microscopy for immunofluorescent staining of cultured cells was performed using 
a Zeiss axiophot microscope (Carl Zeiss microscope division, Oberkochen, Germany) 
with Kodak EPH pl600 (ASA 3200) film.
2.20 Statistical analysis
Statistical analysis of all enzyme activity data was performed using the Mann- 
Whitney U test via Instat statistical software for enzyme assay data.
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2.21 Health-Related Quality of Life in Friedreich’s Ataxia
2.21.1 Patients
Fifty-six patients with clinically defined FRDA, and with confirmed homozygosity for 
the GAA intronic repeat expansions in the FRDA gene were recruited via the Ataxia 
Society. The patients had contacted us in response to an advertisement placed in the 
Ataxia Society magazine asking for volunteers for a therapeutic trial.
2.21.2 Genetic Analysis
Prior to recruitment into this study, the diagnosis of FRDA was confirmed in all 
patients by the detection of the GAA repeat expansion within our own laboratory
2.21.3 Health status measures
A single questionnaire containing demographic questions and the four health status 
measures were sent by post to these 56 patients. The four health status measures used 
were the Barthel Index, General Health questionnaire, Euroqol, and short form 36. 
Questionnaires were sent out at t=0 and resent to non-respondents at 6 weeks, and 
again at 6 weeks after that. Only patients over the age of 18 were sent the 
questionnaire since these health measures have not previously been validated for use 
in children.
The SF-36 contains eight domains and a single question about perceived changes in 
health change over the preceding month. A scoring algorithm converts the raw scores 
onto a scale from 0 (poor health) to 100 (good health). Two summary scales, the 
Physical Component Summary Score (PCS) and the Mental Component Summary 
Score (MCS) can be derived. Scores above 50 imply better health than the mean of 
the general population and scores below 50 imply worse health. There is one further 
unsealed item in the SF-36 asking respondents about health change over the past year. 
Findings can be compared with normative data obtained in the UK 570,571.
Euroqol was developed by a multidisciplinary group of researchers from 5 European 
countries. It requests one of three possible responses of no problem, some problems, 
unable or extreme problems to questions regarding mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression (table 6.1). A single overall score is also 
gained by the Euroqol thermometer, a simple visual analogue scale. The items that 
comprise the Barthel Index and the GHQ 12 are also listed in table 2.1.
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EuroOol Health State SF-36
Mobility (1 item) Physical functioning (10 items)
Self care (1 item) Social functioning (2 items)
Usual activity (1 item) Role limitations due to physical problems (4 items)
Pain/discomfort (1 item) Role limitations due to emotional problems (3 items)
Anxiety/depression (1 item) Mental health (5 items)
Energy/vitality (4 items)
Pain (2 items)
General health perception (5 items)
Barthel GHO 12
Bathing (1 item) Concentration (1 item)
Transfer (1 item) Worry (1 item)
Dressing (1 item) Playing a useful part in things (1 item)
Feeding (1 item) Making decisions (1 item)
Mobility (1 item) Under strain (1 item)
Stairs (1 item) Overcoming difficulties (1 item)
Toilet use (1 item) Enjoying normal activities (1 item)
Grooming (1 item) Facing up to problems (1 item)
Bladder (1 item) Unhappy and depressed (1 item)
Bowels (1 item) Self confidence (1 item)
Worthlessness (1 item)
Happiness (1 item)
Table 2.1
Dimensions of four health measures: Barthel, General Health Questionnaire 12, 
EuroQol Health State and Short Form 36. Numbers in brackets show the number of 
items in each category.
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2.22 Friedreich’s ataxia; Evaluation of ICARS and Factors Influencing 
Clinical Progression. 
2.22.1 Patients.
Patients were recruited via Ataxia UK and by direct referral from consultant 
Neurologists. All assessments and investigations were performed with the approval of 
the Royal Free Hospital Ethics committee.
2.22.2 Genetic Analysis.
Genetic analysis was performed as in 2.21.2
2.22.3 Clinical Assessments
Patients were examined and assessed using ICARS on a total of 209 occasions. 
Examinations were recorded onto videotape. Ten patients were entered into a pilot 
open labelled study following their initial assessments 539, and a further 3 patients 
were added to the pilot study following several assessments. The remaining 64 
patients were assessed on two or three occasions and 50 patients were entered into a 
double-blind, randomised, placebo-controlled treatment trial o f combined vitamin E 
and coenzyme Qio- The same examiner (PEH) performed all assessments. At selected 
assessments patients also underwent studies to evaluate the symptoms associated with 
cardiac (Dr J Joshi, National Amyloidosis centre, Royal Free Hospital), 
neurophysiology (Dr M Al-Khayatt, Department of Neurosciences, Royal Free 
Hospital), speech, swallowing and upper and lower limb co-ordination as part of the 
therapeutic trial.
Activities of daily living (ADL) were scored using a 0 to 36 point scale modified from 
standard scales 572. A maximum of four points from normal to severe disability was 
assigned to speech, swallowing, cutting food and handling utensils, dressing, personal 
hygiene, falling, walking, quality of sitting position, and bladder function.
Retrospective analysis of disease progression was achieved using a patient 
questionnaire and interview. This ascertained five disease stages (0-4) as defined by 
the age at which the patient first: 0) had difficulty walking, 1) always required aid 
while walking outside, 2) used a wheelchair, 3) had to use a wheelchair all the time 
when outside, and 4) had to use a wheelchair all the time when outside or inside.
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Complete 2D echocardiography and Doppler studies were performed using GE 
Vingmed System V performance ultrasound machine with wide band width 2.5mHz 
centre frequency probe with coded harmonics. Left ventricular wall thickness was 
measured from the anterior and posterior walls from short axis cuts at the mitral level, 
papillary muscle and apex, and corrected for body surface area in children.
Nerve conduction studies were performed with a Medelec Saphire 112ME and evoked 
potential using a Digitimer D200. Limb temperatures were maintained at room 
temperature. Sensory action potentials (SAP) and sensory nerve conduction velocities 
(SNCV) were determined in the right median, ulnar, radial and sural nerves. Motor 
studies were performed on the right median and common peroneal nerves by placing 
surface electrodes on the right abductor policis brevis and extensor digitorum brevis 
muscle respectively. Somatosensory evoked potentials (SSEP) were analysed on the 
right median nerve. Latencies to Erbs point (N9), cervical region (N13) and parietal 
cortex (N20) were calculated.
The presence of diabetes mellitus or impaired glucose tolerance was ascertained by 
patient history and by random plasma glucose and HbAlc analysis. Optic neuropathy 
and scoliosis were defined by patient history alone.
2.22.4 Statistical analysis
Single and multiple linear regression analyses were performed using SPSS. 
Retrospective analysis of disease progression was analysed between groups via 
weighted means at subsequent timepoints with the weights based on estimated 
survival curves as described by Zilber et al 1994 573. Due to censored observations at 
intermediate stages the method was slightly modified. Each survival curve was 
bounded by the survival curve of the following stage. Group comparisons were done 
with a closed test procedure of F  tests in repeated measurement ANOVAs (analysis of 
variance).
119
CHAPTER 3
NUCLEAR INFLUENCES ON THE BIOCHEMICAL EXPRESSION OF THE 
A3243G MITOCHONDRIAL DNA MUTATION.
3.1 Introduction
Phenotypic variability is a key feature of the archetypal mitochondrial disorders. 
Patients can present at a wide range of ages with mild or severe disease. Patients may 
have an isolated slowly progressive non-disabling myopathy, or present with a severe 
multi-system disorder that proves rapidly fatal.
Mutation load is generally accepted as a key factor underlying this phenotypic 
variability. However as previously discussed (section 1.8.1.2) a number of studies 
have failed to confirm a threshold effect and alternative mechanisms have been 
suggested to determine the phenotypic consequences of mtDNA point mutations. Both 
nuclear and secondary mtDNA factors have been suggested and the experiments in 
this chapter were designed to explore this hypothesis.
Four aspects have been addressed in this experimentation.
does the nuclear background of the recipient cell influence the level of
A3243G mtDNA that can be established in cybrids,
what is the effect of mutant mtDNA level on MRC function,
what is the effect of mutant mtDNA levels on reactive oxygen species
injury in cybrid clones,
what influence does nuclear background have on these preceeding two 
issues.
To study this mtDNA from patients with severe and mild A3243G associated 
phenotypes was fused with a variety of nuclear backgrounds, and resultant cybrids 
were analysed for mutant load, MRC function, and oxidative damage.
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3.2 Experimental Hypothesis
The phenotypic variability associated with the A3243G common MEL AS pathogenic 
mtDNA mutation is influenced by its nuclear environment and mtDNA genotype.
3.3 Experimental Design
The experiment was designed in two parts. Part A of the experiment was designed to 
test the integrity of the experimental techniques used in part B, and is described in full 
below. Part B forms the core part of the experiment and involves the fusion of 
different A3243G containing mtDNA with different nuclear backgrounds. The effect 
on the MRC function and aconitase activity of the resultant cybrids of varying mutant 
load would allow analysis of the effect of nuclear or mitochondrial background upon 
the expression of the A3243G mutation.
Part A: The generation of cybrid clones containing nuclear and mitochondrial DNA of 
different origins relies on the generation of p° cells that lack mtDNA. The 
introduction of foreign mtDNA to these cells then allows their survival in culture 
conditions that select for cells with intact MRC function. In order to rely upon this 
technique it must first be established to what extent p° cells are truly devoid of 
mtDNA, whether small amounts of native mtDNA persist and whether these have the 
potential to repopulate their parent cells. After fusion of platelets or enucleated 
fibriblasts with p° cells, prolonged culture is necessary for clones to become 
established. There is therefore a hypothetical concern that during this prolonged 
culture, p° cells with levels of native mtDNA below the level of detection may be able 
to repopulate themselves with self mtDNA. These cells would then be able to survive 
the selection process designed to ensure that only p° cells that have successfully fused 
with patient mtDNA proliferate. Therefore in this part of the experimentation the 
mtDNA content of p° cells was tested using semiquantative PCR and 
immunoflourescnece, and these were repeated after the cells had been cultured for a 
further 28 days (the average duration of the cybrid selection process) in culture 
medium free of the mtDNA depleting agent (ethidium bromide or ddC).
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Part B: To investigate the potential contribution of the nuclear DNA and mtDNA 
background to the biochemical expression of mtDNA mutations we identified patients 
who harboured the A3243G common MELAS mtDNA mutation, but who had 
markedly different phenotypes. Patient platelets or enucleated fibroblasts were fused 
with a variety of p° cell lines, thus introducing patient mtDNA into a variety of 
nuclear backgrounds. Neuronal (SHSY-5Y) and embryonal myoblast (Myoe) p° cell 
lines were generated de novo to provide a more physiological in vitro representation 
of the tissues most commonly affected in vivo. Fibroblast (IB3), lung (A549), and 
osteosarcoma (206) p° cell lines were also used. In this way the following sets of 
cybrids would be generated.
A549 206 SHSY-5Y IB3 Myo
Lung Osteosarcoma Neuronal Fibroblast Myoblast
Patient 1 1L 10ST IN IF 1M
Patient 2 2L 20ST 2N 2F 2M
Controls C3 COST CN CF CM
Clones covering a range of mutant loads were isolated and respiratory chain complex, 
aconitase and citrate synthase activities were analysed spectrophotometrically. 
Analysis of the biochemical function of these cell lines would allow the determination 
of the effect of different mtDNA molecules within the same nuclear background (i.e. 
1 versus 2 versus Controls), and the effect of different nuclear backgrounds on the 
same mtDNA molecule (i.e. L versus OST versus N versus F versus M).
3.4 RESULTS
The generation of p° cell lines.
Lung A549p° cells were provided by Dr I Holt (Dunn Human Nutrition Unit, 
University of Cambridge) and osteosarcoma 206 p° cells were provided by Prof G 
Attardi (CalTech, California). Neuronal (SHSY-5Y and NT2), fibroblast (IB3) and 
embryonal myoblast (myoe) p° were generated using standard mtDNA depleting
1 2 2
agents (ethidium bromide 0.005 -  5 pg/ml or dideoxycytidine ddC 1-1 OpM, section 
2.2.4) for up to 120 days.
To determine if the cells had mtDNA depletion DNA extracted from the various cells 
was amplified to generate a 630 bp mtDNA specific product and semi-quantified 
using serial dilutions of the DNA template and the products analysed using agarose 
electorphoresis (section 2.8). To help exclude the presence of a nuclear pseudogene a 
lkb PCR was also performed on some samples (section 2.8) In addition 
immunofluorescence using anti COX 1 antibodies was used to assess the relative loss 
of mtDNA encoded proteins (section 2.18).
Semi-quantitative PCR of A549 p° cells confirmed the absence of a 630bp mtDNA 
product even at the highest DNA template concentration of 50 ng and therefore 
demonstrated that they were p° (Figure 3.1 A). Growth of the cells for a further 28 
days in medium lacking ethidium Bromide (EtBr) gave rise to a faint 630 bp band at 
the highest DNA concentration after PCR amplification (figure 3B). This would imply 
mtDNA levels less than 0.1% of those of wild type p+cells. Immunofluorescence 
using an antibody to a mtDNA encoded subunit (COX I) gave rise to clear cytosolic 
punctate pattern of staining in normal cells, most intense around the nucleus (figure 
3.1C arrow). Immunoflourescence (IF) for A549 cells after EtBr treatment showed a 
loss of this punctate pattern (fig 3.Id arrow) confirming the loss of mtDNA 
demonstrated by PCR. 28 days after removal of EtBr COX I staining showed minimal 
punctate staining in some cells (fig 3.IE arrow) in keeping with the PCR results.
206 p° cells appeared to have significant levels of mtDNA as judged by semi- 
quantitative PCR (Figure 3.2 A) being perhaps 10% residual mtDNA levels compared 
to p+cells. Paradoxically, after removal of EtBr for 28 further days of culture, mtDNA 
levels appeared to have reduced to 1% (fig 3.2B). IF results (figure 3.2 C-E) showed 
that p° cells had lost the punctate pattern of staining seen in p+cells and that there was 
no significant change in the staining of p° cells after 28 days free from the effects of 
EtBr. The punctate staining evident in fig 3.2C was essentially absent in the p° cells at 
t=0 (fig 3.2D arrow). This suggested the p° cells had a lack of functional mtDNA in 
contradiction to the PCR findings.
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Embryonal myoblasts were confirmed to be p° by PCR (fig 3.3A) and to not 
accumulate mtDNA after 28 days of culture in the absence of ddC (Fig 3.3B). Of 
note, the p+cells showed mtDNA detectable to 4 serial dilutions, but at 28 days later, 
after no change in their culture conditions, mtDNA was only detectable to two serial 
dilutions. One could infer that mtDNA cell content varies greatly as a normal 
phenomenon, or perhaps more probably that the technique employed (semi- 
quantitative PCR) has limitations. Immunoflourescence with COX I antibody of 
embryonal myoblasts showed punctate staining (fig 3.3C) but in a less intense pattern 
than that seen in other cell types. p° cells lacked the punctate staining of the p+cells 
cells, and had a different morphology (fig 3.3D arrow). At 28 days after removal of 
the mtDNA depleting agent, there are no discernable changes to the IF pattern (fig 
3.3E arrow).
MtDNA was undetectable by PCR in the SHSY-5Y p° cells (fig 3.5 A) and remained 
so after 28 days in the absence of ethidium bromide (figure 3.5). IF studies again 
showed punctate staining in the p+ cells (fig 3.5C), and absence of this pattern of 
staining in the p° cells (fig 3.5D arrow) and no reaccumulation of staining after 
removal of EtBr (fig 3.5E arrow).
NT2 cells, after prolonged exposed to maximal concentrations of EtBr or ddC, or 
both, failed to achieve p° status (fig 3.4 A). MtDNA content was reduced to 
approximately 1% of normal, but complete irradication of mtDNA from these cells 
was not achieved. The PCR product could be the result of a nuclear pseudogene but 
this potential explanation was excluded by performing a second PCR for a 1 kb 
fragment of a different part of the mtDNA molecule (fig 3.6). There was no evidence 
of an increase in mtDNA levels after removal of EtBr from the culture medium as 
judged by the PCR based technique, althought there was perhaps some increase in 
staining on immunoflourecence (fig 3.4 E).
A549, embryonal myoblasts, and SHSY5Y cells were therefore all shown to be 
suitable for use in platelet fusion experiments. It was apparent that NT-2 cells could
124
not be used for cybrid generation because, despite prolonged exposure to mtDNA 
depleting agent both singly and in combination, they failed to reach p° status. Due to 
the failure of NT-2 cells to reach p° status, IB3 cells (fibroblasts) were substituted 
after being confirmed p° (data not shown). 206 cells were also shown to contain 
residual mtDNA, but after further treatment true p° status was regained (data not 
shown) and these cells were used for cybrid generation. Neither PCR techniques nor 
IF studies provided any clear evidence of the re-accumulation of mtDNA levels after 
the removal of mtDNA depleting agents from the culture medium.
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Figure 3.1 Analysis of mtDNA and COX I in A549 p+ and p° cells.
Semiquantitative PCR of a 630bp mtDNA fragment using serial dilution of cellular 
DNA,(lanes 1 to 5: 50, 5, 0.5,0.05 and 0.005ng DNA). (A) A549 p+ and A549 p° cells 
immediately following ethidium bromide treatment. (B) A549 p+ and A549 p° cells 
after 28 days growth in the absence of ethidium bromide. M is a lOObp ladder.
Immunoflourescence of subunit I of COX in (C) A549 p+ showing clear punctate 
mitochondrial staining (arrow), (D) p° cells after ethidium bromide treatment where 
mitochondrial staining is absent (arrow) and (E) p° cells 28 days after the removal of 
ethidium bromide showing a slight increase in mitochondrial staining (arrow).
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Figure 3.2 Analysis of mtDNA and COX I in 206 osteosarcoma p+ and p° cells.
Semiquantitative PCR of a 630bp mtDNA fragment using serial dilution of cellular 
DNA,(lanes 1 to 4, 50, 5, 0.5,0.05 and 0.005ng DNA). (A) 206 pf and 206 p° cells 
immediately following ethidium bromide treatment. (B) 206 p+ and 206 p° cells after 
28 days growth in the absence of ethidium bromide. M is a lOObp ladder.
Immunoflourescence of subunit I of COX in (C) 206 p+ showing clear punctate 
mitochondrial staining (arrow), (D) p° cells after ethidium bromide treatment where 
mitochondrial staining is absent (arrow) and (E) p° cells 28 days after the removal of 
ethidium bromide showing a slight increase in mitochondrial staining (arrow).
Figure 3.3 Analysis of mtDNA and COX I in embryonal myoblasts (Myoe) p+ and p° 
cells.
Semiquantitative PCR of a 630bp mtDNA fragment using serial dilution of cellular 
DNA,(lanes 1 to 5, 50, 5, 0.5,0.05 and 0.005ng DNA). (A) Myoe p+ and Myoe p° cells 
immediately following ethidium bromide treatment. (B) Myoe p+ and Myoe p° cells 
after 28 days growth in the absence of ethidium bromide. M is a lOObp ladder.
Immunoflourescence of subunit I of COX in (C) Myoe p+ showing clear punctate 
mitochondrial staining (arrow), (D) Myoe p° cells after ethidium bromide treatment 
where mitochondrial staining is absent (arrow) and (E) Myoe p° cells 28 days after the 
removal of ethidium bromide showing a slight increase in mitochondrial staining 
(arrow).
Figure 3.4 Analysis of mtDNA and COX I in NT2 neuronal p+ and p° cells.
Semiquantitative PCR of a 630bp mtDNA fragment using serial dilution of cellular 
DNA,(lanes 1 to 5: 50, 5, 0.5,0.05 and 0.005ng DNA). (A) NT2 pH- and A549 pminus 
cells immediately following ethidium bromide treatment. (B) NT2 p+ and NT2 p 
minus cells after 28 days growth in the absence of ethidium bromide. M is a lOObp 
ladder.
Immunoflourescence of subunit I of COX in (C) NT2 p+ showing clear punctate 
mitochondrial staining (arrow), (D) p minus cells after ethidium bromide treatment 
where mitochondrial staining is absent (arrow) and (E) p minus cells 28 days after the 
removal of ethidium bromide showing an increase in mitochondrial staining (arrow).
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Figure 3.5 Analysis of mtDNA and COX I in SHSY-5Ypf and p° cells.
Semiquantitative PCR of a 630bp mtDNA fragment using serial dilution of cellular 
DNA,(lanes 1 to 5, 50, 5, 0.5,0.05 and 0.005ng DNA). (A) SHSY-5Y p+ and SHSY- 
5Y p° cells immediately following ethidium bromide treatment. (B) SHSY-5Y p+ and 
SHSY-5Y p° cells after 28 days growth in the absence of ethidium bromide. M is a 
lOObp ladder.
Immunoflourescence of subunit I of COX in (C) SHSY-5Y p+ showing clear punctate 
mitochondrial staining (arrow), (D) SHSY-5Y p° cells after ethidium bromide 
treatment where mitochondrial staining is absent (arrow) and (E) SHSY-5Y p° cells 
28 days after the removal of ethidium bromide showing no reaccumulation of punctate 
staining(arrow).
Figure 3.6 Analysis o f  mtDNA content o f  NT-2 p+ and “p°” neuronal cells
Semi-quantitative PCR o f NT-2 p+ and “p°” neuronal cells using primers for a 630 bp mtDNA 
(A), and a 1000 bp mtDNA fragment (B) to exclude a nuclear pseudogene being responsible form 
the result in A. Serial dilutions o f  cellular DNA (lanes lto  5: 50, 5, 0.5, 0.05, and 0.005 ng DNA). 
M is a 100 bp ladder.
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Generation of Cvbrids containing mtDNA from A3243G mutant patients and controls.
Patient details:
All patients were confirmed A3243G positive.
EF was a 62 year old man who had presented 12 years previously with a pure 
myopathy. He had not developed central nervous system disease.
RS was a 44 year old man with a 2 year history of stroke like episodes, cognitive 
decline, seizures, and lactic acidosis.
KK was an 18 year old man diagnosed with MELAS at the age of 8 years. He had 
short stature, mental retardation, lactic acidosis, and seizures. He died of his illness 1 
year after participating in this study.
YK was the mother of KK. She was positive in blood for the A3243G mutation but 
was asymptomatic at the age of 46 years.
CH was a middle-aged lady with a severe phenotype.
BB (52 year old female) and AW (58 year old male) were used as age and sex 
matched healthy controls
RS, KK, and CH therefore represented a severe phenotype, EF exhibited a mild 
phenotype, and YK was an asymptomatic carrier.
Blood samples were taken and fibroblast cultures were established for each patient 
and the proportion of the A3243G mutation quantitated using fluorescent PCR 
analysis as described in section 2.11. Mutation loads are shown in table 3.1 (data not 
available for patient CH). These show that the two patients with severe phenotypes 
had high mutant load in both tissues tested. KK had a much earlier age of onset than 
RS, but had slightly lower mutant loads, some of which (fibroblasts 60%) are some 
way below the normal expected threshold levels of 80-90%. The asymptomatic 
patient YK had low levels in both tissues, whereas in patient EF fibroblast mutant 
levels were significantly greater than those in blood.
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Patient Phenotype Blood % Fibroblasts %
RS severe 77 80
EF mild 7 48
KK severe 72 60
YK asymptomatic 8 22
Table 3.1
A3243G mutation loads as determined by quantitative fluorescence PCR in blood and 
fibroblasts in patients RS EF KK and YK
Fusion of platelets and fibroblasts with p° cells
Platelets and fibroblasts from patients RS EF YK KK and controls were fused with 
SHSY-5Y, A549, 206, IB3 and embryonal myoblast p° cells (section 2.3) as shown in 
table 3.2. All colonies of cells growing in selection medium were harvested by ring 
cloning or picking techniques as described (section 2.4). The number of cybrid lines 
generated for each cell type are represented in Table 3.2.
As regards fusions using A549, 206, SHSY-5Y, and IB3, cybrids were obtained from 
all attempted fusions except the RS/IB3. Embryonal myoblasts appear to generate 
cybrids poorly using this technique, only being successful for the fusion with patient 
RS, and failing to generate cybrids at all for all other attempted fusions. The failure of 
some experiments to generate cybrids does not appear to be dependent upon the 
technique used, because IB3/RS used enucleated fibroblasts whereas myoblast fusions 
were all performed using patient platelets. Platelet fusions from patient CH were a gift 
from Dr Mei Gu and data relating to number of clones obtained is not available.
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Patient Rho-zero cell line
A549 206 SHSH-5Y IB3 Myo
RS 23 15 52
EF 23 29 20 14
Table 3.2 Number of clones isolated from platelet (clear boxes) and enucleated 
fibroblast (light grey boxes) fusions between patients and various p° cell lines. (Dark 
grey boxes refer to fusions not performed).
Distribution of mutant load in cvbrids
DNA was extracted from all cybrids generated, the 630 bp region surrounding the 
A3243G mutation was amplified by PCR, the product digested with Apal, and 
separated on ethidium bromide agarose gels (section 2.11). The ratio of 630 bp to 315 
bp was assessed to determine mutant load, and these were classified according to 
whether they contained 0%, <50%, >50%, or 100% mutant mtDNA. The distribution 
of the clones between these mutant load groups is shown in figure 3.7.
Combining the data from clones from the same cell type from all five patients (fig 
3.7A), shows variation in the distribution of mutant mtDNA content in generated 
cybrids. The majority of SHSY-5Y clones had lower mutant loads, indeed 60% of 
these clones contind only wild type mtDNA. 206 and IB3 cybrids had greater than 
50% mutant load in all cybrids. Myoblasts most commonly generated clones 
containing greater than 50% and A549 cybrids most commonly less than 50%. Only a 
few clones contained 100% mutant load and this only occurred in SHSY-5Y and 206 
cells.
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Figure 3.7. Relationship between number of cybrid clones with varying levels of A3243G 
mtDNA in different cell types ; SHSY5Y ( blue), A549 (green), 206 (yellow), IB3 (red) and 
myoblasts (black). A -  cybrids from all patients studied; B -  from patients with severe phenotype 
(RS, KK); C -  patients with mild phenotype (EF, YK).
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Fig 3.8 Comparison of A3243G mutant load in 72 cybrids as assessed by semi- 
quantitative Apa I digest (x axis) with that as assessed by fluorescent labelled PCR 
(y axis)
When categorized according to phenotype severity of the donor mtDNA (fig 3.7 B+C) 
the same pattern was seen in both groups for SHSY5Y and 206 cells. However a 
different pattern was seen in A549 cells. When mtDNA was derived from patients of a 
severe phenotype, clones had a higher mutant load than when mtDNA was derived 
fom those of a mild phenotpye.
Mild phenotype patients failed to generate any clones of 100% mutant load. However, 
this did occur when the donor mtDNA was derived from severe phenotype patients, 
but the absolute number of these clones was very small. Myoblast fusions only 
succeded when fused with severe phenotype mtDNA. However all of these were 
derived from fusion with a single severe phenotpye patient, and failed to succeed with 
the second severe phenotype patient. This would imply technical factors underlay this 
finding rather than it being attributable to mitochondrial or nuclear genetic factors.
For each cybrid generated that contained >50% mutant load as judged by the Apal 
digest technique (section 2.11) mutation load was determined with greater accuracy 
by fluorescent labelled PCR as described (section 2.11). This was kindly performed 
by Dr Teeraton Pulkes, Institute of Neurology, London. The accuracy of the initial 
estimation of mutant load by visual inspection of Apal digests was assessed with 
reference to the more accurate value obtained by the fluorescent labeled PCR 
technique (fig 3.8). This scatter plot shows a good degree of correlation between the 
two techniques. Only 2.5% of clones were misclassified by the Apal digest technique.
Mitochondrial Enzyme and Aconitase Activities
Spectrophotometry for complexes I. II/III. IV, CS. and Aconitase:
Cybrid clones with 0% or greater than 50% mutant load were selected, grown to a 
suitable number for mitochondrial enrichment and spectrophotometric analysis 
performed as described (section 2.12-2.13 and 2.16).
Analysis of spectrophotometric data:
Complex I, II/III, and IV activities, expressed as CS ratios, and aconitase activities per 
mg protein were plotted against mutant mtDNA load. Clones containing between 0%
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and 50% mutant mtDNA were not analysed further since it was felt that any potential 
threshold effect was unlikely to fall within this range of heteroplasmy. The number of 
clones subjected to spectrophotometric analysis (i.e. both the number containing 0% 
and the number containing mutant mtDNA) is shown in table 3.X. Clones containing 
0% mutant mtDNA (i.e. 100% wild type mtDNA) were used as internal controls. 
Where these were not generated by the fusion experiment, control fusions generated 
from age-matched healthy control individuals were used.
As the number of clones derived for each patient in each cell type was not sufficient 
for the enelysis to be performed for each patient individually the data was pooled. 
First of all the activities were expressed for each cell line, combining the data from all 
patients, and secondly the clones were combined into two groups, those from patients 
with severe and those from patients with a mild MEL AS phenotype.
The spectrophotometric data is shown graphically in figures 3.9-3.16.
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Figure 3.9 Influence of A3243G mutant load upon mitochondrial respiratory chain 
activities in SHSY-5Y cybrids generated by fusion of platelets from all patients. Clones 
containing mutant mtDNA (blue squares) and those containing wild type mtDNA (blue 
diamonds) are shown. The latter act as controls. Citrate synthase ratios w ith ; A NADH 
CoQl reductase B Succinate cytochrome c reductase, C cytochrome oxidase
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Figure 3.10 Influence of A3243G mutant load upon mitochondrial respiratory chain 
activities in A549 cybrids generated by fusion of platelets from all patients. Clones 
containing mutant mtDNA (blue squares) and those containing wild type mtDNA (blue 
diamonds) are shown. The latter act as controls. Citrate synthase ratios with ; A NADH 
CoQl reductase B Succinate cytochrome c reductase, C cytochrome oxidase
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Figure 3.11 Influence of A3243G mutant load upon mitochondrial respiratory chain activities in 
206 cybrids generated by fusion of platelets from all patients. Clones containing mutant mtDNA 
(blue squares) and those containing wild type mtDNA (blue diamonds) are shown. The latter act as 
controls. Citrate synthase ratios w ith ; A NADH CoQl reductase B Succinate cytochrome c 
reductase, C cytochrome oxidase
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Figure 3.12 Influence of A3243G mutant load upon mitochondrial respiratory chain 
activities in IB3 cybrids generated by fusion of platelets from all patients. Clones 
containing mutant mtDNA (blue squares) and those containing wild type mtDNA (blue 
diamonds) are shown. The latter act as controls. Citrate synthase ratios with ; A NADH 
CoQl reductase B Succinate cytochrome c reductase, C cytochrome oxidase
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Figure 3.13 Influence of A3243G mutant load upon mitochondrial respiratoiy chain activities in SHSY5Y, A549 and 206 cybrids generated by fusion 
of patients with a severe MELAS phenotype (RS, KK, CH). Data represents; CXI / CS - NADH CoQl reductase; CX II/III / CS - Succinate cytochrome 
c reductase, CX IV / CS - cytochrome oxidase
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Figure 3.14 Influence of A3243G mutant load upon mitochondrial respiratory chain activities in IB3 and 206 cybrids generated by 
fusion of a patient with a mild MELAS phenotype (EF). Data represents; CXI / CS - NADH CoQl reductase; CX II/III / CS - 
Succinate cytochrome c reductase, CX IV /CS - cytochrome oxidase
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Figure 3.15 Influence of A3243G mutant load upon aconitase activities in; A SHSY5Y ; 
B A549; C 206 and D IB3 cybrids generated by fusion of all patients.
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Figure 3.16 Influence of A3243G mutant load upon aconitase 
activities in A -  SHSY5Y; B -  A549 ; C - 206 cybrids generated by 
fusion of patients with a severe MELAS phenotype and D -IB3 and E -  
206 cybrids generated by fusion of a patient with a mild MELAS 
phenotype (EF). Data represents nmole/min/mg.
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Relationship between A3243G mutant load, nuclear background, and MRC dysfunction
To understand the relationship between mutant load and MRC activity in the different 
cell types the CS ratio for complexes I, II/III, and IV for each clone from all patients were 
plotted against mutant load.
SHSY-5Y clones contained mutant mtDNA up to a level of 76%. Up to this level 
complex I, II/III, and IV showed no decline in activity (fig 3.9). Of course a threshold 
effect above this level could not be excluded. In A549 cells there was a good range of 
mutant loads obtained, with a maximum mutant load of 94% (fig 3.10). These exhibited a 
reduced complex IV activity at above approximately 85% mutant mtDNA. No such trend 
was apparent for complex I and II/III, however the wide spread of activity at low mutant 
clones may mask a threshold effect. 206 cells (fig 3.11) had mutant loads from 76% to 
98% and showed a reduction of complex IV activity above 90% mutant load , but again 
there was a significant spread in the data. No clear trend was seen for complex I and 
II/III. Analysing all patient clones in IB3 cells (fig 3.12), mutant load ranged from 82% to 
100%, and results suggested a threshold of approximately 90% for both complex I and 
complex IV activity. No decline in complex II/III activity was seen.
In an attempt to understand the effect of mtDNA haplotype upon the relationship between 
mutant load and nuclear background clones were analysed in groups depending on 
whether the mtDNA had been derived from a patient with a severe or mild phenotype. 
Only sufficient clones were available to perform this analysis in SHSY-5Y, 206, and 
A549 cell lines (figure 3.13). There was a reduced complex IV activity at high mutant 
load in A549 and 206 cells, and a similar decline in complex II/III activity but only in 
A549 cells. The threshold level was approximately 85% in all of these lines. No threshold 
effect was demonstrable in SHSY-5Y cells but again, in this group no cybrids containing 
greater than 80% mutant mtDNA were obtained.
Only sufficient clones were available to perform analysis in IB3 and 206 cell lines fused 
with mild phenotype patients (fig 3.14). There was a decline at high mutant load (>90%)
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for complex I and complex IV activity in IB3 cells. In 206 cells despite the analysis of 
clones containing 90% A3243G mtDNA no clear biochemical defecit was seen. In 
particular no decline in complex IV activity was seen as in the fusions generated with 
severe phenotype patients (fig 3.13). Again of course a threshold level may exist in 206 
cells at a level of mutant load above that of the maximum cybrid mutant load generated 
by these fusion experiments.
Relationship between A3243G mutant load, cell type, and oxidative damage
In A549 cells, when the data was pooled for all patients studied, aconitase activity 
showed a reduction at low mutant levels ( f i g  3.15B) but no such pattern in any of the 
other cell lines, some of which did not generate clones of mutant load above 80% (eg 
SHSY-5Y cells - f i g  3.15A), whilst others included clones up to 93% or 100% (eg 206 
cells f i g  3.15C and IB3 cells f i g  3.15D respectively).
In an attempt to understand the effect of mtDNA haplotype upon the relationship between 
mutant load and nuclear background, clones were analysed in groups depending on 
whether thee mtDNA had been derived from a patient with a severe or mild phenotype. A 
Aconitase activity in A549 cells fused with mtDNA from severe phenotype patients ( f i g  
3.16 B) was below control levels in all cybrids irrespective of mutant load. In this set of 
cybrids the lowest mutant load assayed was 32%. This might imply a very low threshold 
for ROS cell injury in this setting. Fusions between 206 cells and severe phenotype 
patients also showed a threshold effect for aconitase activity but at a more traditional 
level of 80-90%. The other cybrid sets (severe patients in SHSY-5Y, mild patients in IB3, 
and mild patients in 206) did not demonstrate a threshold effect, in some cases this was 
perhaps due to the lack of high mutant load cybrids for analysis ( f i g  3.16A), whereas in 
other cybrid sets high mutant load clones were available for analysis, but there was a 
wide spread of aconitase activities in clones of similar mutant load ( f i g  3.16 D and E )
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3.6 DISCUSSION
Knowledge of pathological mtDNA mutations has expanded at a rapid rate over the past 
fifteen years. However our understanding of the pathophysiological consequences of 
these mutations has not progressed at an equivalent rate. For instance, as discussed in 
section 1.8.1.2) although many explanations have been proposed for the mechanism 
underlying the clinical variability seen with the A3243G mutation, none have been 
universally accepted. Mt DNA factors have been proposed that may modify the effect of 
the A3243G mutation. The clearest example of this to date is seen with tRNA suppressor 
mutations 122. Nuclear genotype factors, environmental and epigenetic factors have also
790been proposed, and their interaction with the threshold effect explored
The initial part of this experimentation, part A, addressed the robustness of the methods 
employed in generating cybrids. Results from immunofluorescent (IF) and PCR based 
studies showed no evidence of re-accumulation of mtDNA in p° cells once free of the 
influence of the agent initially used to deplete their mtDNA levels, suggesting that this is 
not a potential cofounding factor when analyzing the results of cybrid studies. 
Interpretation of IF photomicrographs is qualitative. Dilutional PCR studies can be 
considered semi-quantitative, and results supported the conclusions drawn from the IF 
studies. The results from part A also illustrate that diferent cell lines required different 
agents in order to successfully render them p°. A549, 206, and embryonal myoblasts all 
became p° in the presence of ethidium bromide. In contrast some cell lines were resistant 
to the effects of ethidium bromide, requiring exposure to ddC in order to render them p°. 
Furthermore, some cell lines never became p° despite prolonged exposure to maximal 
concentrations of ethidium bromide, or ddC, alone or in combination. This was the case 
for the NT2 neuronal cell line (figure 3.6). Maximal doses of these agents were used. At 
higher doses cells failed to proliferate or died. The apparent failure to attain p° status as 
determined by PCR may have been due to the presence of a nuclear pseudogene. This 
possible explanation was refuted by the second PCR for a non-overlapping 1 kilobase 
mtDNA fragment (figure 3.6). Of note, the successful generation of p°NT2 cells has been 
reported after the use of ethidium bromide as a mtDNA depleting agent 721. Why we were
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not able to reduplicate this is unclear. Also, why cell lines should differ in their 
susceptibility to mtDNA depleting agents is unclear but may relate to their ability to 
metabolise or remove the agent. There is some suggestion that this observation mirrors 
the clinical findings of variable tissue susceptibility to the effects of nucleoside analogue 
drugs used to treat the human immunodeficiency virus, for which neuronal toxicity is a 
major dose-limiting factor.
Cybrid studies have suggested that a variety of factors may promote the non-random 
segregation of mutant and wild-type mtDNA in different tissues 186,714,715,716,71?. Using 
206 cells Dunbar et al 714 generated cybrids that had either a stable mitochondrial 
genotype or showed an increase in the proportion of mutant mtDNA. Other cell lines 
however showed a shift to wild type mtDNA, suggesting that the nuclear genetic 
background of the recipient cell line can influence the segregation of mutant and wild- 
type mtDNA. Variability of mutant load has also been seen at the single cell level 718. 
NT2 cells have shown mitotic segregation towards increasing levels of mutant A3243G 
mtDNA 722. This rapid segregation was frequently followed by complete loss of mtDNA. 
These findings suggest that pathological mtDNA mutations are particularly deleterious in 
specific cell types, and may explain some of the tissue-specific aspects of mtDNA 
diseases. Sudden and dramatic changes in heteroplasmy level have also been shown after
7 9growth of clones in selective medium . In one instance this was associated with a gain 
of chromosome 9 724. It was proposed that mtDNA exists in nucleoids containing many 
copies of the genome. These nucleoids may themselves be heteroplasmic, and can be 
reorganized under nuclear genetic controlresulting in shifts of heteroplasmy level.
Non-random segregation of mutant and wild-type mtDNA was also evident in the 
experiments described above as shown by the range of mutant loads found in the cybrids 
generated. The varying effect of different nuclear backgrounds was also evident in the 
success rate of fusion experiments. With p° myoblasts only platelets from patient RS 
generated clones successfully. EF produced clones after fusion with IB3 p° but RS did 
not. All other fusions between all patients and all other p° cell lines were successful. The 
reasons for this are unclear. If it is a real phenomenon it may represent incompatibility
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between different mtDNA molecules and different nuclear backgrounds. It is unlikely to 
be a factor confined to the A3243G mutation itself, because neither wild type nor mutant 
mtDNA containing clones were generated. It could of course be related to technical 
failings in those particular fusion experiments, and thus be an arefactaul finding. To test 
this further, the fusions could be repeated a number of times to see if they consistently 
fail to generate viable clones.
The varied effect of different nuclear backgrounds was also evident, as shown in figure 
3.7, in the range of mutant mtDNA levels tolerated in the cell lines. In fig 3.7A, IB3 and 
206 cells appear to allow higher mutant loads than SHSY-5Y or myoblasts. When 
comparing fusions using mtDNA from patients with a severe phenotype with those using 
mtDNA from patients with a mild phenotype the spread of mutant loads was similar in 
both cases for SHSY-5Y and 206 cells. In contrast, significant variation was seen for 
fusions with A549 p° cells, mtDNA from severe phenotype patients giving cybrids of 
much higher mutant load. This would imply that mtDNA factors also influence the 
resultant mutant load in cybrids. MtDNA sequencing might shed further light upon these 
findings.
Of course, these findings might be influenced by the fact that the donor mtDNA used in 
different fusion experiments contained differing levels of mutant mtDNA. For example 
Patient YK (mild phenotype) platelets contained only 8% A3243G mutant mtDNA, 
whereas the level in her son KK (severe phenotype) was 72%. The fact that the spread of 
mutant load in SHSY-5Y cybrids for fusions generated from severe or mild phenotype 
patient was very similar would argue against the donor mutant mtDNA level being a 
significant factor in determining the mutant mtDNA level in cybrids.
A number of other potential confounding factors should be considered. Not all fusion 
experiments were performed on the same day and therefore conditions might vary. It has 
already been mentioned that some fusions were performed with patient platelets and 
others with enucleated patient’s fibroblasts. This was due to the difficulties in repeatedly 
obtaining platelet samples from patients. This factor might also influence the fusion
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process. Mutant loads varied between patients and between fibroblasts and platelets of a 
single patient. Furthermore the results of mutant loads presented are from the products of 
a single fusion experiment for each patient cell line cross. The data would be more robust 
if the fusions were repeated a number of times. Limitations aside these variations may 
provide evidence that both nuclear DNA and secondary mtDNA influence the ability of 
cells to accept foreign mtDNA, and their ability to tolerate a given level of mutant 
mtDNA. This may be a reflection of both the metabolic demands of the cell line, and the 
ability of its MRC machinery to generate ATP. This latter factor would be determined by 
the efficiency of the multitude of interactions between the nucleus of the p° cell line and 
the introduced mtDNA, both mutant and wild type.
The spectrophotometric experiments presented were designed to investigate the 
relationship between mutant load, MRC activity, aconitase activity (a marker of ROS 
injury), and nuclear background. The concept of a threshold level of mutant mtDNA, 
above which MRC activity and other biochemical parameters are affected adversely, is 
often discussed and accepted. It has been demonstrated in osteosarcoma cells 69 and A549 
cells 71 \  When A3243G levels reach 70-90% a mild defect in complex I has been 
reported; above 90% oxygen consumption falls dramatically, and there is a quantitative 
effect on mitochondrial protein synthesis and an abnormal pattern of translation products 
most clearly affecting ND6 69.
However, a number of unexplained inconsistencies exist. In vivo the A3243G mutation 
appears to have a lower threshold level than the A8344G mutation, but in vitro the
186 719reverse is often true ’ . Threshold levels vary between tissues, potentially related to
varying energy demands. Brain exhibits a low threshold level, and unusually, shows a 
linear relationship between the level of heteroplasmy and defects of oxidative
323phosphorylation . In some cybrid lines mitochondrial protein synthesis activity is 
preserved despite high mutant load and severe mitochondrial dysfunction 581. The steady 
state level of tRNALeu(UUR) and its degree of aminoacylation also vary depending upon 
the nuclear background studied 58°.
152
The results described above support the hypothesis that both the nuclear DNA 
background and the mtDNA haplotype influence the biochemical phenotype of the 
A3243G mutation. Patterns of MRC dysfunction varied between cell lines and also varied 
depending upon the source of the donor mtDNA (ie from severe or mild penotype 
patient). Threshold effects were apparent in some cell lines and for some MRC 
complexes but not in others.
There were of course some limitations in the data. High mutant load clones were not 
generated from all fusion experiments; enzyme activities showed some spread of data 
amongst clones of similar mutant load; data from patients had to be combined into severe 
or mild phenotype groups because numbers of clones generated from single patients were 
too small to allow meaningful analysis.
The pattern of aconitase activity also varied between cell lines. A549 cells fused with 
mtDNA from severe phenotype patients (fig 3.16 B) showed low aconitase levels at all 
mutant loads. This might suggest a high degree of ROS injury even at low mutant levels. 
The reliability of the control data would need confirmation in future studies. In 206 cells 
fused with mtDNA from severe phenotype patients a threshold effect for aconitase 
activity was present at the more common 80-90% level. Aconitase thresholds were not 
demonstrable in other cybrids.
In summary, the data presented goes some way to support the hypothesis that both the 
nuclear DNA background and the mtDNA haplotype influence the biochemical 
expression of the A3243G mtDNA mutation. Repeated attempts at the fusions would 
strengthen the data regarding the range of mutant loads permissible within different 
nuclear backgrounds. However, the experimentation as presented was labour intensive, 
and simply undertaking more upon more fusions, might be too cumbersome an 
experimental design. Different methodologies should be explored to investigate 
genotype-phenotpye correlation in the mitochondrial encephalomyopathies, a core feature 
of these intriguing disorders that still remains to be fully explained pathophysiologically. 
Not until the fundamental secrets of these disorders are unlocked can rational therapeutic
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approaches be planned. Improved understanding of the basic molecular mechanisms will 
also be of relevance to the rapidly growing number of conditions and pathologies in 
which mitochondrial dysfunction is now implicated.
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Chapter 4
The use of xenomitochondrial cybrids to investigate nuclear -mitochondrial 
interactions and the development of cell models of mitochondrial disease.
4.1 Experimental hypothesis
Nuclear DNA and mtDNA work together in a complex symbiotic relationship to produce 
an efficient mitochondrion able to meet the energy requiremtns of the cell and to fulfill 
the other functions of mitochondria. These interactions occur at a number of levels. The 
most obvious is the nuclear and mitochondrially encoded subunits of the mitochondrial 
respiratory chain, but also includes nuclear encoded factors responsible for the import of 
mitochondrially targeted proteins, and mitochondrial transcription and translation factors. 
In chapter 3 I explored the relevance of these nuclear mitochondrial interactions in 
determining the phenotypic manifestation of the A3243G mutation. To explore these 
interactions further, but at a different level I utilized the technique of xenomitochondrial 
cybrids. This technique generates cybrids by fusing nuclear and mtDNA from different 
species. The entire mitochondrial genomes of human, rat, mouse, and a number of non­
human primates, amongst other species, are established. I investigated the potential 
viability and biochemical consequences of human-mouse-rat xenomitochondrial cybrids. 
The resultant xenocybrids also provide useful models of MRC deficiency.
As discussed in depth in chapter 1, literature already exists on the phlyogenetic 
relationships of mtDNA from various species, and also on the ability of nuclear and 
mtDNA to interact adequately or otherwise across these varying phlogenetic distances. 
The experiments described below use xenomitochondrial cybrids to explore the 
development of cellular models of human mitochondrial disease, and to provide further 
insights into the complexities of nuclear mitochondrial interactions.
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4.2 Experimental Design
Mouse fibroblast (STOG) cells were depleted of their mtDNA by the addition of ethidium 
bromide to the culture medium as described (section 2.2.4). Their p° status was confirmed 
by PCR methods as described (section 2.8). Platelets isolated from rat or human blood 
were then fused with these mouse p° cells (section 2.3). Resultant cybrids were isolated 
and the origin of their nuclear and mitochondrial DNA was confirmed by PCR techniques 
as described (section 2.5). Clones were grown to sufficient quantity to allow the isolation 
of the mitochondrial fraction, and spectrophotometric analysis of these samples was 
performed as described (section 2.12)
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4.3 Results:
Mouse fibroblasts (STOG) a gift from Dr Paul Simons, Dept of Anatomy, Royal Free 
Campus, Royal Free and University College Medical School, University College London, 
were cultured as described (section 2.2). They were grown in the presence of ethidium 
bromide (5pg/ml) for 30 days (section 2.2.4) and the level of mtDNA determined semi- 
quantitatively by PCR amplification (section 2.8). DNA extracted from untreated STOG 
fibroblasts showed a clear band at 300 bp, and the intensity of the band could be seen at 
0.005pg DNA template. After 30 days of ethidium bromide treatment a 300 bp product 
was not detectable even using 50 pg DNA template, (see figure 4.1).
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Figure 4.1
1.2% agarose gel of 315kb semi-quantitative mtDNA PCR of STOG p+ cells before (upper) and 
after (lower) 30 days culture in 5pg/ml Ethidium Bromide. The five lanes represent 1:10 serial 
dilutions of template DNA (50ng, 5ng, 0.5ng, 0.05ng, 0.005ng) from left to right.
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Human platelets were freshly prepared and fused with STOG p° cells on four occasions 
(section 2.3). On all occasions they failed to generate any viable clones. However fusion 
with mus musculus or ratus norvegicus platelets both generated similar numbers of viable 
clones. DNA was extracted from cybrids in a standard way (section 2.5). A number of 
primer pairs were designed by automated (DNAstar, Lasergene 98 -  Primer select 
software) and manual techniques to distinguish human, mouse, and rat mtDNA:
primer pair 1 fl (9559..9578) 5’-GAA CAG GCA TCA CCC CGC TA 
rl (9847..9868) 5’CGG ATG AAG CAG ATA GTG AGG A
primer pair 2 f l  (3315..3335) 5’-ACC CTA GCA GAA ACA AAC CGG 
r2 (4107..4129) 5’-CAG GAG GAT AAT TAT TGA GGC TG
primer pair 3 f3 (3356..3376) 5’-GGC TTT AAC GTC GAA TAC GCC 
r3 (4209..4229) 5’-TAG TGG AAT GGG GCT AGT CCA
primer pair 4 f4 (2829-2848) 5’-GCA AAG GCC CCA ACA ACG AA 
r4 (3266-3243) 5’-GTC AGG CGG GGA TTA ATA GTC AGA
primer pair 5 f5 (12520-12540) 5’-GAT TCC ACC CCC TCA CGA CTA 
r5 (12875-12855) 5’-GAG GGC GAG GCT TCC GAT TAC
Standard PCR conditions were used with an annealing temperature of 60°C. The origin of 
mtDNA contained within mus musculus / mus musculus (MM) and mus musculus / ratus 
norvegicus (RM) clones was assessed using per pimer pair 2 and Bam HI restriction 
enzyme digestion._The five pairs of primers designed were tested for their specificity for 
rat, mouse and human mtDNA. DNA was extracted from human p+ cells (H), mouse 
STOG p+ cells (Mp+), mouse blood (Mb), and rat blood (Rb). The per products were run 
on a 1.2% agarose gel (figure 4.2). Results of these reactions, summarised in table 4.1,
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show that only primer pair 2 with BamHl digest was able to clearly distinguish between 
human, rat, and mouse mtDNA.
Primers H Mp+ Mb Rb
1 0 + + (+)
2 0 + + +
2+digest cut cut no
3 0 0 + +
3+digest no no
4 0 0 + +
5 + (500) +(380) +(380) 0
Table 4.1 Summary of the results of PCR with primer pairs 1 to 5 (+/- BamHl 
digest) performed on human p+ cells (H), mouse STOG p+ cells (Mp*), mouse blood 
(Mb), and rat blood (Rb). 0 = no PCR product, + = PCR product obtained, (+) = faint 
PCR product obtained, (xxx) = size of PCR product in base pairs. RE digest results show 
whether a PCR product was cut by BamHl (cut) or not (no).
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Figure 4.2 Primer design for distinguishing human/mouse/rat mtDNA
Polymerase chain reaction products for primer pairs 1,2,3,4,and 5, and BamHl digest products for 
primer pairs 2 and 3. Samples A=human p+ cells, B=mouse p+ cells, C=mouse blood, D=rat 
blood, E=water blank.
Of the five Mus musculus / mus musculus (MM) clones grown up and analysed all 
contained only mouse mtDNA as assessed by PCR. All these clones after PCR with 
primer pair 2 and BamHl digest generated a 565 and 250 bp fragment (figure 4.3). 
Similarly, of the ten mus musculus / ratus norvegicus (RM) clones grown up and 
analysed all contained only rat mtDNA (see figure 4.3), generating a single product of 
815 bp after the same PCR and digest. This PCR also excludes, within the levels of 
detection of the PCR, the coexistence of both mouse and rat mtDNA in any of the clones
Individual clones were grown up until sufficient quantity (20 confluent 10 cm plates) was 
obtained for extraction of the mitochondrial fraction and subsequent spectrophotometric 
analysis of the mitochondrial respiratory chain complexes I,II, III, II/III, IV and CS 
(section 2.12). Data was analysed using Mann-Whitney U test as described in section 
2.20. This revealed a significant reduction in complex I activity (34% of control 
mouse/mouse cybrids), complex III activity (60% of control mouse/mouse cybrids), and 
complex IV activity (43% of control mouse/mouse cybrids), and no significant difference 
in complex II activity figure 4.4).
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Figure 4.3
Rat or mouse mtDNA content of cybrids obtained by fusing mouse or rat platelets with STOG p° 
mouse fibroblasts to generate mouse-mouse (MM) and rat-mouse (RM) clones. PCR performed 
using pair 2 primers and subsequent BamHl restriction enzyme digest.
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Figure 4.4
Mitochondrial respiratory chain activities expressed as citrate synthase (CS) ratios for complex I 
(Cxi), complex II/III (Cx II/III), and complex IV (CxIV), and CS activities in xenocybrid clones. 
Ratios are mean + SEM values for mouse/mouse (n=5) and rat/mouse (n=9) xenocybrids. For Cx 
II and Cx III mouse n=4 and rat n=3. Statistical sinificance by Mann-Whitney U teat: *p,0.05,
**p<0.001.
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4.4 Discussion;
The introduction of rat mtDNA into a mouse nuclear background was able to generate 
viable clones. Human mtDNA introduced into mouse p° cells did not produce viable 
cybrids, presumably because the two genomes are phyllogenetically too diverse to allow 
adequate “cross-talk”. The rat-mouse xenomitochondrial cybrids exhibited impaired 
respiratory chain function. Despite this significant impairment MRC activity was 
obviously adequate enough to allow cell survival and proliferation. These defects were 
present despite the finding that mitochondrial mass as evaluated by citrate synthase 
activity per mg protein was 38% greater in RM cybrids. This may be a reflection of 
mitochondrial proliferation in response to impaired MRC function. EM studies of RM 
cybrid mitochondria would provide further information.
The maintenance and expression of rat mtDNA in a mouse cell implies that the 
machinery of replication (DNA polymerase y, single-strand binding proteins, RNases 
required for producing replication primers etc), transcription (RNA polymerase, 
transcription termination factors, RNA processing enzymes, etc), and translation 
(initiation and elongation factors, aminoacyl tRNA synthetases, ribosomal proteins, etc.) 
are still able to function sufficiently to permit cell survival despite the mtDNA nucleotide 
changes present in the foreign mitochondria. However, the partial defects in respiratory 
chain complexes detected in these experiments would imply that assembly of functional 
OXPHOS complexes is sensitive to such changes, and whilst still able to function, they 
do so with reduced efficiency. Transcription and translation studies and the use of two- 
dimensional denaturing gels to assess subunit structure would be of interest to further 
investigate the efficiency of interactions between these two genomes from different 
species.
Other studies have shown that the presence of less then 2% of self mtDNA results in 
cellular respiration at 40% of parental lines. With time in culture the levels of self 
mtDNA rise, and when at 10% normal respiratory function is restored. This pattern is 
similar to that seen in studies of the threshold effect of some pathogenic mtDNA
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mutations, when similar levels of wild type mtDNA (6-15%) can complement enzymatic 
defects 68’624’625. Despite this increase in the level of self mtDNA with the passage of time 
in culture, a complete replacement by mouse mtDNA does not occur. This may be 
because once normal respiratory function is restored the selection advantage in favour of 
self mtDNA is lost. A similar phenomenon is described in human cells with an ATP6 
gene mutation 626. Native mtDNA was not detectable in rat-mouse cybrids although the 
potential for accumulation exists during the period between PCR based ascertainment of 
mtDNA content and growing up of sufficient quantities of cells for spectrophotometry.
Functional incompatibilities appear to be species specific. This may be influenced by
627 628variable rates of evolutionary change ’ . The rate of substitution in mitochondrial
encoded proteins in mammals is at least one order of magnitude greater than it is in fish 
629. The mtDNA mutation rate of rodents has been estimated at 4.8 -  9.7% per Myr, and 
in humans at 2% per Myr 597’630. This factor is probably the key influence on the 
compatibility of the interactions between mtDNA and nuclear DNA from different 
species. Xenomitochondrial cybrids could be generated across different species barriers 
because this technology provides a useful addition to the tools available for the 
exploration of nuclear-mitochondrial interactions, and adds to the currently available 
models of human mitochondrial disease.
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CHAPTER 5
THE ROLE OF MITOCHONDRIAL RESPIRATORY CHAIN FUNCTION IN 
SPORADIC FOCAL DYSTONIA.
5.1 Introduction
The evidence to implicate mitochondria in the pathogenesis of a range of non-archetypal 
predominantly neurodegenerative conditions is described in detail in chapter 1. In this 
chapter the role of mitochondrial dysfunction in dystonia is explored further. This 
potential pathogenic link has been proposed for a number of reasons that include the fact 
that dystonia may occur in patients with LHON, and that the gene responsible for Mohr- 
Tranebjaerg syndrome has been discovered to be a mitochondrial transport protein. 
However it remains to be established whether mitochondrial dysfunction underlies other 
forms of dystonia? As described below this experiment used skeletal muscle obtained 
from patients with sporadic focal dystonia to look for evidence of mitochondrial 
dysfunction.
5.2 Experimental hypothesis
Mitochondrial dysfunction is involved in the pathophysiology of sporadic focal dystonia, 
and this biochemical defect would be detectable in the muscle of affected individuals.
5.3 Results
Ten patients with a diagnosis of sporadic focal dystonia and undergoing selective 
denervation of the sternocleidomastoid muscle for treatment of their spasmodic torticollis 
were identified. In all patients the stemocledomastoid muscle was biopsied at the time of 
surgery. Control samples were obtained from 4 patients undergoing a variety of cranio- 
cervical surgical procedures. In three controls the splenius muscle was sampled, and in 
one the paraspinal muscle. All patient and control details are summarized in table 5.1. All
167
patients (but no controls) had previously been treated with botulinum toxin to the affected 
muscle.
Muscle samples from the 10 patients and 4 age-matched controls were frozen in liquid 
nitrogen at the time of collection. An aliquot was then removed and homogenised 
(section 2.15). Spectrophotometric analysis was undertaken of complex I, II/III, and IV of 
the mitochondrial respiratory chain, citrate synthase and aconitase as described above 
(section 2.12). Protein estimations were performed (section 2.17). The activities from 
patients and controls were expressed as citrate synthase ratios and compared using the 
Mann-Whitney U test (section 2.20).
All muscle samples underwent blinded histological and electron-microscopic evaluation. 
Ethical approval was obtained from the Ethics committees of the Royal Free Hospital and 
the National Hospital for Neurology and Neurosurgery.
The mean activities for complexes II/III, IV, and aconitase were lower in patients than in 
controls. Statistical significance however was not reached for any of these biochemical 
parameters (figure 5.1). Histology and electron microscopy examination (table 5.1), 
performed by Professor Landon, Institute of Neurology, showed abnormalities in three of 
four controls, and six of the 10 patients. The unexpected findings in the control samples 
were of RRFs in all three cases. These findings were suggestive of a mitochondrial 
myopathy in the controls. EM findings were not available for all patients. Two controls 
showed large peripheral collections of excess abnormal mitochondria. These 
mitochondria had abnormal christae and paracrystalline inclusions. The histological 
abnormalities in the patient samples were more suggestive of denervation secondary to 
botulinum toxin therapy. RRFs were found in patient 9, SDH changes (RRF equivalents) 
in patient 3, and occasional COX negative fibres in patient 8.
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■  Control
■  Dystonia
Cx I (x50) Cx II/III (x50) CxIV Aconitase (x2)
Figure 5.1
Mitochondrial Respiratory Chain (Complexes I, II/III, and IV) expressed as citrate synthase ratios 
and aconitase activites for sporadic focal dystonia patients (n=10) vs Controls (n=4),. Values shown 
are mean activities with standard error bars.
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Table 5.1 i Patient and Control details, light and electron microscopy findings
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Cl 58 sp bi Abnormal numerous RRF usually COX-ve Abn mt, abn christae + crystalline inclusions
C2 66 sp csm mitochondrial myopathy
C3 80 ps ocf Numerous RRFs usually COX-ve. Myopathic widespread abnormalities, excess abn mt
C4 52 sp pt Normal
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P8 42 scm St Normal
P9 30 scm c+gd Normal
P10 39 scm St
Table 5.1 Patient and Control details, light and electron microscopy findings
Muscle biopsied: sp=splenius, ps=paraspinal, scm=stemocleidomastoid.
Diagnosis: bi=basilar invagination, csm=cervical spondylotic myelopathy, ocf= 
occipital cervical fusion for Rheumatoid arthritis, pt=pineal tumour, st=spasmodic 
torticollis, ptcd=post traumatic cervical dystonia, c+gd=cervical and generalized 
dystonia.
VFS=variation in fibre size (expressed in pm), IA+A=type I fibre atrophy and 
angulation, IIA+A= type II atrophy and angulation, Cent Nuc=central nuclei 
(+=present or 0=absent), Con tissue= connective tissue (+=increased or 0=normal), 
I/II propn= fibre type proportions, ox=oxidative, L/G/ADA/P/AP=lipid, glycogen, 
adenine deaminase, phosphorylase, acid phosphatase. RRF=Ragged red fibre, 
COX=cytochrome oxidase, SDH=succinate dehydrogenase.
5.4 Discussion
Several strains of evidence exist to implicate mitochondria in the pathogenesis of 
dystonia. This study found no evidence of a mitochondrial defect in muscle from 
patients with sporadic focal dystonia.
The small number of patients and controls limited the analysis. This reflects the 
difficulties in obtaining muscle samples from dystonic patients. Surgical therapies are 
rarely performed in this patient group. The advent of more effective medical 
therapies, mainly botulinum toxin, compounds this problem. Other limitations include 
the fact that scm was analysed for patients and neck extensor muscles for controls. A 
significant concern is the quality of the control samples. Three of the four controls had 
histochemical mitochondrial changes in their muscle biopsies. Whether these are 
pathological or physiological is uncertain. Although differences in the biochemical
f.Q'y
and histological properties of different muscle groups are recognized , there is no 
literature on mitochondrial function in normal neck muscles.
Furthermore, the dystonias are a heterogeneous group of disorders. It is known that 
similar phenotypes can result from different genetic mutations. It is therefore possible 
that our group of patients could have had a number of different conditions, and hence 
different pathogeneses. Eight of the ten patients had a diagnostic label of spasmodic
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torticollis. Of the other two, one was diagnosed with cervical and generalized 
dystonia, and the other with post-traumatic dystonia. These may well be different 
disease entities. A future study could analyse samples from genetically defined 
homogeneous groups of patients. Drug effects may also affect results, and exposure to 
botulinum toxin prior to muscle biopsy may have biochemical and histological 
consequences. This chemical denervation may mask biochemical defects.
Platelets are a more easily accessible tissue allowing greater numbers of patients to be
studied. However they may not necessarily be representative of biochemical changes
within the basal ganglia. The complex I defect found in Parkinson’s disease platelets
is however also present in the substantia nigra . Previous reports have shown that
680platelets from patients with sporadic dystonia have a 21% complex I deficiency , a 
defect that is corrected when platelets are fused with p° cells 681. This finding could 
have three potential explanations: i) the platelet defect was the consequence of a 
heteroplasmic mtDNA mutation, and after generation of the cybrids the mutation load 
fell below the threshold required to cause a biochemical defect; ii) the defect could be 
caused by a nuclear gene defect, and fusion with a new nuclear environment 
complements that defect; iii) an endogenous or exogenous toxin circulating in blood 
or bone marrow may induce the complex I defect in platelets.
Muscle may not be the ideal tissue in which to analyse mitochondrial function in this 
patient group. Neuronal tissue may be of greater interest but would prove difficult to 
obtain. The archetypal mitochondrial encephalomyopathies are renowned for their 
tissue specific clinical and biochemical manifestations. Little is known about 
mitochondrial respiratory chain function in the basal ganglia of dystonic patients. 
Pathological specimens would be required or biochemical information could be 
gleaned from magnetic resonance spectroscopy.
This is the first study to assess MRC function in dystonic muscle. No significant 
disturbance on MRC was found. It is of note that whilst none of our patients 
biochemical parameters were significantly reduced, the values for complex I activity 
was the least reduced from the control values. The absence from muscle of a complex 
I defect as found in platelets would support the previously proposed hypothesis of a
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circulating toxin being responsible for the complex I defect found in patient platelets. 
However, this theory would require a circulating toxin to damage platelets in the 
circulation or bone marrow, to cross the blood brain barrier and cause mitochondrial 
dysfunction in the basal ganglia, but yet leave mitochondrial function in myocytes 
intact. This seems unlikely. Future studies of this nature should involve larger 
numbers of patients, with more uniformly defined disease entities. Controls should be 
better matched for age and muscle biopsied, since the current control data adversely 
affects the validity of the findings of this study.
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CHAPTER 6
FRIEDREICH’S ATAXIA: ASSESSING PATIENTS AND EVALUATING  
THERAPIES.
6.1 Introduction:
A number of potential therapies now exist for FRDA. Several other therapeutic agents 
are likely to become available as our understanding of the pathogenesis of this 
condition improves. The size of their treatment effect is difficult to predict. They may 
either worsen the disease, have no effect, slow disease progression, halt disease 
progression, or potentially reverse, partially or wholly, already established disability. 
The outcome will depend on whether the agents protect cells from further damage or 
are able to repair already damaged cells.
The effective assessment of the diverse clinical presentations associated with FRDA is 
central to the evaluation of these novel therapies. This requires the evaluation and 
validation of disease measures, which may be patient-orientated, clinically based, or 
employ surrogate markers of disease activity. Trials in FRDA are further complicated 
by the relative rarity of the disease, its chronicity, and the potentially small size of any 
treatment effect. In common with other chronic conditions, the slowness of 
progression makes prospective studies problematic. Treatment trials for rare 
conditions are complicated by the small number of patients available. Large placebo 
controlled trials may therefore not be feasible. One substitute is the use of historical 
controls to predict the expected rate of disease progression. A detailed understanding 
of the natural history of FRDA and the factors that influence disease progression is 
therefore necessary. Retrospective analysis of disease progression and survival have 
shown a median time from disease onset to wheelchair confinement in FRDA of 11 
years, and a 75% survival for more than 34 years after disease onset 429.
Historically, the use of ataxia scales followed on from the success of scales for basal 
ganglia disorders and has involved a variety of different scales. The Inherited Ataxia 
Clinical Rating Scale (IACRS) was published in 1980 . These scales and a variety
of novel or modified scales have been used to assess ataxic patient groups and
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determine the efficacy of therapeutic trials but their validity has not been rigorously 
tested 526.
More recently the International Co-operative Ataxia Ratings Scale (ICARS) 555 has 
been developed for the evaluation of potential pharmacological therapies for ataxia. 
ICARS is a 100 point scale that consists of four components, posture and gait, kinetic, 
speech, and oculomotor and uses arbitrary, non-linear, subjective, semi-quantitative 
scales in an attempt to assign a value of the severity of the ataxia for an individual 
patient. ICARS has been used to assess patients with FRDA 685 539 and AVED 55°. To 
date, despite its use in a number of therapyeutic trials there has been no systematic 
validation of the usefulness of ICARS as a measurement tool for FRDA or any other 
ataxic disorder 686.
Perhaps more significantly the degree of disability and the impact of FRDA as 
assessed from the patients’ perspective are poorly understood and poorly documented. 
FRDA clearly exerts a considerable, although as yet unquantified, impact on general 
levels of functioning and well being. In virtually all patients with FRDA the disability 
includes impaired mobility, swallowing, speech and thus communication, while in a 
significant population of patients cardiac disease, scoliosis, impairment of vision and 
hearing, and diabetes may impact further on the burden of disability.
The measurement of functioning and well-being from the patient’s perspective has 
become central to the assessment of health and the evaluation of treatment regimes. 
Consequently, measures variably referred to as health status, quality of life, or health 
related quality of life instruments are advocated when attempting to assess the 
outcome of health-care interventions. These measures are often not disease specific 
and encompass physical, psychological, and social function. While the value of these
(ion
measures in certain neurological disease is now well established the general use of 
such measures in neurology has lagged behind that in other medical specialties. 
Indeed, there is currently no disease specific measure for ataxia, nor have any of the 
non-specific measures been evaluated in this group of conditions.
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6.2 Health-Related Quality of Life in Friedreich’s Ataxia
6.2.1 Introduction:
The ability of four generic health status measures to assess 56 patients homozygous 
for the FRDA repeat expansion was evaluated. The 36-item Short Form Health 
Survey (SF-36), the self-report Barthel Index (BI), The General Health Questionnaire 
(GHQ 12), and the EuroQol were used. These health care measures are well 
established and validated. The SF-36 is perhaps the best known measure, developed 
from the Rand Corporation’s Health Insurance Experiment and the subsequent
570 688 •Medical Outcomes Study . Its brevity allows for rapid and easy completion yet it 
covers a core set of domains of functioning and well-being. The Barthel Index is 
already recommended for use in elderly populations, rehabilitation and stroke 
patients. Goldberg’s general health_questionnaire (GHQ) is the most commonly used 
international scale of general psychiatric morbidity. Developed in London 30 to 40 
years ago, it was designed to detect anxiety and depression. Since it includes 
psychosomatic items it may measure physical health status in addition to psychiatric 
morbidity. Its use has been validated in over fifty studies. The Euroqol is widely used 
internationally, and provides a standardized non-disease specific survey instrument 
for describing health related quality of life.
6.2.2 Experimental Design
Four generic health status measures (SF-36, BI, GHQ 12, and EuroQol) were sent to 
56 patients homozygous for the FRDA repeat expansion. The questionnaires were 
resent to those patients who had not responded by six weeks. Methodologies relating 
to patients, genetic analysis, and health status measures are as detailed in section
2.22.1 -  2.21.3. The questionnaires are included in appendix 2.
This work was performed in conjunction with Dr JM Cooper and Dr J Bradley of the 
Department of Clinical Neurosciences, Royal Free Campus, Royal Free and 
University College Medical School, University of London, who helped with the 
distribution of questionnaires, and Dr JC Hobart of the Department of Clinical 
Neurology and Neurorehabilitation, Neurological Outcome Measures Unit, Institute
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of Neurology, Queen Square, London, who assisted with the statistical analysis of the 
replies.
6.2.3 Results:
Of the 56 patients sent the questionnaire, 54 responded immediately, and only 3.6% 
needed the questionnaire resent at 6  weeks. The ages of the 56 patients ranged from 
18 to 57 years (mean 31.0 ± 8 .6 ). 57% were female, and 95% Caucasian. Age of onset 
ranged from 2 to 30 years, and averaged 13.7 years ±6.4. Disease duration varied 
from 4 to 38 years with an average of 18.1 years ±8.4. We questioned patients about 
their employment status, and of the 56, 41% were in employment, 26% retired due to 
their ataxia, 2 % retired for other reasons, 18% unemployed, and 13% were students. 
64% of our patients were educated beyond the minimum school leaving age, and 25% 
of our cohort had a degree or equivalent qualification. As regards marital status, 59% 
were single, 21% married, 5% divorced, and 14% living with a partner. Regarding 
mobility, bearing in mind the average disease duration of 18.1 years, 14% walked 
unaided, 30% walked with an aid, and 55% were wheelchair users.
Descriptive statistics for the self-report Barthel (BI), GHQ 12, EuroQol thermometer, 
and EuroQol Helath state are shown in table 6.1, and those for the eight domains of 
the SF-36 questionnaire in table 6.2. Mean scores were near the mid-point of the 
possible scale-range for role limitation physical, general health perceptions and 
vitality of the SF-36, and for the GHQ 12 suggesting that the distribution of the scores 
on these instruments is near normal and likely to detect change. Standard deviation 
was high, implying variability and thus the ability to detect change and discriminate 
between individuals, for all measures except the GHQ 12. Standard deviation was 
particularly high for role limitation physical and emotional of the SF-36. Floor and 
ceiling effects describe the percentage of patients scoring the maximum and minimum 
scores respectively. They represent the extent to which the measured range of an 
attribute is restricted and should ideally be below 15%. This was exceeded in all 
components of the SF-36 except general health perceptions, vitality, and mental 
health. Floor and ceiling effects were of desirable levels for BI, GHQ 12, Euroqol 
thermometer, and Euroqol health state. Skewness is a measure of how normal a
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distribution of scores is. A positive value indicates that scores cluster to the left of the 
mean, and a significant positive result was obtained for SF-36 physical function, and 
the GHQ 12. Sizeable negative skew values were obtained for all other measures 
except the SF-36 vitality.
Barthel Index GHQ 12 EuroQol
thermometer
Euroqol 
Health State
N 47 51 55 45
Missing data 16% 9% 1 .8 % 19.6%
Scale range 
(midpoint)
0 -2 0 ( 1 0 ) 12-48(30) 0-100(50) -0.594-1.00
Score range 2 - 2 0 12-40 20-95 -0.09-1.00
Mean (sd) 13.5(4.7) 25.0(6.1) 64.3(19.1) 0.53(0.3)
Floor % 0 0 0 0
Ceiling % 8.5 2 . 0 0 2 . 2
Skewness -0.580 0.678 -0.748 -0.902
Table 6.1
Descriptive statistics for the self-report Barthel, GHQ 12, EuroQol thermometer, and 
EuroQol Health state.
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Range Score
Dimension N
(missing 
data %)
Scale Score Mean (sd) Floor
%
Ceiling
%
Skew
Physical
function
54(3.6) 0 - 1 0 0 0-90 21.7 (23.7) 20.4 0 1.401
Role
limitations-
physical
55(1.8) 0 - 1 0 0 0 - 1 0 0
50.9 (42.5
27.3 36.4 0.059
Bodily pain 56(0) 0 - 1 0 0 2 2 - 1 0 0 78.3 (22.6) 0 39.3 -0.814
General
health
perceptions
55(1.8) 0 - 1 0 0 5-100 46.8 (23.4) 0 1 . 8 0.217
Vitality 55(1.8) 0 - 1 0 0 0-85 49.8 (22.3) 1 . 8 0 -0.0474
Social
functioning
56(0) 0 - 1 0 0 0 - 1 0 0 71.4 (27.3) 1 . 8 28.6 -0.885
Role
limitations-
emotional
53(5.4) 0 - 1 0 0 0 - 1 0 0 73.0 (37.6) 15.1 58.5 -1.056
Mental
health
55(1.8) 0 - 1 0 0 24-100 67.2 (21.3) 0 1 . 8 -0.404
Table 6.2
Descriptive statistics for the eight domains of the SF-36 questionnaire.
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6.2.4 Discussion:
The use of health instruments in neurology is well established. This is particularly true 
for the evaluation of outcomes after head injury 689 stroke, epilepsy, Parkinsons 
disease, motor neurone disease, spinal injury, and multiple sclerosis 69°. These health 
measures may be generic or disease-specific. General measures of health status allow 
comparison with other patient groups. Disease specific measures are more sensitive to 
change than generic measures, but may be too narrowly focused and thus fail to 
capture broader outcome measures. Generic and disease specific scores, and utility 
measures can be used simultaneously. No disease specific measures exist for the 
evaluation of ataxia, and no literature on the use of generic measures in this group of 
conditions could be found despite an extensive literature search.
The SF-36 covers facets of life that one would assume to be relevant to patients with 
ataxia. These are the ability to perform work and daily activities, and physical and 
social functioning. The reliability, validity, and responsiveness of the SF-36 have 
been previously well established 69 \  It has previously been used in a number of 
neurological disorders 692'694. Our results show that the impact of FRDA is significant. 
Three components of the SF-36 score showed a significant percentage of patients 
exhibiting maximum poor health scores. This floor effect was significant for physical 
function, physical role limitations, and emotional role limitations. All other 
parameters had negligible floor effects and the validity of the score and its usefulness 
in assessing change are therefore not compromised. Four components of the scale 
(physical role limitations, bodily pain, social functioning, and emotional role 
limitations) showed significant ceiling effects, suggesting that a sizeable percentage of 
our FRDA group reported no disability for these parameters. However two of these 
(physical role limitations and emotional role limitations) also had significant floor 
effects showing the group to be spread across the whole range with significant 
percentages at either extreme.
The three potential responses to the five items of the Euroqol health state 
questionnaire are combined to give a five-digit response set (eg 13212). Therefore 243 
(35) potential health states exist within this measure. The Euroqol thermometer, a 
simple visual analogue scale, provides a single overall score. This is a supplementary
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self-assessed measure of overall health status rather than a valuation of utility. The 
Barthel Index assesses ten clinically relevant items of physical dependence in personal 
activities of daily living. These are bathing, transferring, dressing, feeding, mobility, 
stairs, toilet use, grooming, bladder, and bowel function. The general health 
questionnaire concentrates on broad components of psychiatric morbidity. GHQ 12 is 
the shortest version of the general health questionnaire, but is as efficient as the 30- 
item version. The self report Barthel Index, GHQ 12, Euroqol thermometer, and 
Euroqol Health State exhibited no floor effect and ceiling effects were likewise 
negligible. However data was missing from 16% of the Barthel Index and almost 20% 
of the Euroqol health state.
This study documents for the first time the substantial impact that Friedreich’s ataxia 
has on the health status of patients. It has, as might be expected, particularly severe 
impact on physical functioning, but is also severely deleterious on emotional aspects 
of health status, social functioning, and mental health.
Further studies will evaluate the impact on health status over time, and the impact on 
the health status of care givers which has been shown to be an important factor in 
Alzheimers disease 695, and motor neurone disease 696. Treatments offering benefit to 
the patients might also benefit carers. The health status of carers also has implications 
for support services and charitable organisations. Further studies are underway to 
design a quality of life measure specific for FRDA.
The impact of FRDA on patients has until now consisted only of descriptive studies of 
the clinical features of the condition and data on parameters such as age of onset, 
wheelchair use, and age of death. This study has provided the first large-scale 
evaluation of the self-reported health status of patients with FRDA, and clearly 
describes the human impact of the disease. The findings show these measures to 
provide a meaningful and valid picture of the impact of Friedreich’s ataxia on the 
daily lives of those living with it. The data obtained will enhance our understanding of 
FRDA, and will be of use in the analysis of future trials that use quality of life as a 
primary outcome variable, allowing another dimension to the evaluation of the 
efficacy of potential therapeutic interventions.
182
6.3 Friedreich's ataxia: Evaluation of ICARS and Factors Influencing
Clinical Progression. 
6.3.1 Experimental Design
77 patients, homozygous for the FRDA repeat expansion, from 67 different pedigrees 
were assessed clinically using ICARS as the scoring system. They also underwent 
echocardiography and neurophysiological evaluation. Methodologies concerning 
patients, genetic analysis, clinical assessment and statistical analysis are detailed in 
sections 2.22.1 -  2.22.4
6.3.2 Results
The data is summarised in table 6.3. There were similar numbers of males (37) and 
females (40), with a broad range of disease onset (2 - 27 years of age). In the vast 
majority gait ataxia was the presenting feature. Other features bringing patients to 
medical attention included pes cavus ( 2  patients), scoliosis ( 1 ), upper limb 
incoordination (2), family history of FRDA in asymptomatic individuals (1), and 
sphincter disturbance (1). The average time from symptom onset to diagnosis was 4.5 
±3.9 years, ranging from 4 years prior to the onset of symptoms in the sibling of an 
affected patient, to 17 years after symptom onset. In those at the upper end of this 
range disease onset tended to have been prior to the introduction of genetic testing. 
At the time of assessment the patients were between 10 - 57.7 years of age and disease 
duration ranged between 1.7 - 39.7 years. The size of the smallest GAA repeat 
(GAA1) ranged between 130-1080. There was an inverse relationship between GAA1 
and age of onset (figure 6.1). In the 62 patients questioned the ADL scores ranged 
between 2 - 2 6  (mean 13.6 ± 5.2).
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Clinical Feature Percent Clinical Feature Percent Clinical Feature Percent
Number of patients 77 Retained LL reflexes 8  a Dysphagia 60
Number of families 67 Absent SSEPs $
M ale: Female 37 :40 Extensor plantars 94 Sphincter 3 9  c N9 74
disturbance N13 61
Mean age 24.3 ± 10 Severely impaired 56 Severely impaired 3 d N20 37
(range) (10-57.7) vibration vision
Mean age of onset 11.9 ± 6.3 Scoliosis 6 8 Square wave jerks # 5 Absent SAP *
(range) (2 - 27) Radial 50
Mean disease 12.4 ±7 .8 Pes cavus# 62 Fixation instability# 16 Ulnar 80
duration (range) (1.7-39.7) Median (F2) 63
Mean GAA1 size 725 ± 229 Diabetes mellitus 5 b LVH by echo 42e Sural 83
(range) (130- 1080)
Table 6.3. Percentage prevalence of clinical features in Friedreich’s ataxia patients not assessed as part of the ICARS.
a. Defined as individuals with knee or ankle deep tendon reflexes
b. Diabetes was determined by a requirement for insulin or a raised random glucose or HbAlc level.
c. Minimum criteria: patients reporting mild urinary hesitancy, urgency or retention < once per month
d. Patients previously investigated for optic atrophy,
e. LVH defined by an intra ventricular septal thickness > 11mm
# n=63, $ n = 54
184
Age of
Onset
(years)
0 l l l »   I I .....
0 2 0 0  4 0 0  6 0 0  8 0 0  1 0 0 0  1 2 0 0
GAA1
Figure 6.1
Relationship between the size of the smaller GAA repeat (GAA1) and age of 
onset in 77 FRDA patients. Gradient 0.0184 years / GAA, correlation 
coefficient, R=0.666, p<0.001.
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Atypical clinical presentations included three cases of onset over the age of 25 years, 
and six cases with some preservation of lower limb (LL) deep tendon reflexes and a 
further 6 patients in whom some of the upper limb reflexes were still present. These 
patients tended to have a slightly older disease onset, and a shorter GAA1 repeat size 
than the remaining patients, but similar ICARS scores. The differences did not reach 
statistical significance.
fx\n
The prevalence of clinical features generally mirrored that of previous studies 
However, dysphagia, rarely commented on in previous studies, was reported by 60% 
of these patients in whom it was graded as moderate (choking more than once a 
month, 40%) or more severe (20% of patients). Sphincter disturbance was reported by 
39%, where it was moderate (moderate hesitance, urgency, or retention once a month, 
or urinary incontinence less than once a month, %) or more severe (% of patients). 
Skeletal abnormalities were common. Pes cavus was present in 62%, and scoliosis in 
68%, with 31% of those with scoliosis requiring corrective surgery. Only 5% of 
patients were known to be diabetic, with one further patient having a raised HbAlc 
level.
The clinical features of the patients as indicated by the total ICARS score (scale range
0-100) was quite diverse with a score ranging between 23 and 95 (mean 52.7 ±17.1). 
Analysis of how the total ICARS and four component scores changed with increasing 
patient age demonstrated that all scores fell on the scale with no floor or ceiling 
effects with the exception of posture and gait scores which increasingly reached a 
maximum above the age of 23.9 years (Figure 6.2).
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Relationship between patient age at assessment and the distribution of total ICARS 
score (A), and the four component scores of ICARS; posture and gait (B), kinetic (C), 
speech (D), and ocular (E), in 77 patients with FRDA.
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To determine if there was any relationship between clinical progression and GAA1 
size, patient age and disease duration the total ICARS and the four individual 
component scores were correlated with these parameters using single or multiple 
linear regression analyses (Table 6.4). The most significant correlation was between 
total ICARS, GAA1 and patient age with 49% of the variation in total ICARS score 
being attributable to these two combined variables. ICARS component scores were 
variably related to repeat length, disease duration, and age. Ocular scores, determined 
by the presence or absence of nystagmus, hypo or hypermetric saccades, and saccadic 
intrusion of pursuit movements, failed to correlate with these disease parameters 
(Table 6.4).
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Independent Variable
Dependent GAA1 Disease Age GAA1 / GAA1 /
Variable (number) Duration
(years)
(years) Duration Age
Total grad 
R2
0.021
0.077*
1.34
0.366**
0.71
0.170**
0.027/1.43
0.489**
0.05/1.29
0.490**
Kinetic grad 
R2
0.009
0.072*
0.576$ ♦
0.318
0.28
0.123*
0.012/0.617 ♦ *
0.431
0.021/0.525 ♦ ♦
0.393
Ocular grad NS NS NS NS NS
R2 0.012 0.021 0.00 0.037 0.015
Posture grad 
+ gait R2
0.011
0.080*
0.682
0.343**
0.386
0.181**
0.014/0.731 ♦ ♦
0.468
0.027/0.698 ♦ ♦
0.517
Speech grad 
R2
NS
0.001
0.064
0.212**
0.048 ♦ ♦0.191
0.0/0.065
0.212**
0.001/0.062 ♦ ♦0.239
Table 6.4
Relationship between ICARS and ICARS component scores and various 
disease parameters. Gradients (grad) relate to the changes in clinical score per 
unit of the independent variable, unless the relationship was not significant 
(NS). Correlation coefficients (R2 values) for 77 FRDA patients when 
correlated with various disease parameters. Single and multiple linear 
regression analyses were performed using SSPS. * = p <0.05, ** = p <0.001
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Visualisation of the combined influence of increasing age and GAA1 size on total 
ICARS scores was achieved by dividing the 77 patients into 4 groups according to the 
size of their GAA1 (<600, 600-750, 751-900 and >900 GAA), to give approximately 
equal numbers of patients in each group (Figure 6.3). The linear regression analysis 
for these groups showed a correlation indicating a progression of; 0.87, 0.54, 1.85 and 
2.26 ICARS points per year in the <600, 600-750, 751-900 and >900 groups 
respectively.
Retrospective analysis of disease progression was determined in the 4 patient groups. 
This identified a graded progression between the different stages in proportion to the 
size of GAA1 size. The mean time from onset of walking difficulties to wheelchair 
confinement for outdoor use was 17.9, 14.9, 10.3, and 9.5 years in the <600, 600-750, 
751-900 and >900 GAA groups respectively (figure 6.4). The value for the patient 
group as a whole was 11.2 years.
The ocular subscore of ICARS is a cumulative score of gaze-evoked nystagmus, 
abnormalities of ocular pursuit, and dysmetria of the saccade. Pursuit movements 
were slightly fragmented in 40%, and clearly fragmented in 33% of patients. 
Nystagmus was present in only 6% of patients, and in these patients only a few non­
sustained beats were seen. Saccades were hypermetric in 70%, and hypometric in 
19% of patients. Further evaluation of parameters not included in ICARS revealed 
fixation instability in the primary position in 16%, square wave jerks in 5% of patients 
and reduced saccadic velocity in 24%, (but only clearly so in 5%) of all patients.
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Figure 6.3
Relationship between patient age and total ICARS score in groups of patients with GAA1 repeat sizes 
in the range; A: >900 GAA (X, n=23), solid line, gradient = 2.26, R2=0.51 p <0.001 B: 751-900 GAA 
(open square, n=16), dotted line, gradient = 1.85, R2=0.58 p <0.001 C: 600-750 GAA (open diamond, 
n=18), long dashed line, gradient = 0.54, R2=0.167 p =0.09 D: <600 GAA (closed triangle, n=20) 
dashed-dotted line, gradient = 0.87, R2=0.328 p =0.06 E: represents the linear regression lines for each 
patient group taken from graphs A-D.
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Retrospective analysis of disease progression in 77 patients with FRDA according to GAA1 size, 
expressed as mean disease scores against disease duration. The patient groups and symbols used are 
as for figure 6.3.
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Electrocardiography revealed one patient to be in fast atrial fibrillation while all 
others were in sinus rhythm. Hypertrophic changes were identified in 42% of patients 
using echocardiography criteria (IVS >llmm). Additional findings were coarctation 
of the aorta requiring stenting in one patient, prominent papillary muscles in 5 
patients, and systolic apical cavity obliteration in 2 patients. As a group the fraction 
shortening was 32.6 ± 5.2%, (normal values 28-37%) suggesting there was normal 
heart function in the majority of patients.
LVDd and LVDs demonstrated a significant positive correlation with disease 
duration, patient age and ICARS score (Table 6.5), but an inverse correlation with 
GAA1 size. This suggested LV dilation increased with increasing age, disease 
duration and clinical severity, but larger GAA1 sizes were associated with decreasing 
LV dilation. Fraction shortening showed an inverse correlation with disease duration 
and clinical score (table 6.5) suggesting heart function deteriorated with disease 
progression. PWd correlated poorly with the disease parameters analysed. However, 
IVS demonstrated a significant decline with increasing age suggesting less 
hypertrophy as the patients aged, and a near significant increase with GAA1 size 
suggesting more severe hypertrophy with larger genetic abnormalities (Table 6.5).
Neurophysiological evaluation was performed in 54 patients. Sural, radial, ulnar and 
median F2 nerve action potentials were undetectable in 83, 50, 80, and 63% of the 
patients respectively. The patients with undetectable SAP had larger GAA1 repeat 
sizes and higher clinical scores (ICARS) (table 6.5), but did not show significant 
differences between age or disease duration. In those patients where it was detectable 
the mean sensory action potentials were severely decreased to 1.5 ± 0.83 pV (control 5 
-30pV), 3.18 ± 1.67pV (control 21 - 80pV), 1.62 ± 0.97pV (control 15 - 50pV) and 
1.97 ± 0.94pV (control 16 - 65pV) in the sural, radial, ulnar and median (F2) nerves 
respectively.
The mean conduction velocities for sural, radial, ulnar and median nerves were 
respectively 39.3 ±3 .1  m/s (control 46.5 ± 4.0m/s), 48.9 ± 5.3 m/s (control 63 ± 
6.0m/s), 44.1 ± 6.35 m/s (control 57 ± 5.0m/s), and 49 ± 5.4 m/s (control 56.9 ± 
4.0m/s). Somatosensory evoked potentials were undetectable at N9, N13 and N20 in
193
74, 61 and 37% of the patients respectively. In those with detectable responses, the 
latencies were similar to normal at N9, N13 with latencies of: 9.88 ± 1.05 msec 
(normal 9.83 ± 2.11msec), 13.9 ± 2.4 msec (normal 13.55 ± 2.14msec) but longer at 
N20 with a latency of 26.7 ±5.8 msec (normal 19.27 ± 2.22msec). In the patients with 
measurable SSEPs there were no significant correlations between the SSEP values 
and other disease parameters (GAA1 size, patient age, disease duration or ICARS 
score). In those patients with undetectable SSEPs the ICARS scores were significantly 
higher and the GAA1 repeat sizes tended to be larger, although these were not 
statistically significant (Table 6.5). Mean motor conduction velocity were slightly 
decreased to 50.6 ±3.5 m/s (normal 56.7 ±3.8 m/s) for the median nerve and 40.5 ± 
7.4 m/s (normal 49.9 ±5.9 m/s) for the common peroneal.
Correlation of the detectable neurophysiology results with GAA1 size, patient age, 
disease duration and ICARS score revealed the following significant correlations: 
Mdndml, mfwave and cmapw all showed a significant positive correlation with 
disease duration, age and clinical severity; Cpdml a positive correlation with clinical 
severity; Cmapa a significant inverse correlation with genetic severity and age and 
Cmapk a significant inverse correlation with genetic severity (Table 6.5).
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GAA Duration Age ICARS
LVDd grad -0.009 0.280 0.282 0.068
R2 0.163** 0.183** 0.306** 0.052*
LVDs grad -0.0058 0.28 0.231 0.09
R2 0.075* 0.204** 0.230** 0.104**
FS grad NS -0.211 NS -0.102
R2 0.001 0.099** 0.032 0.113**
IVS grad NS NS -0.047 NS
R2 0.049 0.017 0.063* 0.002
mdndml grad NS 0.026 0.02 0.012
R2 0.003 0.135** 0.125** 0.177**
cmapw grad -0.015 0.6 0.496 NS
R2 0.134** 0.243** 0.265** 0.014
Mfwave grad NS 0.143 0.118 0.084
R2 0.025 0.128** 0.138** 0.254**
cpdml grad NS NS NS 0.04
R2 0.057 0.014 0.005 0.15**
Cmapa grad -0.0039 NS -0.039 NS
R2 0.172** 0.004 0.172** 0.039
Cmapk grad -0.0035 NS NS NS
R2 0.163** 0.004 0.056 0.04
Table 6.5
Relationship between various echocardiographic and neurophysiological parameters 
and genetic abnormality (GAA1), disease duration, patient age or clinical severity 
(ICARS). Gradients (grad) relate to the changes in clinical score per unit of the 
independent variable, unless the relationship was not significant (NS). Correlation 
coefficients (R2 values) for 77 FRDA patients when correlated with various disease 
parameters. Linear regression analyses were performed using SSPS. * = p <0.05, **
= p <0.01
LVDd= left ventricular diameter in diastole; LVDs= left ventricular diameter in 
systole; FS=fraction shortening; IVS= interventricular shortening; mdndml= median 
distal motor latency; cmapw= median compound motor action potential at the wrist; 
Mfwave= median f  wave; cpdml= common peroneal distal motor latenct; Cmapa= 
common peroneal compound motor action potential at the ankle; Cmapk= common 
peroneal compound motor action potential at the knee.
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6.3.3 Discussion
The understanding of the genetic and biochemical features of FRDA has markedly 
increased over the last decade. Although this knowledge has enabled the trial of a 
number of therapeutic interventions, analysis of their influence upon disease 
progression has been limited by the absence of a validated assessment protocol.
The prevalence of the clinical features observed in this cohort of FRDA patients is 
broadly in keeping with those of previous reports. However, fewer patients were 
found to be diabetic than previously reported while dysphagia and sphincter 
disturbance appears as a common complaint in FRDA. These differences are most 
likely to be due to case selection or differences in the criteria used to define the 
various clinical features. The recognition of these disease complications is important 
for the long term care of patients with FRDA.
Various surrogate markers have been used to assess therapeutic effects of treatment 
regimes including 31PMRS 490 and markers of oxidative stress 483, but ultimately 
clinical parameters and patient orientated outcome measures are required to confirm 
any benefits.
In this study neither the total ICARS score nor its component scores showed any 
significant floor effect, but the posture and gait score reached a ceiling at a relatively 
early age (23 years), with 17% of patients in this cohort, scoring above the 95th 
centile, and 2 patients scoring maximum points. This score makes up 34% of the total 
ICARS score; consequently this component of the ICARS score is of limited use in 
patients with relatively advanced disease.
Total ICARS scores correlated well with parameters associated with disease 
progression including age, disease duration and GAA1 size. Analysis of the ICARS 
component scores demonstrated that kinetic, and posture and gait scores correlated 
well with these disease parameters, while the speech component correlated to an 
intermediate level. The assessment of speech in ICARS is highly subjective, is limited 
to the analysis of only one specific phrase, and relies upon the subjective
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interpretation of fluency and intelligibility. More detailed speech analyses may be 
required to give results that correlate more closely with disease progression.
Of the ICARS component scores, oculomotor parameters correlated extremely poorly 
with disease parameters. A number of studies have investigated the prevalence of 
ocular and oculomotor manifestations of FRDA 698,699. However, the relationship 
between oculomotor manifestations, disease duration and progression, and the use of 
ocular parameters to assess treatment effects has, to date, been left largely unexplored. 
While some ocular features, including square wave jerks, were absent from the 
ICARS they involved relatively small numbers of patients. The absence of any 
progression of the ocular defects with disease progression or GAA1 size may indicate 
that the evaluation of ocular involvement is either too crude and may require a more 
sensitive protocol, or that there is no progression of these symptoms.
In common with other scales, ICARS is not a continuous scale and often the steps 
between points are relatively large with some patients falling between values. Many 
of the clinical symptoms associated with FRDA are not evaluated in the ICARS score. 
Included in this list are; cardiological and neurophysiological features, loss of 
reflexes, vibration sense, skeletal abnormalities, diabetes, swallowing problems, 
sphincter abnormalities and some ocular signs including blindness. These may make 
up a significant component of any treatment effect and need to be assessed separately.
The rate of clinical progression, as assessed by either ICARS or the retrospective 
clinical data, was shown to be dependent upon the size of the GAA1. This clearly 
links the severity of the primary cause of the disease with the rate of clinical 
progression. Previous observations have shown that the residual level of frataxin is 
inversely related to the size of GAA1 439. Consequently the larger GAA1 alleles lead 
to lower frataxin levels and a more aggressive disease. This understanding and 
quantification of varying rates of disease progression will be of value in measuring 
potential treatment effects.
The patients involved in this study may not be a random representation of the whole 
FRDA population. Patients with severe disability or advanced cardiac disease may 
have been prevented from participating in our study due to mobility difficulties or
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because they are less inclined to volunteer for assessment. Only patients over the age 
of 10 were accepted for assessment, therefore potentially skewing our patient 
population. However, the confounding aspects of child development and an ability to 
participate in certain assessments may mean the assessment of children may require a 
modified approach. This will be most evident with therapies that are disease 
modifying rather than curative where it will be preferable to treat patients either early 
on in the disease or in pre-symptomatic individuals, many of these patients will fall 
into the younger age group.
In conclusion we have been able to demonstrate that ICARS is a valid and useful tool 
to assess the clinical symptoms and progression of FRDA. Using cross sectional 
ICARS data we have clearly shown that disease progression is predominantly 
determined by the size of the genetic abnormality (GAA1). Consequently it is 
particularly important to consider this in the design of long-term therapies and 
especially for those therapies aimed at modifying disease progression. Posture and 
gait scores reached a maximum relatively early in the course of the disease making it 
less suitable for patients with a more advanced disease. In addition there are a number 
of features not assessed properly by ICARS and therefore require additional 
assessments. As with many clinical scales the subjectivity involved adds to the 
variability of the scores and this may be particularly evident in the kinetic 
components. This can be addressed by using additional tests less prone to subjectivity. 
Whether electrophysiological or echocardiographic parameters provide good 
measures of treatment response remains uncertain and may need more long-term 
follow-up. Further work was completed and continues, assessing quantitative 
measures of ataxia in these patients. These include tests of upper and lower limb 
dexterity, timed walks, peg board tests and tests of dysarthria. These, and their 
comparison with ICARS will be the subject of future publications.
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6.4 Antioxidant treatment of Patients with Friedreich’s ataxia: 3 year follow up.
6.4.1 Introduction
The identification of the FRDA gene product frataxin as a nuclear encoded 
mitochondrially targeted protein 438,463,469,470, and the finding of mitochondrial iron 
accumulation, increased sensitivity to oxidative stress, deficits of respiratory chain 
complex activities and in vivo impairment of cardiac and skeletal muscle tissue energy 
metabolism in patients with FRDA, has paved the way for the development of rational 
therapeutic interventions. Consequently these findings have suggested that patients with 
FRDA may benefit from antioxidant, mitochondrial enhancement, or iron chelation 
therapy. These findings have also provided surrogate disease markers that can be utilised, 
in parallel with clinical and patient orientated outcome measures, to monitor the response 
to novel therapeutic agents. We therefore undertook a pilot study to determine any 
clinical and bioenergetic benefits of long-term vitamin E and coenzyme Qio therapy in 
patients with Friedreich's ataxia. We followed 10 patients with genetically defined 
Friedreich's ataxia after 1, 2 and 3 years on the same therapy and determined the effect
upon; the clinical progression of the disease using ICARS and echocardiography; and on
11
the mitochondrial bioenergetics of the heart and skeletal muscle using P-MRS.
In vivo phosphorous magnetic resonance spectroscopy (31P-MRS) is a non-invasive
technique that detects phosphorous containing compounds and cytosolic pH, and can thus
be used to assess tissue oxidative metabolism. The major detectable compounds are ATP,
phosphocreatine (PCr) and inorganic phosphate (Pi). Free (metabolically active) ADP,
the major regulator of oxidative phosphorylation, can be calculated from the MRS data
using the creatine kinase equilibrium equation 700. Cardiac 31 P-MRS enables the in vivo
11
measurement of the PCr to ATP ratio. This has been shown by P-MRS and 
conventional biochemistry to be a good measure of the energetic state of cardiac muscle 
’ . Cardiac PCr to ATP ratio has previously been shown to be significnalty reduced in
FRDA patients with and without cardiac hypertrophy 703. Skeletal muscle provides an
• * 3 1ideal tissue in which to assess in vivo mitochondrial ATP production rate using P-MRS.
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It can be studied at rest, during exercise, and during the recovery phase 704. During 
incremental exercise there is a progressive reduction of PCr as it is hydrolysed via the 
creatine kinase reaction in order to buffer the ATP concentration. As soon as the exercise 
is stopped the PCr concentration begins to return to its pre-exercise levels, as PCr is re­
synthesised from ATP. ATP production during recovery from exercise is entirely due to 
oxidative phosphorylation 704, thus PCr re-synthesis rate reflects the mitochondrial rate of 
ATP production. Mean muscle Vmax in FRDA patients has been shown to be reduced to 
34% of the normal mean and is strongly dependent upon the size of GAA1 490’539.
6.4.2 Experimental Design:
Acknowledgements: this work was performed in conjunction with others. Dr J Crilley 
performed all echocardiography; Dr R Lodi and Dr B Rajagopalan performed all MRS 
studies in conjunction with Drs DJ Taylor, Dr A Blamire, Dr D manners, and Dr P Styles 
all of the MRC Biochemical and Clinical Magnetic Resonance Unit, Department of 
Biochemistry, University of Oxford and Oxford Radcliffe Hospital, Oxford, UK. Genetic 
analysis was performed by Dr J Bradley. All clinical evaluations were performed by 
myself. The trial was orchestrated by Dr JM Cooper and Prof AHV Schapira. Funding for 
the trial was provided by the Ataxia Society. All drugs were provided by Pharma Nord.
Subjects -  Ten FRDA patients (5 males, age range 16-40 years, mean ± SD 28 ± 6 years) 
were studied. At zero months their MRS data were compared to 10 healthy volunteers for 
the calf skeletal muscle (5 males, age range 22-41, mean ± SD 28 ± 5 years) and 10 
different healthy volunteers for the cardiac muscle 31P-MRS (5 males, age range 16-40 
years, mean ± SD 28 ± 6 years). The diagnosis of FRDA was confirmed by detection of 
a GAA repeat expansion in the first intron of both alleles of the frataxin gene 474. The 
GAA expansion was in the range 290 tom900 repeats for the shorter of the two alleles. 
Patients were assessedneurologically, and with MRS and echocardiography at 
0,3,6,11,23,and 35 months. Informed consent was obtrained from all patients and 
volunteers. The trial was conducted with the ethical approval of the Central Oxford and 
Royal Free Hospital Ethics Committees.
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31 •P-MRS -  Patients laid prone in the magnet and standard spin-echo MRI were used to 
position the heart in the centre of the magnet. Cardiac 31P spectra were acquired using a 7 
cm circular surface coil placed below the chest. Data were acquired using a slice selective
1-dimensional spectroscopic image imaging technique that separately localises signal 
from the chest wall and myocardium 705. Skeletal muscle 31P-MRS spectra were obtained 
from the right calf muscle at rest, during an aerobic incremental exercise of plantar 
flexion and the following recovery phase 706. Relative concentrations of inorganic 
phosphate (Pi), PCr and ATP were obtained. The maximum rate of mitochondrial ATP 
synthesis (Vmax) was calculated 707
Echocardiography -  2D and M-mode imaging from parasternal and apical windows was 
performed at the above time points using Sonos-5500 (Hewlett Packard, Bracknell, 
United kingdom). Images were recorded on optical disk for subsequent analysis. Standard 
M-mode measurements were made using established criteria 708.
Clinical evaluations -  were performed at 0, 6, 11, 18, 23, and 35 months, using ICARS as 
described above.
Statistical analysis -  Individual tests were taken as abnormal when they fell outside the 
normal range. In view of the low number of subjects, non-parametric tests were used. The 
Mann-Whitney U-test was used to compareindependent groups and the Wilcoxon’s 
matched pair test to compare dependent groups (i.e. data collected from FRDA patients 
before and during therapy). Statistical significance was taken as p  < 0.05. Correlation 
coefficients were calculated by linear regression.
6.4.3 Results:
After 6 months therapy cardiac PCr to ATP ratios increased by more than 50% in the 
FRDA patients as a group. Cardiac PCr to ATP ratio did not increase in two patients, 
both of whom had LVH, but one of these was the only patient with a normal cardiac PCr 
to ATP ratio before therapy. There was a greater degree of PCr/ATP recovery in the 4
201
FRDA patients without cardiac hypertrophy (+70%) than in the 5 patients with LVH 
(+37%). Skeletal muscle Vmax increased for the group by 34% after 6 months therapy, 
and was unchanged in only 2 patients. At 35 months cardiac and skeletal muscle energy 
metabolism as judged by 31 P-MRS showed a sustained improvement (figure 6.5).
Echocardiography data suggests the fraction shortening at the 35 month time point for the 
patients as a whole was significantly increased relative to the pre-therapy data (figure
6.6). The total ICARS score and posture and gait, and kinetic component did not differ 
significantly from the pre-treatment group values (figure 6.7). Comparison of the 
progression of the patients' clinical scores with cross-sectional data suggested the clinical 
scores for 8 patients were better than predicted while 2 patients scores declined as 
expected (figure 6.8).
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6.4.4 Discussion
The vitamin E and coenzyme Qio doses used in this study were well tolerated, and are 
similar to those administered to patients with other neurodegenerative disorders where 
likewise no side effects were reported 709’710. Both drugs localise to cellular membranes, 
including mitochondrial membranes, and act as free radical scavengers in addition to the 
role of coenzyme Qio in electron transfer. The two antioxidants were combined to 
amplify their efficacy.
This pilot study demonstrated that antioxidant therapy in FRDA can improve surrogate 
bioenergetic parameters after six months therapy, and that this improvement is 
maintained over a prolonged period of time. The more marked bioenergetic improvement 
after therapy found in cardiac compared to skeletal muscle may reflect a higher 
dependence on frataxin and greater accumulation of iron and free radical mitochondrial 
damage in FRDA heart. The greater degree of PCr/ATP improvement in patients without 
LVH than those with LVH may indicate that the presence of LVH reduces the rate of 
bioenergetic recovery and that antioxidant therapy may be more effective if started before 
cardiomyopathy becomes established. Indeed, if the bioenergetic deficit precedes cardiac 
hypertrophy, then the early initiation of antioxidant therapy in FRDA may prevent the 
development of cardiac hypertrophy by reversing the bioenergetic abnormality. In 
addition to these improvements of surrogate markers, prolonged therapy was associated 
with a significant improvement in heart function as measured by fraction shortening. This 
latter finding is important because cardiac disease is often the life-limiting factor in 
FRDA.
Clinical progression of the disease however, as judged by ICARS and its component 
scores, did not change significantly over the course of the trial. It may be however that 
the treatment only served to slow the expected rate of progression of the disease rather 
than to cause improvement from baseline. In order to assess this the total ICARS score 
over 35 months for each of the ten individuals in the trial was compared with expected 
disease progression as generated by cross-sectional data. This analysis implied that eight
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patients were deteriorating less rapidly than would have been expected. The validity of 
using cross sectional data to predict disease progression remains uncertain.
Based upon the results of this pilot study a double blind placebo controlled trial of 
combined coenzyme Qio and vitamin E in FRDA is currently underway.
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APPENDIX
Homogenisation buffer 
Sucrose 0.25M
Tris-HCl lOmM
EDTA-K2 ImM
pH 7.4
Modified Tvrodes buffer
NaCl 150mM
NaH2P04 0.55mM
NaHC03 7mM
KC1 2.7mM
Glucose 5.6mM
EDTA-K2 ImM
pH 7.4
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International Co-operative Ataxia Rating Scale (ICARS)
SPEECH
1. FLUENCY
("a mischievous spectacle in Czechoslovakia)
Repeated several times
0 Normal
1 Mild modification of fluency----------------------------------------------------
2 Moderate modification of fluency
3 Considerably slow and dysarthric speech
4 No speech __________
2. DYSARTHRIA: clarity of speech
0 Normal ----------------
1 Suggestion of slurring
2 Definite slurring, most words understandable
3 Severe slurring, speech not understandable __________
4 No speech
POSTURE + GAIT
***lf patient cannot walk 10 metres even with support of someone score maximum 
points for 3 and 4 and go to 5
3. WALKING CAPACITY
10 metre,
single step pivot half turn
1.5 m from wall
support from wall, 1 stick, 2 sticks /  stroller, 1 arm, 2 arms 
tandem walk distance ?
0 Normal (> 8 sequential steps in tandem).
1 Almost normal but can't tandem walk.(<4 sequential steps in tandem)
2 Walks without support, but clearly abnormal + irregular.
3 Walks without support but considerable staggering, difficulties with half turn.
4 Walking with autonomous support not possible episodic support of wall for 10 m walk
5 Walking only possible with one stick
6 Walking only possible with two special sticks or stroller
7 Walking only with accompanying person (one arm)
8 Walking impossible even with support from accompanying person
Can the patient RUN JUMP
Time to walk 10 metres secs
4. GAIT SPEED
If 4 or greater in 3 above - score 4 in this test
0 Normal
1 Slightly reduced
2 Markedly reduced
3 Extremely slow
4 Walking with autonomous support no longer possible
5. SPREAD OF FEET (natural position, eyes open, no support).
Stand in natural position 
Distance between medial malleoli
0 Normal <10 cm
1 10-25 cm
2 25-35 cm
3 >35 cm
4 standing in natural position no longer possible
6. STANDING EYES OPEN
Ask the patient to proceed from one state to the next to obtain the maximum state 
possible. For times score best of 3 attempts
Stand in natural position (time) is support needed 
Stand with feet together (time)
Stand with feet in tandem position 
Stand on one foot (time)
0 Normal, able to stand on one foot for > 10 secs [TIME sec , up to 1 min?]
1 Able to stand with feet together, and in tandem(> 10 sec), but not 1 above
2 Able to stand with feet together, but not in tandem [TIME_____sec, up to 1 min?]
3 Stand in natural position with no or moderate sway [TIME_____ sec, up to 1 min?]
4 Stand in natural position without support, with considerable sway + corrections
5 Needs strong support of one arm to stand in natural position
6 Unable to stand at all, even with strong support of 2 arms --------------
***lf cannot stand unaided for 30 sec, score max points for 7 + 8 
and go to 9
7. BODY SWAY (feet together, eyes open)
Monitor over 30 secs
0 Normal
1 Slight oscillations ( <1cm at level of head)
2 Moderate oscillations (1 -1 Ocm at level of head)
3 Severe oscillations ( >10 cm at level of head) threatening upright position.
4 Immediate falling
8. BODY SWAY (feet together eyes closed)
Monitor over 30 secs
0 Normal
1 Slight oscillations (<1 cm at level of head)
2 Moderate oscillations (1-10 cm at level of head)
3 Severe oscillations ( >10 cm at level of head) threatening upright position.
4 Immediate falling
9. QUALITY OF SITTING POSITION
Monitor over 30 secs
Thighs together, feet on floor
Hard flat surface, standard chair with a back
Arms folded
0 Normal
1 With mild oscillations of the trunk
2 With moderate oscillations of the trunk and legs (intermittent contact with chair)
3 With severe dysequilibrium, (needs contact with chair back or sides)
4 Impossible (needs continuous contact with chair back and sides)
OCULOMOTOR
10. GAZE EVOKED NYSTAGMUS
0 Normal
1 Transient
2 Persistent but moderate
3 Persistent and severe
11. PURSUIT: saccadic
0 Normal
1 Slightly saccadic
2 Clearly saccadic
12. DYSMETRIA
0 Absent
1 Bilateral clear overshoot or undershoot of the saccade
KINETIC FUNCTIONS
13. FINGER-NOSE (decomposition + dysmetria)
Patient sitting on chair 
Begin with hand on knee 
3 times each arm
0 No trouble
1 Oscillating movement without decomposition of the movement
2 Segmental movement in 2 phases and / or moderate dysmetria in reaching nose
3 Segmental movement in more than 2 phases and / or considerable dysmetria in 
reaching nose / finger
4 Dysmetria preventing the patient from reaching the nose
R L
14. FINGER-NOSE (intention tremor)
The studied tremor is that appearing during the ballistic phase of the movement
0 No trouble
1 Simple swerve of the movement
2 Moderate tremor with estimated amplitude < 10cm
3 Tremor with estimated amplitude between 10 and 40 cm
4 Severe tremor with estimated amplitude >40cm
R L
15. FINGER - FINGER TEST (action tremor and / or instability)
Sitting
Maintain medially 2 index fingers pointing at each other I cm apart 
for 10 seconds at level of thorax
0 Normal
1 Mild instability
2 Moderate oscillations of finger with estimated amplitude <10cm
3 Considerable oscillations of finger with estimated amplitude 10-40cm
4 Jerky movements with estimated amplitude >40cm
R L
16. PRONATION-SUPINATION
Sitting
Raise forearms vertically, elbows and shoulder 9 (f in front of body 
pronate /  supinate hand as fast as possible 
Each arm assessed separately
0 Normal
1 Slightly irregular and slowed
2 Clearly irregular and slowed but without sway of the elbow
3 Extremely irregular and slowed movement, with sway of the elbow
4 Movement completely disorganised or impossible
R L
17. KNEE - TIBIA (LOWERING OF HEEL)
Supine, visual control. Raise one leg place heel on knee and slide down anterior tibiaI 
surface to foot.
Note Decomposition of movement and intention tremor 
3 times each leg
0 Normal
1 Lowering of heel in continuous axis, but the movement is decomposed in several 
phases, without real jerks, or abnormally slow
2 Lowering jerkily in the axis
3 Lowering jerkily with lateral movements (not falling off leg or outside width of leg)
4 Lowering jerkily with extremely strong lateral movements (falling off leg, failing to hit 
upper part of foot) or test impossible
R L
18. ACTION TREMOR OF HEEL ON KNEE
Patient lifts foot onto knee and holds heel on knee for a few seconds
0 No trouble
1 Tremor stopping immediately when the heel reaches the knee
2 Tremor stopping in less than 10 secs after reaching the knee
3 Tremor continuing for more than 10 seconds after reaching the knee
4 Uninterrupted tremor or test impossible
R L
19. ARCHIMEDES' SPIRAL
Sitting at table, Paper fixed,Dominant hand
Move from centre to outside in a continuous movement
0
1
2
3
4
on the line
deviates from line in places 
mostly off line but not 
crossing other neighbouring 
dotted line 
crosses lines 
incomplete and no 
resemblance to spiral
* •  •  •  *
Non ICARS Clinical Assessments
20. HYPERTONIA
21. HYPOTONIA
22. INCREASED REFLEXES - upper limbs 
Biceps, triceps, supinator deep tendon reflexes
0 normal
1 slight
2 very brisk (poly kinetic and/or presence of clonus)
23. INCREASED REFLEXES - lower limbs 
Knee and ankle deep tendon reflexes
0 normal
1 slight
2 very brisk (poly kinetic and/or presence of clonus)
24. DECREASED REFLEXES - upper limb
0 normal
1 reduced
2 absent
25. DECREASED REFLEXES - lower limb
0 normal
1 reduced
2 absent
26. PLANTERS
0 normal
1 no response from big toe
2 Babinski
SUMMARY
Biceps Triceps Supinator Knee Ankle Planters
Right
Left
0 absent
+/- present with re-inforcement
+ normal
++ brisk but not pathologic
+++ pathologically brisk
27. VIBRATION
At styloid apophysis of ulnar bone 
Tibial tuberosity 
External malleolus
0 normal
1 decreased at lower limbs
2 decreased at upper and lower limbs
3 absent at lower limbs
4 absent at upper and lower limbs
General Health Questionnaire (GHQ-12)
• We would like to know if you have any medical complaints and how your helath has 
been, over the pat few weeks
• Please answer all the questions on the following pages simply by marking the 
answer which you think most nearly applies to you
• Remember that we want to know about present and recent complaints, not about 
those that you have had in the past
Have you recently: _________________________________________
1. Been able to 
concentrate on 
whatever you’re doing?
Better than 
usual
Same as 
usual
Worse than 
usual
Much worse 
than usual
2. Lost much sleep 
over worry?
Not at all No more than 
usual
Rather more 
than usual
Much more 
than usual
3. Felt that you are 
playing a useful part in 
things?
More so than 
usual
Same a s 
usual
Less useful 
than usual
Much less 
useful
4. Felt capable of 
making decisions 
about things?
More so than 
usual
Same as 
usual
Less so than 
usual
Much less 
capable
5. Felt constantly under 
strain
Not at all No more than 
usual
Rather more 
than usual
Much more 
than usual
6. Felt you could’nt 
overcome your 
difficulties?
Not at all No more than 
usual
Rather more 
than usual
Much more 
than usual
7. Been able to enjoy 
your normal day-to-day 
activities?
More so than 
usual
Same as 
usual
Less so than 
usual
Much less 
than usual
8. Been able to face up 
to your problems?
More so than 
usual
Same as 
usual
Less able than 
usual
Much less 
able
9. Been feeling 
unhappy and 
depressed?
Not at all No more than 
usual
Rather more 
than usual
Much more 
than usual
10. Been losing 
confidence in yourself?
Not at all No more than 
usual
Rather more 
than usual
Much more 
than usual
11. Been thinking of 
yourself as a worthless 
person?
Not at all No more than 
usual
Rather more 
than usual
Much more 
than usual
12. Been feeling 
reasonably happy, all 
things considered?
More so than 
usual
About same 
as usual
Less so than 
usual
Much less 
than usual
Name:
1. Are you 
1 female
Town of Residence:
2 Male
2. What is your age? (years) and date of birth? ... day ... month ...year
3. To which ethnic group do you belong?
1 White
2 Indian
3 Black/Caribbean
4 Pakistani
5 Black/African
6 Bangladeshi
7 Black/Other (please specify)
8 Chinese
9 Any other ethnic group (please specify)
4. Roughly when did your Friedreichs ataxia start
5. Roughly when was your Friedreichs ataxia diagnosed
6. Concerning your mobility indoors, please tick the most appropriate box 
I I I walk unaided
dH I use a stick or frame, or hold onto furniture or somebody when walking 
I I I use a wheelchair
7. Are you? (please circle one)
1 Single
2 Separated
3 Married
4 Divorced
5 With a partner
6 Widowed
8. Do you live? (please circle one):
1 Alone
2 With others (e.g. family, friends)
EUROQOL
By placing a tick in one box in each group below, please indicate which statement 
best indicates your own health state today.
Do not tick more than one box in each group
Mobility
I have no problems walking about □
I have some problems walking about □
I am confined to bed □
Self-Care
I have no problems with self-care □
I have some problems washing and dressing myself □
I am unable to wash and dress myself □
Usual activities (e.g. work, study, housework, family or leisure-activities)
I have no problems with performing my usual activities □
I have some problems with performing my usual activities □
I am unable to perform my usual activities □
Pain/Discomfort
I have no pain or discomfort □
I have moderate pain or discomfort □
I have extreme pain or discomfort □
Anxiety/Depression
I am not anxious or depressed □
I am moderately anxious or depressed □
I am extremely anxious or depressed □
To help people say how 
Good or bed a health state 
is, we have drawn a scale 
(rather like a thermometer) 
on which the best state you 
can imagine is marked 100 
and the worst you can 
imagine is marked 0.
We would like you to indicate 
on this scale how good or bad 
your own health is today, 
in your opinion.
Please do this by drawing a 
line from the box below to 
whichever point on the scale 
indicates how good or bad 
your health state is.
Y o u r  o\\  11 
h e a l t h  s t a t e  
t o d a \
75
50
0
25
100
It will help us to understand your answers better if we have a little background data 
from everyone, as covered in the following questions
1. What is your age in years<
2. Are you male
female
3. Are you a current smoker
an ex-smoker 
a never smoker
4. Which of the following best describes your main activity
In employment or self-employment
Retired
Housework
Student
Seeking work
Other (please specify
5. Did your education continue after the minimum school leaving age?
Yes
No
6. Do you have a degree or equivalent professional qualification
Yes
No
7. If you know your postcode please write it here
Thank you for taking the time to complete this questionnaire.
□ 
□
□
□
□
 
oi 
□
□
□
□
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□
□
□
□
□
□
POSTAL BARTHEL INDEX
• These are some questions about your ability to look after yourself
• They may not seem to apply to you. Please answer them all.
• Tick one box in each section
1. Bathing... In the bath or shower, do you:
manage on your own? 
need help getting in or out? 
need other help? 
never have a bath or shower? 
need to be washed in bed?
(remember- tick one box only)
Transfer.. Do you move from bed to chair:
on your own? 
with a little help from one person? 
with a lot of help from one or more person? 
not at all?
(remember- tick one box only)
Dressing. Do you get dressed:
Feeding..
Mobility..
(remember- tick one box only)without any help? 
just with help with buttons? 
with someone helping you most of the time?
Do you eat food:
without any help? (remember -  tick one box only)
with help cutting food or spreading butter? 
with more help?
Do you walk indoors:
without any help apart from a frame? (remember- tick one box only)
with one person watching over you?
with one person helping you?
with more thanone person helping?
not at all?
or do you use a wheelchair independently (e.g. round corners)?
6. Stairs.. Do you climb stairs at home:
□ without any help? (remember -  tick one box only)
□ with someone carrying your frame?
□ with someone encouraging you?
□ with physical help?
□ not at all?
□ don’t have stairs?
7. Toilet use... Do you use the toilet or commode:
□ without any help? (remember -  tick one box only)
□ with some help but can do something?
□ with quite a lot of help?
8. Grooming... Do you brush your hair and teeth, wash your face and shave:
□ without help? (remember -  tick one box only)
□ with help?
9. Bladder... Are you incontinent of urine?
□ never (remember -  tick one box only)
□ less than once a week
□ less than once a day
□ more often
□ or do you have a catheter managed for you?
10. Bowels... Do you soil yourself?
□ never (remember -  tick one box only)
□ occasional accident
□ all the time
□ or do you need someone to give you an enema?
Please check that you have answered all the questions. Thank you very much for your help.
Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36)
• This survey asks for your views about your health. This information will help 
keep track of how well you are able to do your usual activities.
• Answer every question by marking the answer as indicated
• If you are unsure about how to answer a question please give the best 
answer you can.
1. In general, would you say your health is:
Circle one 
Excellent 1
Very good 2
Good 3
Fair 4
Poor 5
2. Compared to one year ago, how would you rate your health in general now?
Circle one
Much better now than one year ago 1
Somewhat better now than one year ago 2
About the same as one year ago 3
Somewhat worse now than one year ago 4
Much worse now than one year ago 5
3. The following questions are about activities you might do during a typical 
day. Does your health now limit you in these activities? If so, how much?
Circle one number
ACTIVITIES Yes, 
limited a 
lot
Yes, 
limited a 
little
No, not 
limited at 
all
a) Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports
1 2 3
b) Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf
1 2 3
c) Lifting or carrying groceries 1 2 3
d) climbing several flights of stairs 1 2 3
e)climbing one flight of stairs 1 2 3
f)Bending, Kneeling, stooping 1 2 3
g) Walking more than a mile 1 2 3
h) Walking half a mile 1 2 3
i) Walking one hundred yards 1 2 3
j) Bathing or dressing yourself 1 2 3
4. During the past 4 weeks, have you had any of the fillowing problems with your 
work or other regular daily activities as a result of your physical helath?_______
Circle one number on each line Yes No
a) Cut down the amount of time you spent on work or other 
activities
1 2
b) Accomplished less than you would like 1 2
c) Were limited in the kind of work or other activities 1 2
d) Had difficulty performing the work or other activities (for 
example, it took extra effort)
1 2
5. During the past four weeks, have you had any of the following problem with 
your work or other regular daily activities as a result of any emotional 
problems (such as feeling anxious or depressed)?
Circle one number on each line Yes No
a) Cut down on the amount of time you spent on work or other 
activities
1 2
b) Accomplished less than you would like 1 2
c) Did’nt do work or activities as carefully as usual 1 2
6. During the past four weeks, to what extent has youe physical helath or 
emotional problems interfered with your normal social activitieswith family, 
friends, neighbours, or groups?
Circle one
Not at all 1
Slightly 2
Moderately 3
Quite a bit 4
Extremely 5
7. How much bodily pain have you had during the past four weeks?
Circle one
None 1
Very mild 2
Mild 3
Moderate 4
Severe 5
Very severe 6
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)
Circle one
Not at all 1
A little bit 2
Moderately 3
Quite a bit 4
Extremely 5
9. These questions are about how you feel and how things have been with you 
during the past four weeks. For each question, please give the one answer 
that comes closest to the way you have been feeling. How much of the time 
during the past four weeks -
Circle one number on each 
line
All of
the
time
Most 
of the 
time
A good 
bit of 
the time
Some 
of the 
time
A little 
of the 
time
None 
of the 
time
a) Did you feel full of life? 1 2 3 4 5 6
b) Have you been a very 
nervous person?
1 2 3 4 5 6
c) Have you felt so down in the 
dumps that nothing could 
cheer you up?
1 2 3 4 5 6
d) Have you felt calm and 
peaceful?
1 2 3 4 5 6
e) Did you have a lot of 
energy?
1 2 3 4 5 6
f) Have you felt downhearted 
and low?
1 2 3 4 5 6
g) Did you feel worn out 1 2 3 4 5 6
h) Have you been a happy 
person?
1 2 3 4 5 6
i) Did you feel tired? 1 2 3 4 5 6
10. During the past four weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities(like visiting with 
friends, relatives, etc.)?
Circle one
All of the time 1
Most of the time 2
Some of the time 3
A little of the time 4
None of the time 5
11. How TRUE or FALSE is each of the following statements for you?
Circle one number on each line Definitely
true
Mostly
true
Don’t
know
Mostly
false
Definitely
false
a) I seem to get ill a little easier than 
other people
1 2 3 4 5
b) I am as healthy as anybody I know 1 2 3 4 5
c) I expect my health to get worse 1 2 3 4 5
d) My health is excellent 1 2 3 4 5
Thank you very much for your help.
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